<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Neurosci.</abbrev-journal-title>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fncel.2023.1105247</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cellular Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Karvandi</surname> <given-names>Mohammad Sobhan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2181045/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Sheikhzadeh Hesari</surname> <given-names>Farzam</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aref</surname> <given-names>Amir Reza</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/164715/overview"/>
</contrib> 
<contrib contrib-type="author" corresp="yes">
<name><surname>Mahdavi</surname> <given-names>Majid</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x0002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1722783/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz</institution>, <addr-line>Tabriz</addr-line>, <country>Iran</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Medical Oncology, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute and Harvard Medical School</institution>, <addr-line>Boston, MA</addr-line>, <country>United States</country></aff>
<aff id="aff4"><sup>4</sup><institution>Institute of Biochemistry and Biophysics, University of Tehran</institution>, <addr-line>Tehran</addr-line>, <country>Iran</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Danuta Jantas, Maj Institute of Pharmacology (PAN), Poland</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Andrii Domanskyi, Orion Corporation (Finland), Finland; A. Raquel Esteves, University of Coimbra, Portugal; Katarzyna Z. Kuter, Maj Institute of Pharmacology (PAN), Poland</p></fn>
<corresp id="c001">&#x0002A;Correspondence: Majid Mahdavi <email>majid.mahdavi&#x00040;tabrizu.ac.ir</email> <email>majidmahdavi&#x00040;ut.ac.ir</email></corresp>
<fn fn-type="other" id="fn001"><p><bold>Specialty section</bold>: This article was submitted to Cellular Neurophysiology, a section of the journal Frontiers in Cellular Neuroscience</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>17</volume>
<elocation-id>1105247</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>02</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2023 Karvandi, Sheikhzadeh Hesari, Aref and Mahdavi.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Karvandi, Sheikhzadeh Hesari, Aref and Mahdavi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract><p>Neuronal loss is one of the striking causes of various central nervous system (CNS) disorders, including major neurodegenerative diseases, such as Alzheimer&#x02019;s disease (AD), Parkinson&#x02019;s disease (PD), Huntington&#x02019;s disease (HD), and Amyotrophic lateral sclerosis (ALS). Although these diseases have different features and clinical manifestations, they share some common mechanisms of disease pathology. Progressive regional loss of neurons in patients is responsible for motor, memory, and cognitive dysfunctions, leading to disabilities and death. Neuronal cell death in neurodegenerative diseases is linked to various pathways and conditions. Protein misfolding and aggregation, mitochondrial dysfunction, generation of reactive oxygen species (ROS), and activation of the innate immune response are the most critical hallmarks of most common neurodegenerative diseases. Thus, endoplasmic reticulum (ER) stress, oxidative stress, and neuroinflammation are the major pathological factors of neuronal cell death. Even though the exact mechanisms are not fully discovered, the notable role of mentioned factors in neuronal loss is well known. On this basis, researchers have been prompted to investigate the neuroprotective effects of targeting underlying pathways to determine a promising therapeutic approach to disease treatment. This review provides an overview of the role of ER stress, oxidative stress, and neuroinflammation in neuronal cell death, mainly discussing the neuroprotective effects of targeting pathways or molecules involved in these pathological factors.</p></abstract>
<kwd-group>
<kwd>neurodegenerative diseases</kwd>
<kwd>cell death</kwd>
<kwd>ER stress</kwd>
<kwd>UPR &#x02013; unfolded protein response</kwd>
<kwd>oxidative stress</kwd>
<kwd>ROS</kwd>
<kwd>neuroinflammation</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="228"/>
<page-count count="24"/>
<word-count count="20812"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="introduction" id="s1">
<title>Introduction</title>
<p>Neurodegenerative diseases are nervous system disorders in which millions of people, especially the elderly, are being affected worldwide. The rising prevalence of these diseases has put the world with a serious challenge (Bloem et al., <xref ref-type="bibr" rid="B18">2021</xref>; Milo&#x00161;evi&#x00107; et al., <xref ref-type="bibr" rid="B145">2021</xref>). Despite the developments in this field of study and advancements in pharmacological aspects, there is not a promising drug to consummately cure neurodegenerative diseases yet (Pohl and Kong Thoo Lin, <xref ref-type="bibr" rid="B161">2018</xref>). However, there are still so many studies to alleviate disease symptoms and extend life span (Breijyeh and Karaman, <xref ref-type="bibr" rid="B19">2020</xref>). Neurodegenerative diseases are mostly characterized by toxic protein aggregates with abnormal conformation within neurons or neuroglia, leading to memory, cognitive, and/or movement disorders (Dugger and Dickson, <xref ref-type="bibr" rid="B44">2017</xref>). These diseases include a wide range of neurological disorders, but the major types are Alzheimer&#x02019;s disease (AD), Parkinson&#x02019;s disease (PD), Huntington&#x02019;s disease (HD), and amyotrophic lateral sclerosis (ALS; Lezi and Swerdlow, <xref ref-type="bibr" rid="B117">2012</xref>). Protein misfolding and accumulation of amyloid-&#x003B2; (A&#x003B2;) and phosphorylated Tau is the major pathological feature in AD, as well as &#x003B1;-synuclein in PD, and mutant superoxide dismutase 1 (mSOD1) in ALS (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). Clinical manifestations in these kinds of diseases mainly occur as a consequence of neuron dysfunction or neuronal cell death (Andreone et al., <xref ref-type="bibr" rid="B7">2020</xref>). Besides apoptosis, depending on the conditions, other different types of cell deaths, such as ferroptosis, necroptosis, and parthanatos are also possible to affect cell fidelity (Wang et al., <xref ref-type="bibr" rid="B200">2018</xref>; Ferrada et al., <xref ref-type="bibr" rid="B54">2020</xref>; Reichert et al., <xref ref-type="bibr" rid="B165">2020</xref>; David et al., <xref ref-type="bibr" rid="B35">2022</xref>; Mangalmurti and Lukens, <xref ref-type="bibr" rid="B137">2022</xref>). The mitochondria and endoplasmic reticulum (ER) play crucial role in the occurrence of neuronal cell death among many other organelles (Gorman et al., <xref ref-type="bibr" rid="B69">2012</xref>; Johnson et al., <xref ref-type="bibr" rid="B97">2021</xref>; Markovinovic et al., <xref ref-type="bibr" rid="B138">2022</xref>). Mitochondria are dynamic organelles that participate in producing energy and maintaining cellular redox balance, among many other functions (Johri and Beal, <xref ref-type="bibr" rid="B98">2012</xref>). Therefore, mitochondrial dysfunction, including excessive reactive oxygen species (ROS) production, mitochondrial calcium overload, loss of the mitochondrial membrane potential leading to release of apoptosis-inducing factor (AIF), and other pro-apoptotic factors could lead to caspase activation and cell death (Culmsee and Plesnila, <xref ref-type="bibr" rid="B33">2006</xref>; Kaminskyy and Zhivotovsky, <xref ref-type="bibr" rid="B100">2014</xref>; Hoffmann et al., <xref ref-type="bibr" rid="B85">2021</xref>). Evidence also reveals that mitochondrial DNA (mtDNA) mutations are present in patients with neurodegeneration (Johri and Beal, <xref ref-type="bibr" rid="B98">2012</xref>). Also, aberrant ROS production and imbalance in antioxidant activity could influence mitochondria and impair mitochondria&#x02019;s function, leading cells to death (Angelova and Abramov, <xref ref-type="bibr" rid="B8">2018</xref>; Doroudian et al., <xref ref-type="bibr" rid="B42">2021</xref>), which is explained in the following sections. Of note, ROS can also contribute to the production of protein aggregates and exacerbate disease pathology (Van Dam and Dansen, <xref ref-type="bibr" rid="B196">2020</xref>).</p>
<p>On the other hand, the ER is a large and dynamic organelle responsible for protein folding and maturation. Once a protein folds with an abnormal conformation, the misfolded protein enters the ER-associated degradation (ERAD) pathway to prevent the following plausible detrimental effects of the protein (Schwarz and Blower, <xref ref-type="bibr" rid="B174">2016</xref>). Aberrant misfolded proteins or aggregates can potentially trigger the process &#x0201C;Unfolded Protein Response&#x0201D; (UPR) to attenuate ER stress or initiate apoptosis pathways (Schwarz and Blower, <xref ref-type="bibr" rid="B174">2016</xref>). UPR has three signaling arms, including IRE1-&#x003B1;, PERK, and ATF6, which are highly conserved pathways (Shi et al., <xref ref-type="bibr" rid="B175">2022</xref>). However, toxic protein aggregates may also undergo degradation by lysosomes (i.e., autophagy), to ameliorate disease progression (Djajadikerta et al., <xref ref-type="bibr" rid="B41">2020</xref>). Autophagy is able to activate or inhibit the apoptosis signaling to maintain intracellular balance or induce neuronal cell death (Gupta R. et al., <xref ref-type="bibr" rid="B73">2021</xref>). All three UPR arms, Ca<sup>2+</sup> release, and oxidative stress can directly or indirectly activate autophagy induction (Andhavarapu et al., <xref ref-type="bibr" rid="B6">2019</xref>; Ramirez-Moreno et al., <xref ref-type="bibr" rid="B163">2019</xref>; Ren et al., <xref ref-type="bibr" rid="B167">2021</xref>). Although protein aggregates are the key reasons for the pathology of neurodegenerative diseases, other factors, including activation of glutamate ionotropic receptors, excitotoxicity from dysregulation of neuronal calcium homeostasis, dysfunction of lysosomes, aberrant cell-cycle re-entry, and impairments in axonal transport and synaptic function can also contribute to neuronal injury or death in various neurodegenerative diseases such as AD and PD (Emerit et al., <xref ref-type="bibr" rid="B48">2004</xref>; Fricker et al., <xref ref-type="bibr" rid="B55">2018</xref>; Sushma and Mondal, <xref ref-type="bibr" rid="B186">2019</xref>; Behl et al., <xref ref-type="bibr" rid="B14">2021</xref>; Hoffmann et al., <xref ref-type="bibr" rid="B85">2021</xref>). In addition, increased levels of inflammatory factors in the serum and brain tissue, known as neuroinflammation, participates in the pathophysiology of neurodegenerative diseases (Calsolaro and Edison, <xref ref-type="bibr" rid="B22">2016</xref>). Emerging evidence indicates that neuroinflammation can be the cause and consequence of both ER stress and oxidative stress (Salminen et al., <xref ref-type="bibr" rid="B171">2009</xref>; Sochocka et al., <xref ref-type="bibr" rid="B179">2013</xref>; Pintado et al., <xref ref-type="bibr" rid="B159">2017</xref>). A neurotoxic microenvironment caused by the activation of microglial cells and release of cytotoxic inflammatory factors in the CNS can affect cell fidelity and induce neuronal cell death (Behl et al., <xref ref-type="bibr" rid="B14">2021</xref>; Wu and Zou, <xref ref-type="bibr" rid="B205">2022</xref>). This can be carried out by triggering pyroptosis, an inflammasome-mediated type of cell death (Kovacs and Miao, <xref ref-type="bibr" rid="B108">2017</xref>). However, the undeniable contribution of age, genetics, and environmental factors in the disruption of neuronal homeostasis and subsequently neuronal cell death cannot be discounted (Bejanin et al., <xref ref-type="bibr" rid="B15">2017</xref>).</p>
<p>There have been clinical trials targeting neuropathological hallmarks of neurodegenerative diseases, investigating glucagon-like peptide-1 receptor (GLP-1R) agonists, monoclonal antibodies against toxic protein aggregates, antioxidant agents, beta-secretase (BACE1) inhibitors and other receptor inhibitors such as 5HT-6 serotonin receptor inhibitor (<xref ref-type="table" rid="T1">Table 1</xref>, Hung and Fu, <xref ref-type="bibr" rid="B91">2017</xref>). The results were controversial, as there was no evidence of beneficial effect on patients&#x02019; cognitive and functional status in most trials; while in some cases the condition of patients who received drugs worsened, compared with those who received placebo (<xref ref-type="table" rid="T1">Table 1</xref>, Egan et al., <xref ref-type="bibr" rid="B46">2019</xref>). These results indicate that novel agents with different features must be studied and trialled. Given the complex interplay of ER stress, oxidative stress, and neuroinflammation in the pathology of most neurodegenerative diseases, developments in the knowledge of underlying mechanisms may be crucial for researchers to propose a promising therapeutic strategy to achieve a more efficient treatment for neurodegenerative diseases.</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption><p>Clinical trials associated with neurodegenerative diseases.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left"><bold>Trial Identification</bold></th>
<th align="center"><bold>Drug used</bold></th>
<th align="center"><bold>Drug description</bold></th>
<th align="center"><bold>Delivery route</bold></th>
<th align="center"><bold>Disease</bold></th>
<th align="center"><bold>Phase</bold></th>
<th align="center"><bold>Status</bold></th>
<th align="center"><bold>Results</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>NCT03659682</bold></td>
<td align="center">Semaglutide</td>
<td align="center">GLP-1R agonistprevents neurons from apoptosis, alleviates oxidative stress and neuroinflammation (Chen et al., <xref ref-type="bibr" rid="B27">2023</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Not yet recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT03439943</bold></td>
<td align="center">Lixisenatide</td>
<td align="center">GLP-1R agonist prevents neurons from apoptosis, alleviates oxidative stress and neuroinflammation (Chen et al., <xref ref-type="bibr" rid="B27">2023</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Unknown</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT04305002</bold></td>
<td align="center">Exenatide</td>
<td align="center">GLP-1R agonist prevents neurons from apoptosis, alleviates oxidative stress and neuroinflammation (Chen et al., <xref ref-type="bibr" rid="B27">2023</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT04232969</bold></td>
<td align="center">Bydureon (Exenatide)</td>
<td align="center">GLP-1R agonist prevents neurons from apoptosis, alleviates oxidative stress and neuroinflammation (Chen et al., <xref ref-type="bibr" rid="B27">2023</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">PD</td>
<td align="center">III</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT04154072</bold></td>
<td align="center">NLY01</td>
<td align="center">a pegylated form of exenatide (Lv et al., <xref ref-type="bibr" rid="B131">2021</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT04269642</bold></td>
<td align="center">PT320</td>
<td align="center">sustained-release Exenatide (Li et al., <xref ref-type="bibr" rid="B119">2019</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT04777409</bold></td>
<td align="center">Semaglutide</td>
<td align="center">GLP-1R agonist prevents neurons from apoptosis, alleviates oxidative stress and neuroinflammation (Chen et al., <xref ref-type="bibr" rid="B27">2023</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT02953665</bold></td>
<td align="center">Liraglutide</td>
<td align="center">GLP-1R agonist prevents neurons from apoptosis, alleviates oxidative stress and neuroinflammation (Chen et al., <xref ref-type="bibr" rid="B27">2023</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT00004731</bold></td>
<td align="center">Coenzyme Q10</td>
<td align="center">An antioxidant involved in electron transport chain (Gherardi et al., <xref ref-type="bibr" rid="B64">2022</xref>)</td>
<td align="center">NA</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT00608881</bold></td>
<td align="center">Coenzyme Q10</td>
<td align="center">An antioxidant involved in electron transport chain (Gherardi et al., <xref ref-type="bibr" rid="B64">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">HD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">CoQ had no effect on avoiding functional decline in HD patients (Mcgarry et al., <xref ref-type="bibr" rid="B142">2017</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT01892176</bold></td>
<td align="center">Coenzyme Q10</td>
<td align="center">An antioxidant involved in electron transport chain (Gherardi et al., <xref ref-type="bibr" rid="B64">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">PD</td>
<td align="center">II and III</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT00243932</bold></td>
<td align="center">Coenzyme Q10</td>
<td align="center">An antioxidant involved in electron transport chain (Gherardi et al., <xref ref-type="bibr" rid="B64">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">ALS</td>
<td align="center">II</td>
<td align="center">Completed</td>
<td align="center">Showed insufficient promise to warrant phase III testing (Kaufmann et al., <xref ref-type="bibr" rid="B103">2009</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT00740714</bold></td>
<td align="center">Coenzyme Q10 with VitE</td>
<td align="center">VitE: a fat-soluble antioxidant (Blaner et al., <xref ref-type="bibr" rid="B17">2021</xref>)</td>
<td align="center">Oral</td>
<td align="center">PD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">No evidence of benefit</td>
</tr>
<tr>
<td align="left"><bold>NCT00076492</bold></td>
<td align="center">CoQ10 and GPI 1485</td>
<td align="center">GPI 1485: a neuroimmunophilin ligand (Poulter et al., <xref ref-type="bibr" rid="B162">2004</xref>)</td>
<td align="center">NA</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT03514875</bold></td>
<td align="center">MitoQ</td>
<td align="center">A mitochondrial reactive oxygen species scavenger (Piscianz et al., <xref ref-type="bibr" rid="B160">2021</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">NA</td>
<td align="center">Withdrawn</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT00329056</bold></td>
<td align="center">MitoQ</td>
<td align="center">A mitochondrial reactive oxygen species scavenger (Piscianz et al., <xref ref-type="bibr" rid="B160">2021</xref>)</td>
<td align="center">Oral</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT04777331</bold></td>
<td align="center">Prasinezumab</td>
<td align="center">Humanized monoclonal antibody against aggregated &#x003B1;-synuclein (Pagano et al., <xref ref-type="bibr" rid="B156">2022</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT03114657</bold></td>
<td align="center">Crenezumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">Could not reduce clinical decline in participants with early AD (Ostrowitzki et al., <xref ref-type="bibr" rid="B155">2022</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT03491150</bold></td>
<td align="center">Crenezumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">Crenezumab was unlikely to meet its primary endpoint</td>
</tr>
<tr>
<td align="left"><bold>NCT00676143</bold></td>
<td align="center">Bapineuzumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">Phase 3 studies showed no clinical benefit</td>
</tr>
<tr>
<td align="left"><bold>NCT00606476</bold></td>
<td align="center">Bapineuzumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">AD</td>
<td align="center">II</td>
<td align="center">Terminated</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT01656525</bold></td>
<td align="center">Gantenerumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">AD</td>
<td align="center">I</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT02051608</bold></td>
<td align="center">Gantenerumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Completed</td>
<td align="center">Gantenerumab doses up to 1200 mg resulted in robust amyloid-&#x003B2; plaque removal at 2 years (Klein et al., <xref ref-type="bibr" rid="B104">2019</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT04374253</bold></td>
<td align="center">Gantenerumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT03444870</bold></td>
<td align="center">Gantenerumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT03443973</bold></td>
<td align="center">Gantenerumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Avgerinos et al., <xref ref-type="bibr" rid="B9">2021</xref>)</td>
<td align="center">Subcutaneous</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT05310071</bold></td>
<td align="center">Aducanumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Dhillon, <xref ref-type="bibr" rid="B38">2021</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT03639987</bold></td>
<td align="center">Aducanumab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Dhillon, <xref ref-type="bibr" rid="B38">2021</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">AD</td>
<td align="center">II</td>
<td align="center">Terminated</td>
<td align="center">Study was discontinued based on futility analysis conducted on Phase III trials</td>
</tr>
<tr>
<td align="left"><bold>NCT05108922</bold></td>
<td align="center">Aducanumab, Donanemab</td>
<td align="center">Monoclonal antibody against A&#x003B2; (Decourt et al., <xref ref-type="bibr" rid="B36">2021</xref>)</td>
<td align="center">Intravenous (IV) infusion</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Active, not recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT03582137</bold></td>
<td align="center">Cannabidiol</td>
<td align="center">A major constituent of <italic>Cannabis sativa L.</italic> (Karimi-Haghighi et al., <xref ref-type="bibr" rid="B101">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">PD</td>
<td align="center">II</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT01502046</bold></td>
<td align="center">Sativex</td>
<td align="center">Contains Tetrahydrocannabinol and Cannabidiol in a 1:1 molecular ratio (Cristino et al., <xref ref-type="bibr" rid="B32">2020</xref>)</td>
<td align="center">Oromucosal Spray</td>
<td align="center">HD</td>
<td align="center">II</td>
<td align="center">Completed</td>
<td align="center">No significant molecular effects were detected on the biomarker analysis No significant symptomatic effects were detected at the prescribed dosage and for a 12-week period (L&#x000F3;pez-Send&#x000F3;n Moreno et al., <xref ref-type="bibr" rid="B127">2016</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT04075435</bold></td>
<td align="center">High CBD/low THC sublingual solution</td>
<td align="center">CBD: Cannabidiol THC: Tetrahydrocannabinol</td>
<td align="center">Sublingual</td>
<td align="center">AD</td>
<td align="center">Early phase I</td>
<td align="center">Recruiting</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT02783573</bold></td>
<td align="center">Lanabecestat (AZD3293)</td>
<td align="center">BACE1 inhibitor (Patel et al., <xref ref-type="bibr" rid="B158">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">Did not slow cognitive or functional decline (Wessels et al., <xref ref-type="bibr" rid="B203">2020</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT02245737</bold></td>
<td align="center">Lanabecestat (AZD3293)</td>
<td align="center">BACE1 inhibitor (Patel et al., <xref ref-type="bibr" rid="B158">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">II and III</td>
<td align="center">Terminated</td>
<td align="center">Did not slow cognitive or functional decline (Wessels et al., <xref ref-type="bibr" rid="B203">2020</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT02956486</bold></td>
<td align="center">Elenbecestat (E2609)</td>
<td align="center">BACE1 inhibitor (Patel et al., <xref ref-type="bibr" rid="B158">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">No evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo</td>
</tr>
<tr>
<td align="left"><bold>NCT01600859</bold></td>
<td align="center">Elenbecestat (E2609)</td>
<td align="center">BACE1 inhibitor (Patel et al., <xref ref-type="bibr" rid="B158">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">I</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT01496170</bold></td>
<td align="center">Verubecestat (MK-8931)</td>
<td align="center">BACE1 inhibitor (Patel et al., <xref ref-type="bibr" rid="B158">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">I</td>
<td align="center">Completed</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT01739348</bold></td>
<td align="center">Verubecestat (MK-8931)</td>
<td align="center">BACE1 inhibitor (Patel et al., <xref ref-type="bibr" rid="B158">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">II and III</td>
<td align="center">Terminated</td>
<td align="center">Did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer&#x02019;s disease (Egan et al., <xref ref-type="bibr" rid="B45">2018</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT01953601</bold></td>
<td align="center">Verubecestat (MK-8931)</td>
<td align="center">BACE1 inhibitor (Patel et al., <xref ref-type="bibr" rid="B158">2022</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Terminated</td>
<td align="center">Cognition and daily function were worse among patients who received verubecestat than among those who received placebo Did not improve clinical ratings of dementia among patients with prodromal Alzheimer&#x02019;s disease (Egan et al., <xref ref-type="bibr" rid="B46">2019</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT01689246</bold></td>
<td align="center">TRx0237</td>
<td align="center">Tau aggregation inhibitor (Hung and Fu, <xref ref-type="bibr" rid="B91">2017</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Completed</td>
<td align="center">No evidence of benefits for patients with mild to moderate Alzheimer&#x02019;s disease (Gauthier et al., <xref ref-type="bibr" rid="B60">2016</xref>)</td>
</tr>
<tr>
<td align="left"><bold>NCT03539380</bold></td>
<td align="center">TRx0237</td>
<td align="center">Tau aggregation inhibitor (Hung and Fu, <xref ref-type="bibr" rid="B91">2017</xref>)</td>
<td align="center">NA</td>
<td align="center">AD</td>
<td align="center">NA</td>
<td align="center">Available</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left"><bold>NCT02585934</bold></td>
<td align="center">Intepirdine (RVT-101) and donepezil</td>
<td align="center">Intepirdine: 5HT-6 serotonin receptor inhibitor (Hung and Fu, <xref ref-type="bibr" rid="B91">2017</xref>) Donepezil: acetylcholinesterase inhibitor (Marucci et al., <xref ref-type="bibr" rid="B139">2021</xref>)</td>
<td align="center">Oral</td>
<td align="center">AD</td>
<td align="center">III</td>
<td align="center">Completed</td>
<td align="center">Did not produce statistical improvement over placebo on cognition or activities of daily living in mild-to-moderate AD dementia patients (Lang et al., <xref ref-type="bibr" rid="B111">2021</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2">
<title>ER stress-induced cell death in neurodegenerative diseases</title>
<sec id="s2-1">
<title>Mechanism of ER stress-induced apoptotic cell death</title>
<p>The ER is known as an organelle involved in protein maturation and folding (Read and Schr&#x000F6;der, <xref ref-type="bibr" rid="B164">2021</xref>). Toxic protein aggregates in neurodegenerative diseases, pathogen-associated molecular patterns (PAMPs), danger-associated molecular patterns (DAMPs), ROS, and reactive nitrogen species (RNS), can disrupt protein folding processes in the ER lumen, leading to ER stress (Zhang and Kaufman, <xref ref-type="bibr" rid="B212">2008</xref>). In the condition of ER stress, the aggregation of unfolded or misfolded proteins within the ER lumen of neurons and neuroglia leads to failure of ER in maintaining protein homeostasis through UPR and ERAD. For instance, accumulation of tau protein in AD can affect essential components of ERAD and block this pathway, leading to the accumulation of more misfolded proteins in the ER lumen (Hetz and Saxena, <xref ref-type="bibr" rid="B82">2017</xref>; Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). Subsequently, UPR-dependent inflammation and apoptotic pathways are induced, resulting in neuronal cell death (Sprenkle et al., <xref ref-type="bibr" rid="B182">2017</xref>; Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). The ER stress can also be induced by ER Ca<sup>2+</sup> dysregulation, impairments in vesicular trafficking, or any defects in UPR components (Cooper et al., <xref ref-type="bibr" rid="B31">2006</xref>; Sprenkle et al., <xref ref-type="bibr" rid="B182">2017</xref>). PKR-like ER kinase (PERK), inositol-requiring transmembrane kinase/endoribonuclease 1 &#x003B1; (IRE1&#x003B1;), and activating transcription factor 6 (ATF6) are three vital sensor proteins that are involved in UPR regulation (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). Under normal conditions, these proteins are inactive due to association with ER chaperone proteins such as Immunoglobulin binding protein (BiP) or 78 kDa glucose-regulated protein (GRP78), which are members of heat shock protein families (Halperin et al., <xref ref-type="bibr" rid="B78">2014</xref>).</p>
<p>Under ER stress conditions, the misfolded proteins interact with the substrate binding domain of BiP. Consequently, BiP is released and leads to dimerization and auto-phosphorylation of PERK, as well as intramembrane proteolysis of ATF6 and phosphorylation of IRE1&#x003B1;. Subsequently, the UPR cascade activates to maintain protein homeostasis (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). To elaborate, the phosphorylation of the alpha subunit of eukaryotic translation initiation factor (eIF2&#x003B1;) followed by activation of PERK occurs through BiP dissociation. This process inhibits protein synthesis to prevent overload of proteins in the ER lumen (Hetz and Saxena, <xref ref-type="bibr" rid="B82">2017</xref>; Almeida et al., <xref ref-type="bibr" rid="B5">2022</xref>), therefore attempting to restore protein homeostasis (Da Silva et al., <xref ref-type="bibr" rid="B34">2020</xref>). Besides, under prolonged ER stress conditions and failure in the UPR mechanism, p-eIF2&#x003B1; promotes activating transcription factor 4 (ATF4) translation, which enhances up-regulation of pro-apoptotic factors, including CHOP (also known as GADD153; Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). Eventually, down-regulation of anti-apoptotic Bcl-2 family makes neurons more susceptible to death (Doyle et al., <xref ref-type="bibr" rid="B43">2011</xref>; Hetz and Saxena, <xref ref-type="bibr" rid="B82">2017</xref>; Da Silva et al., <xref ref-type="bibr" rid="B34">2020</xref>; <xref ref-type="fig" rid="F1">Figure 1A</xref>). Moreover, it has been claimed that TRB3 genes, GADD34, death receptor 5 (DR5), ER oxidase 1 (ERO1), and other apoptotic molecules can potentially receive apoptosis signals from CHOP and induce cell death (Taalab et al., <xref ref-type="bibr" rid="B187">2018</xref>; Da Silva et al., <xref ref-type="bibr" rid="B34">2020</xref>). ATF4 also induces transcription of the p53-upregulated modulator of apoptosis (PUMA), which results in ER-stress-induced neuronal apoptosis (Galehdar et al., <xref ref-type="bibr" rid="B57">2010</xref>). Interestingly, experiments have indicated that CHOP could not induce apoptosis in PUMA-deficient neurons, demonstrating the key role of PUMA in CHOP-induced neuronal apoptosis (Galehdar et al., <xref ref-type="bibr" rid="B57">2010</xref>). Moreover, in IRE1-&#x003B1; signaling pathway, the second arm of UPR, after the release of BiP by aggregated proteins, IRE1-&#x003B1; undergoes oligomerization and auto-phosphorylation. p-IRE1&#x003B1; facilitates neuronal death by activation of the apoptotic-signaling kinase-1 (ASK1) and other apoptotic factors as a result of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) pathways activation (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). This pathway may induce p53 activation and lead to the upregulation of Bcl-2 associated X (BAX) protein, which triggers the release of cytochrome C (Cyt C) from the mitochondria to the cytosol and cause apoptotic neuronal cell death (Stefani et al., <xref ref-type="bibr" rid="B184">2012</xref>). Furthermore, the RNase activity of IRE1&#x003B1; plays a critical role in splicing the mRNA coding for X-box binding protein 1 (XBP1) and increases the expression of genes involved in ER machinery, such as BiP (Lee et al., <xref ref-type="bibr" rid="B112">2003</xref>; Hirota et al., <xref ref-type="bibr" rid="B83">2006</xref>; Chen et al., <xref ref-type="bibr" rid="B25">2022</xref>). Besides outlined functions, IRE1&#x003B1; participates in the degradation of some mRNAs and microRNAs, known as &#x0201C;regulated IRE1&#x003B1;-dependent decay&#x0201D; (RIDD; Hetz and Saxena, <xref ref-type="bibr" rid="B82">2017</xref>; <xref ref-type="fig" rid="F1">Figure 1B</xref>). Mutations in Presenilin 1 and 2 (PS1 and PS2), which are frequently involved in AD, can inhibit IRE1 and impair UPR, leading to AD pathology and neuronal cell death (Doyle et al., <xref ref-type="bibr" rid="B43">2011</xref>). ATF6 is the third sensor protein of UPR cascades which is embedded in the ER membrane. By interaction of aggregated proteins with ATF6 in the ER lumen and release of BiP, ATF6 translocates to the Golgi apparatus and undergoes proteolysis. Subsequently, cleaved ATF6 induces transcription of ER chaperones and XBP1 in the nucleus and participates in protein homeostasis (Da Silva et al., <xref ref-type="bibr" rid="B34">2020</xref>; <xref ref-type="fig" rid="F1">Figure 1C</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p>The role of three arms of UPR in inducing apoptosis and the neuroprotective effects of particular inhibitors (shown in yellow box). <bold>(A)</bold> The PERK pathway: interaction of substrate binding domain of BiP with misfolded or aggregated proteins leads to BiP dissociation, dimerization, and autophosphorylation of PERK, which further causes eIF2&#x003B1; phosphorylation. Phosphorylated eIF2&#x003B1; induces cell death by transcription of apoptotic factors by means of ATF4 transcription factor as well as inhibition of protein synthesis. <bold>(B)</bold> The IRE1 pathway: after dissociation of BiP from IRE1 receptor by misfolded or aggregated proteins in the ER lumen, IRE1 undergoes oligomerization and autophosphorylation. This results in mRNA degradation termed &#x0201C;regulated IRE1alpha-dependent decay&#x0201D; (RIDD) and inducing apoptotic factors by initiating JNK/MAPK cascade. To mitigate ER stress, the IRE1 pathway also leads to XBP1 mRNA splicing to transcript ER chaperones to improve ER machinery. <bold>(C)</bold> The ATF6 pathway: translocation of ATF6 to the Golgi apparatus as a result of BiP dissociation, and the proteolysis of ATF6 in Golgi brings out an activated ATF6 transcription factor to transcript ER chaperones and XBP1 for ER machinery.</p></caption>
<graphic xlink:href="fncel-17-1105247-g0001.tif"/>
</fig>
</sec>
<sec id="s2-2">
<title>ER stress-associated alterations of apoptotic factors</title>
<p>In AD, A&#x003B2; can trigger ER stress, mitochondrial fragmentation, and neuronal death through ER Ca<sup>2+</sup> release by ryanodine receptors (RyRs) and inositol triphosphate receptors (IP3R; Chami and Checler, <xref ref-type="bibr" rid="B23">2020</xref>). Based on studies, overexpression of RyRs contributed to Ca<sup>2+</sup> dysregulation in AD mouse models and cell lines. In addition, increase in IP3 receptor-mediated Ca<sup>2+</sup> signaling was indicated in AD patients&#x02019; fibroblast cells (Callens et al., <xref ref-type="bibr" rid="B21">2021</xref>). A&#x003B2; oligomer-dependent ER stress responses can subsequently activate different kinases which phosphorylate specific epitopes on tau leading to the development of neurofibrillary tangles (NFTs) and propagating AD pathology (Sprenkle et al., <xref ref-type="bibr" rid="B182">2017</xref>). A&#x003B2; peptides can activate ASK1 and JNK pathways, which can subsequently mediate ER stress-induced apoptosis (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). Both ASK1 and JNK were reported to be upregulated in transgenic mouse brains and post-mortem AD samples, respectively (Galvan et al., <xref ref-type="bibr" rid="B58">2007</xref>; Sbodio et al., <xref ref-type="bibr" rid="B173">2019</xref>). It has been revealed that CHOP activation plays a crucial role in the triggering and progression of pathological hallmarks of AD. In agreement, CHOP and its downstream effectors, including caspase-12 and GADD34, are markedly upregulated in the brains of AD patients (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). In addition, phosphorylated forms of PERK and eIF2&#x003B1; were significantly increased in the hippocampal pyramidal cells and frontal cortex of AD patients (Stutzbach et al., <xref ref-type="bibr" rid="B185">2013</xref>). The evidence also shows that ER chaperones, including BiP, are also upregulated in the cerebrospinal fluid (CSF) and AD brains (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>).</p>
<p>Mutations in PARK7, a gene involved in familial PD, might activate ASK1-induced neuronal death in PD. This can be due to the dysfunction in protecting against the Daxx-ASK1 cell death axis, which plays a key role in the completion of signaling pathways from cell surface death receptors (Chang et al., <xref ref-type="bibr" rid="B24">1998</xref>; Homma et al., <xref ref-type="bibr" rid="B88">2009</xref>). In addition, upregulation of ER stress markers, such as GRP78, p-PERK, and p-eIF2&#x003B1; in dopaminergic (DA) neurons of post-mortem PD samples (Shi et al., <xref ref-type="bibr" rid="B175">2022</xref>), demonstrate their function in initiating apoptosis pathways, which could cause serious clinical implications. According to evidence, upregulation in ER stress markers, including BiP and CHOP in post-mortem HD brains, may be associated with neuronal death in HD (Shi et al., <xref ref-type="bibr" rid="B175">2022</xref>). Mutation in genes such as SOD1, a gene encoding Superoxide dismutase 1 (SOD1), can also induce ER stress in neurons in ALS and cause neuronal damages (Sprenkle et al., <xref ref-type="bibr" rid="B182">2017</xref>). ALS-associated mutations in vesicle-associated membrane protein-associated protein B (VAPB) can physically interact with ATF6 and disturb its natural function (Hetz and Saxena, <xref ref-type="bibr" rid="B82">2017</xref>). Patients with ALS-associated VAPB mutations indicated malfunctions in Ca<sup>2+</sup> signaling and storage, excessive ER stress, and neuronal death as a result of inhibition of ATF6 (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>). Furthermore, upregulation of PERK, IRE1&#x003B1;, and ATF6 was found in the ALS mouse models (Ghemrawi and Khair, <xref ref-type="bibr" rid="B63">2020</xref>; Zhao et al., <xref ref-type="bibr" rid="B215">2022</xref>).</p>
</sec>
<sec id="s2-3">
<title>Targeting ER stress-induced apoptotic cell death</title>
<p>According to the critical role of ER stress in the occurrence of neuronal cell death in neurodegenerative diseases, targeting associated pathways seem to have hopeful effects on protecting neurons from death (<xref ref-type="fig" rid="F1">Figure 1</xref>). Among three arms of UPR in ER stress conditions, the PERK pathway is the most well-studied in the neuroprotective effects of inhibition of ER stress. In parallel with this, Salubrinal, an anti-ER stress compound, has been well investigated in neurodegenerative disease pathology and treatment (Gupta S. et al., <xref ref-type="bibr" rid="B74">2021</xref>; Ajoolabady et al., <xref ref-type="bibr" rid="B3">2022</xref>). Salubrinal is an activator of UPR, which raises ER chaperone levels, including BiP. It inhibits eIF2&#x003B1; dephosphorylation which can attenuate neuronal death by interfering with death-related signaling pathways, including ATF4 or ASK1 (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Niso-Santano et al., <xref ref-type="bibr" rid="B151">2011</xref>; Wu et al., <xref ref-type="bibr" rid="B204">2014</xref>; Sprenkle et al., <xref ref-type="bibr" rid="B182">2017</xref>). Accumulating evidence indicates that Salubrinal reduced ER accumulation of &#x003B1;-synuclein and significantly protected against &#x003B1;-synuclein-mediated dopaminergic (DA) neuronal death in transgenic mouse models (Colla et al., <xref ref-type="bibr" rid="B30">2012</xref>). Also, Salubrinal reduced the accumulation of mutant huntingtin (mHTT) by upregulation of BiP and p-eIF2&#x003B1;, and prevent neuronal cell death (Maity et al., <xref ref-type="bibr" rid="B134">2022</xref>). In addition, the drug Adaptaquin blocks Tribbles pseudokinase 3 (Trib3) induction by inhibiting ATF4 and CHOP activity probably through an eIF2&#x003B1;-independent mechanism, leading to neuronal protection in mouse models of PD (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). More investigation is required for the neuroprotective effects of Adaptaquin in ER stress-induced neuronal cell death (Karuppagounder et al., <xref ref-type="bibr" rid="B102">2016</xref>; Aime et al., <xref ref-type="bibr" rid="B2">2020</xref>). Moreover, the PKR inhibitor &#x0201C;C16&#x0201D; can reduce transcriptional induction of pro-apoptotic target genes of ATF4, such as CHOP, Trib3, and PUMA (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). This could significantly reduce MPP+ and 6-OHDA neurotoxin-induced neuronal cell death in PD models (Demmings et al., <xref ref-type="bibr" rid="B37">2021</xref>). According to the experimental study, PUMA expression can be downregulated by directly targeting CHOP to decrease ER stress-induced neuronal apoptosis (Galehdar et al., <xref ref-type="bibr" rid="B57">2010</xref>). Notably, pharmacological inhibition of ATF4, using imidazole-oxindole PKR inhibitor, indicated neuroprotection against neurotoxin-induced cell death in PD models (Demmings et al., <xref ref-type="bibr" rid="B37">2021</xref>). Comparing motor neuron death in ATF4-ablated transgenic ALS mouse models with those expressing normal levels of ATF4 demonstrated the possible role of ATF4 ablation in neuroprotection against ALS by reducing apoptosis components, including CHOP (Matus et al., <xref ref-type="bibr" rid="B141">2013</xref>). Likewise, another study revealed an increase in neuronal death in PD rat models by overexpression of ATF4 using recombinant Adeno-Associated Virus (rAAV; Gully et al., <xref ref-type="bibr" rid="B71">2016</xref>). Halliday et al. (<xref ref-type="bibr" rid="B77">2017</xref>) revealed the inhibition of UPR-induced p-eIF2&#x003B1; signaling and neuronal survival by two chemical compounds termed &#x0201C;Trazodone&#x0201D; and &#x0201C;dibenzoylmethane&#x0201D; (DBM) in prion-infected mice (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>), presumably by reversing translational attenuation and lowering levels of ATF4 and CHOP which needs to be more inquired in other neurodegenerative diseases including AD and PD. Interestingly, it has been demonstrated that PERK inhibitor GSK2606414 (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>), despite its pancreatic toxicity (Halliday et al., <xref ref-type="bibr" rid="B76">2015</xref>), inhibits and reduces PERK expression, which has a neuroprotective effect on DA neurons in Substantia Nigra pars compacta (SNpc) of PD mouse models, and improves the motor performance and neuronal excitability of PD mice (Mercado et al., <xref ref-type="bibr" rid="B144">2018</xref>). In addition, inhibition of PERK signaling with IRSIB has been investigated in ALS rodent models, and a reduction in ATF4 and CHOP levels has been indicated (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>), which results in significant neuronal survival. In the same study, a reduction in IRE1-dependent signaling has also been indicated (Halliday et al., <xref ref-type="bibr" rid="B76">2015</xref>, <xref ref-type="bibr" rid="B77">2017</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption><p>The function and target molecules of drugs tested in neurodegenerative disease models in different cellular stress conditions.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left"><bold>Condition</bold></th>
<th align="center"><bold>Drug name</bold></th>
<th align="center"><bold>Target Molecule(s)</bold></th>
<th align="center"><bold>Function</bold></th>
<th align="center"><bold>Reference</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">ER stress</td>
<td align="center">Salubrinal</td>
<td align="center">ATF4</td>
<td align="center">Inhibit transcription of apoptotic factors</td>
<td align="center">Kim et al. (<xref ref-type="bibr" rid="B001">2014</xref>) and Ghemrawi and Khair (<xref ref-type="bibr" rid="B63">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Salubrinal</td>
<td align="center">ASK1</td>
<td align="center">Prevent apoptosis by affecting downstream molecules of JNK/MAPK pathway</td>
<td align="center">Ghemrawi and Khair (<xref ref-type="bibr" rid="B63">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Adaptaquin</td>
<td align="center">ATF4</td>
<td align="center">Inhibit transcription of apoptotic factors</td>
<td align="center">Aime et al. (<xref ref-type="bibr" rid="B2">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">C16</td>
<td align="center">ATF4</td>
<td align="center">Inhibit transcription of apoptotic factorsreduce neuronal death caused by neurotoxins</td>
<td align="center">Demmings et al. (<xref ref-type="bibr" rid="B37">2021</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Trazodone</td>
<td align="center">p-eIF2&#x003B1;</td>
<td align="center">Decrease ATF4 levels</td>
<td align="center">Halliday et al. (<xref ref-type="bibr" rid="B77">2017</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Dibenzoylmethane</td>
<td align="center">p-eIF2&#x003B1;</td>
<td align="center">Decrease ATF4 levels</td>
<td align="center">Halliday et al. (<xref ref-type="bibr" rid="B77">2017</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">GSK2606414</td>
<td align="center">PERK</td>
<td align="center">Inhibit PERK pathway by preventing the phosphorylation of eIF2&#x003B1;</td>
<td align="center">Mercado et al. (<xref ref-type="bibr" rid="B144">2018</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">IRSIB</td>
<td align="center">PERK</td>
<td align="center">Reduce ATF4 and CHOP levels</td>
<td align="center">Halliday et al. (<xref ref-type="bibr" rid="B76">2015</xref>) and Halliday et al. (<xref ref-type="bibr" rid="B77">2017</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">KIRA6</td>
<td align="center">IRE1</td>
<td align="center">Break IRE1 oligomersinhibit RNase activity of IRE1</td>
<td align="center">Ghosh et al. (<xref ref-type="bibr" rid="B65">2014</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Kaempferol</td>
<td align="center">ATF6, IRE1, PERK, CHOP</td>
<td align="center">Reduce the expression of mentioned factors</td>
<td align="center">Abdullah and Ravanan (<xref ref-type="bibr" rid="B1">2018</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">DHCR24</td>
<td align="center">BiP, CHOP</td>
<td align="center">Reduce the expression of mentioned factorsattenuate apoptotic signaling pathways</td>
<td align="center">Lu X. et al. (<xref ref-type="bibr" rid="B129">2014</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">xestospongin C</td>
<td align="center">IP3R</td>
<td align="center">Regulate Ca2+ homeostasis</td>
<td align="center">Wang et al. (<xref ref-type="bibr" rid="B201">2019</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Ryanodine</td>
<td align="center">RyR</td>
<td align="center">Regulate Ca2+ homeostasis</td>
<td align="center">Adasme et al. (<xref ref-type="bibr" rid="B002">2015</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">4-Phenyl Butyric acid</td>
<td align="center">Unfolded protein</td>
<td align="center">Interaction between hydrophobic regions of the chaperone and hydrophobic regions of the unfolded protein</td>
<td align="center">Pao et al. (<xref ref-type="bibr" rid="B003">2021</xref>)</td>
</tr>
<tr>
<td align="left">Oxidative stress</td>
<td align="center">Humanin</td>
<td align="center">Pro-apoptotic Bcl-2 family</td>
<td align="center">Inhibit CytC and AIF release</td>
<td align="center">Ma and Liu (<xref ref-type="bibr" rid="B004">2018</xref>) and Hazafa et al. (<xref ref-type="bibr" rid="B80">2021</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">L-NAT</td>
<td align="center">Caspase</td>
<td align="center">Inhibit CytC and AIF releaseinhibit caspase activity</td>
<td align="center">Li et al. (<xref ref-type="bibr" rid="B005">2015</xref>) and Sirianni et al. (<xref ref-type="bibr" rid="B178">2015</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">NAS</td>
<td align="center">NA</td>
<td align="center">Increase antioxidant levels</td>
<td align="center">Yoo et al. (<xref ref-type="bibr" rid="B211">2017</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">CoQ10</td>
<td align="center">Mitochondrial permeability transition pore</td>
<td align="center">Inhibit CytC and AIF release</td>
<td align="center">Young et al. (<xref ref-type="bibr" rid="B006">2007</xref>) and Akanji et al. (<xref ref-type="bibr" rid="B4">2021</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Diphenyleneiodonium</td>
<td align="center">NADPH oxidase</td>
<td align="center">Inhibit ROS production by NOX activity</td>
<td align="center">Chocry and Leloup (<xref ref-type="bibr" rid="B007">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Apocynin</td>
<td align="center">NADPH oxidase</td>
<td align="center">Inhibit ROS production by NOX activity</td>
<td align="center">Chocry and Leloup (<xref ref-type="bibr" rid="B007">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">VAS2870</td>
<td align="center">NADPH oxidase</td>
<td align="center">Inhibit ROS production by NOX activity</td>
<td align="center">Chocry and Leloup (<xref ref-type="bibr" rid="B007">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Aucubin</td>
<td align="center">Nrf2</td>
<td align="center">Regulating mitochondrial membrane potential and decreasing ROS generation</td>
<td align="center">Wang et al. (<xref ref-type="bibr" rid="B008">2020</xref>) and Li Y. C. et al. (<xref ref-type="bibr" rid="B118">2021</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Salidroside</td>
<td align="center">Pro-apoptotic Bcl-2 family caspase</td>
<td align="center">Inhibit CytC and AIF release inhibit caspase activation</td>
<td align="center">Wang et al. (<xref ref-type="bibr" rid="B202">2015</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Borneol</td>
<td align="center">pro-apoptotic Bcl-2 family</td>
<td align="center">Inhibit Cyt C and AIF release</td>
<td align="center">Hur et al. (<xref ref-type="bibr" rid="B93">2013</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">[6]-Gingerol</td>
<td align="center">Free radicals</td>
<td align="center">Scavenge free radicals and decrease phospholipid peroxidation</td>
<td align="center">Lee et al. (<xref ref-type="bibr" rid="B114">2011</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Isoorientin</td>
<td align="center">GSK-3&#x003B2;</td>
<td align="center">Blocks GSK-3&#x003B2; <italic>via</italic> an ATP noncompetitive inhibition to attenuate tau hyperphosphorylation</td>
<td align="center">Liang et al. (<xref ref-type="bibr" rid="B009">2016</xref>)</td>
</tr>
<tr>
<td align="left">Neuroinflammation</td>
<td align="center">Rosmarinic acid</td>
<td align="center">miR-155-5p</td>
<td align="center">Attenuate inflammation by miR-155&#x02013;5p regulation</td>
<td align="center">Lv et al. (<xref ref-type="bibr" rid="B132">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Alpha1-antitrypsin</td>
<td align="center">Calpain</td>
<td align="center">Inhibit calpain activity</td>
<td align="center">Feng et al. (<xref ref-type="bibr" rid="B52">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Alpha1-antitrypsin</td>
<td align="center">NA</td>
<td align="center">Attenuate microglial inflammation</td>
<td align="center">Feng et al. (<xref ref-type="bibr" rid="B52">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Epigallocatechin-3-gallate</td>
<td align="center">NA</td>
<td align="center">Attenuate neuroinflammation</td>
<td align="center">Cheng C.-Y. et al. (<xref ref-type="bibr" rid="B28">2021</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Aucubin</td>
<td align="center">NF-&#x003BA;B, JNK, p38, and ERK</td>
<td align="center">Reduce phosphorylation levels of mentioned factors to decrease inflammatory factor overexpression</td>
<td align="center">Li Y. C. et al. (<xref ref-type="bibr" rid="B118">2021</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Hesperetin</td>
<td align="center">TLR4, NF-&#x003BA;B ERK, p38 MAPK</td>
<td align="center">Modulate TLR4/NF-&#x003BA;B signaling pathway downregulate the phosphorylation of ERK and p38 MAPK</td>
<td align="center">Jo et al. (<xref ref-type="bibr" rid="B0010">2019</xref>) and Muhammad et al. (<xref ref-type="bibr" rid="B148">2019</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">15d-PGJ2</td>
<td align="center">PPAR-<sub>&#x003B3;</sub></td>
<td align="center">Inhibit production of interleukins</td>
<td align="center">Xu et al. (<xref ref-type="bibr" rid="B208">2008</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Anakinra</td>
<td align="center">IL-1</td>
<td align="center">Inhibit pyroptosis mediated by IL-1&#x003B2;</td>
<td align="center">Wang et al. (<xref ref-type="bibr" rid="B201">2019</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">GW501516</td>
<td align="center">PPAR-&#x003B2;/&#x003B4;</td>
<td align="center">Attenuate NLRP3-mediated neuroinflammation</td>
<td align="center">Chen et al. (<xref ref-type="bibr" rid="B26">2019</xref>) and Altinoz et al. (<xref ref-type="bibr" rid="B0011">2021</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">MCC950</td>
<td align="center">NLRP3 inflammasome</td>
<td align="center">Inhibit inflammasome activation</td>
<td align="center">Gordon et al. (<xref ref-type="bibr" rid="B68">2018</xref>) and Deora et al. (<xref ref-type="bibr" rid="B0012">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Dihydromyricetin (DHM)</td>
<td align="center">NLRP3 inflammasome</td>
<td align="center">Inhibit inflammasome activation</td>
<td align="center">Feng et al. (<xref ref-type="bibr" rid="B51">2018</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Benzyl isothiocyanate (BITC)</td>
<td align="center">IL-1&#x003B2;, NLRP3 inflammasome</td>
<td align="center">Inhibition of IL-1&#x003B2; release and NLRP3 inflammasome</td>
<td align="center">Lee et al. (<xref ref-type="bibr" rid="B113">2016</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Dopamine</td>
<td align="center">Dopamine D1 receptor</td>
<td align="center">The binding of cAMP with NLRP3 and NLRP3 degradation</td>
<td align="center">Yan et al. (<xref ref-type="bibr" rid="B209">2015</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Baicalein</td>
<td align="center">NLRP3 inflammasome, Caspase</td>
<td align="center">Decreasing pro-inflammatory cytokines production</td>
<td align="center">Rui et al. (<xref ref-type="bibr" rid="B170">2020</xref>)</td>
</tr>
<tr>
<td/>
<td align="center">Resveratrol</td>
<td align="center">NF-&#x003BA;B</td>
<td align="center">Decrease phosphorylation of NF-&#x003BA;B Inhibit microglial activation</td>
<td align="center">(Zhong et al. (<xref ref-type="bibr" rid="B217">2012</xref>), Zhang et al. (<xref ref-type="bibr" rid="B214">2017</xref>), and Huang et al. (<xref ref-type="bibr" rid="B0013">2021</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Inhibition of the IRE1 pathway is also a possible way to attenuate neuronal cell death. For instance, Kinase-Inhibiting RNase Attenuator 6 (KIRA6) inhibits apoptosis by breaking IRE1 oligomers and inhibiting RNase activity of IRE1&#x003B1; (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Ghosh et al., <xref ref-type="bibr" rid="B65">2014</xref>). Given the vital role of ASK1 in IRE1-mediated UPR and inducing apoptosis, targeting and deletion of ASK1 in mutant SOD1-transgenic mice have been indicated to mitigate motor neuronal death (Homma et al., <xref ref-type="bibr" rid="B88">2009</xref>). Additionally, evidence shows that overexpression of XBP1 protects DA neurons against neurotoxin-induced ER Stress-associated cell death (Valdes et al., <xref ref-type="bibr" rid="B195">2014</xref>; Shi et al., <xref ref-type="bibr" rid="B175">2022</xref>). Furthermore, upregulation of autophagy by targeting XBP1 in ALS and HD models is known to be another way of protection from neuronal cell death (Remondelli and Renna, <xref ref-type="bibr" rid="B166">2017</xref>). The experiments have been demonstrated that ablation of ATF6 facilitates DA neuronal death caused by neurotoxins, including 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-pyridinium (MPP+; Shi et al., <xref ref-type="bibr" rid="B175">2022</xref>). This indicates the plausible role of the third arm of UPR pathways in inducing neuronal death. Kaempferol (<xref ref-type="table" rid="T2">Table 2</xref>), a plant-derived ER stress-induced cell death inhibitor, has also reduced the expression of ATF6, PERK, IRE1&#x003B1;, as well as CHOP in Brefeldin A (BFA)-induced ER stress in IMR32 cell lines. More investigations is needed to determine whether it is effective in animal and human neurodegenerative models (Abdullah and Ravanan, <xref ref-type="bibr" rid="B1">2018</xref>). It is also claimed that 3&#x003B2;-Hydroxysteroid-&#x00394;24 reductase (DHCR24) can protect neuronal cells by reducing BiP and CHOP levels and attenuating ER stress-specific apoptotic signaling pathways (<xref ref-type="table" rid="T2">Table 2</xref>; Lu X. et al., <xref ref-type="bibr" rid="B129">2014</xref>). Targeting other indirect factors involved in ER stress, such as IP3 receptors and Ryanodine receptors, has also been examined. Remarkably, the first research confirming blocking Inositole triphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) to decrease ER stress-induced Ca<sup>2+</sup> dyshomeostasis in DA neurons revealed that a RyRs blocker (RY) markedly reduced 6-OHDA-induced cytosolic Ca<sup>2+</sup> increases. In contrast, an IP3Rs blocker (Xes) had no considerable effect on cytosolic Ca<sup>2+</sup> levels and neuronal cell death (<xref ref-type="table" rid="T2">Table 2</xref>). Moreover, pre-treatment with an ER stress inhibitor 4-phenyl butyric acid (4-PBA) had a neuroprotective effect on DA neurons from 6-OHDA-induced apoptosis (<xref ref-type="table" rid="T2">Table 2</xref>; Huang et al., <xref ref-type="bibr" rid="B90">2017</xref>).</p>
</sec>
</sec>
<sec id="s3">
<title>Oxidative stress-induced apoptotic cell death in neurodegenerative diseases</title>
<sec id="s3-1">
<title>Mechanism of oxidative stress-induced apoptotic cell death</title>
<p>Healthy mitochondria produce ROS as a byproduct of oxidative phosphorylation mainly as signaling messengers (Hajam et al., <xref ref-type="bibr" rid="B75">2022</xref>; Trushina et al., <xref ref-type="bibr" rid="B194">2022</xref>), while defective mitochondria generate aberrant amounts of ROS and cause oxidative stress and suspend cellular homeostasis due to the disruption of the balance between ROS generation and antioxidant function (<xref ref-type="fig" rid="F2">Figure 2</xref>; H&#x000F6;hn et al., <xref ref-type="bibr" rid="B86">2020</xref>; Holubiec et al., <xref ref-type="bibr" rid="B87">2022</xref>). Neurons are susceptible to produce free radicals due to being metabolically very active. Evidently, any pathological situation or dysfunction in neurons can generate excess ROS leading to oxidative stress (Bhat et al., <xref ref-type="bibr" rid="B16">2015</xref>). Given that the metabolism rate of neurons is very high, the brain has a high oxygen consumption rate (20%&#x02013;25% of the total body oxygen consumption). Furthermore, the high content of easily peroxidizable unsaturated fatty acids (PUFA) and the relative paucity of antioxidant enzymes compared with other organs makes the brain vulnerable to free radical damage (Nunomura et al., <xref ref-type="bibr" rid="B152">2007</xref>; Rocha et al., <xref ref-type="bibr" rid="B168">2018</xref>). Therefore, the excessive production of ROS and RNS resulting from various factors, including calcium influx and mitochondrial dysfunction, can compromise cell fidelity and exacerbate disease progression. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), superoxide anion (O<sub>2</sub><sup>&#x02212;</sup>), and highly reactive hydroxyl radical (HO<sup>&#x02022;</sup>) are the ROS involved in neurodegeneration. The RNS, such as nitric oxide (NO), are also found to have a deleterious effect on neurons (Singh et al., <xref ref-type="bibr" rid="B177">2019</xref>; Korovesis et al., <xref ref-type="bibr" rid="B106">2023</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p>Cause and consequences of ROS production in the CNS and the neuroprotective effects of inhibitory factors (shown in yellow box).</p></caption>
<graphic xlink:href="fncel-17-1105247-g0002.tif"/>
</fig>
<p>ROS adversely affects the oxidation or peroxidation of specific macromolecules such as lipid peroxidation to malondialdehyde (MDA), protein carbonylation, and oxidation of specific nucleic acids (Singh et al., <xref ref-type="bibr" rid="B177">2019</xref>). It has been claimed that ROS allows Cyt C and AIF to be released from the inner mitochondrial membrane (IMM) and initiate an apoptotic cascade (<xref ref-type="fig" rid="F2">Figure 2</xref>; Bhat et al., <xref ref-type="bibr" rid="B16">2015</xref>). The neural brain cells are enriched in PUFA, such as docosahexaenoic acid, arachidonic acid, and cardiolipin, which makes cells susceptible to lipid peroxidation and subsequent outcomes (H&#x000F6;hn et al., <xref ref-type="bibr" rid="B86">2020</xref>; Falabella et al., <xref ref-type="bibr" rid="B50">2021</xref>). For example, Cardiolipin (CL), a specific phospholipid of IMM, located in the sites of ROS production in the mitochondrial electron transport chain, can potentially be a target for ROS due to its high composition of unsaturated acyl chains. After peroxidation by ROS, CL is supposed to be involved in the conformational changes in IMM and the release of pro-apoptotic proteins, including Cyt C (Bhat et al., <xref ref-type="bibr" rid="B16">2015</xref>; Falabella et al., <xref ref-type="bibr" rid="B50">2021</xref>). However, a serine protease called HTRA2 takes part in the inhibition of pro-apoptotic protein release from mitochondria, but its function may not be sufficient, or it may be disturbed (Bhat et al., <xref ref-type="bibr" rid="B16">2015</xref>). Moreover, the brain is also enriched in redox-active metals (copper and iron) that involve in generating free radicals and peroxidation of lipids (Sbodio et al., <xref ref-type="bibr" rid="B173">2019</xref>; Falabella et al., <xref ref-type="bibr" rid="B50">2021</xref>). These metals could be reduced by proteins such as A&#x003B2;, which leads to the formation of H<sub>2</sub>O<sub>2</sub> and pro-apoptotic lipid peroxidation (LPO) products, such as 4-hydroxy-2-nonenal (HNE; Opazo et al., <xref ref-type="bibr" rid="B154">2002</xref>; Jiang et al., <xref ref-type="bibr" rid="B96">2009</xref>). In addition to the role of HNE in decreasing antioxidant levels by reacting with sulfhydryl groups (Taso et al., <xref ref-type="bibr" rid="B190">2019</xref>), HNE forms stable adducts with amine or thiol groups in proteins and may eventually anomalously activate caspases and triggers neuronal cell death (<xref ref-type="fig" rid="F2">Figure 2</xref>; Gaschler and Stockwell, <xref ref-type="bibr" rid="B59">2017</xref>; Barrera et al., <xref ref-type="bibr" rid="B13">2018</xref>). It has been demonstrated that Cadmium (Cd) could easily penetrate the blood-brain barrier and contribute to neurotoxicity. Cd can induce mitochondrial ROS production in neurons as well as downregulation of x-linked inhibitor of apoptosis (XIAP), leading to an increase in mouse double minute 2 (MDM2). Consequently, decrease in p53 facilitates neuronal apoptosis cell death (<xref ref-type="fig" rid="F2">Figure 2</xref>; Zhao et al., <xref ref-type="bibr" rid="B216">2020</xref>).</p>
<p>ROS can influence protein oxidation and contribute to the formation of insoluble protein aggregates (<xref ref-type="fig" rid="F2">Figure 2</xref>), including A&#x003B2; peptides and NFTs, &#x003B1;-synuclein, and mSOD1. Oxidative stress can enhance expression of gamma-secretase and beta-secretase (BACE1) through activation of MAPK pathway and involves in A&#x003B2; production in neurons and amyloidogenic processing of amyloid precursor protein (APP; Tamagno et al., <xref ref-type="bibr" rid="B188">2005</xref>; Lin and Beal, <xref ref-type="bibr" rid="B122">2006</xref>; H&#x000F6;hn et al., <xref ref-type="bibr" rid="B86">2020</xref>). Oxidative stress also increases tau phosphorylation by activation of glycogen synthase kinase 3 (GSK3; Lin and Beal, <xref ref-type="bibr" rid="B122">2006</xref>). ROS also mediate JNK/stress-activated protein kinase pathways, which subsequently contributes to hyper-phosphorylation of tau proteins, formation of intracellular NFTs, and A&#x003B2;-induced neuronal death (Liu et al., <xref ref-type="bibr" rid="B125">2017</xref>). Indeed, hydrogen peroxide and deficiency of mitochondrial antioxidant enzymes has been tested in animal models, which led to increase in A&#x003B2; levels (Gerakis and Hetz, <xref ref-type="bibr" rid="B62">2019</xref>) and neuronal cell death (Lin and Beal, <xref ref-type="bibr" rid="B122">2006</xref>). Interestingly, it has been revealed that neurons close to A&#x003B2;-plaques seem to be more at risk of cell death due to more severe toxicity of the microenvironment caused by oxidative stress in AD (Xie et al., <xref ref-type="bibr" rid="B207">2013</xref>). A&#x003B2;-mediated oxidative stress can enhance the activity of a serine/threonine phosphatase, known as calcineurin, and promotes neuronal death by associating with caspases and/or triggering pro-apoptotic Bcl-2 proteins (<xref ref-type="fig" rid="F2">Figure 2</xref>; Awasthi et al., <xref ref-type="bibr" rid="B10">2005</xref>; Akanji et al., <xref ref-type="bibr" rid="B4">2021</xref>). Moreover, ROS can have noxious effects by affecting Ca<sup>2+</sup> cation channels on the ER and plasma membrane. Impaired Ca<sup>2+</sup> channels can, in turn, lead to Ca<sup>2+</sup> influx to the cytosol, as well as impairment in pumping intracellular Ca<sup>2+</sup> out of the cell to maintain homeostasis (Brini et al., <xref ref-type="bibr" rid="B20">2014</xref>). Toxic levels of calcium can trigger cell death through activation of apoptotic factors, including calcium-dependent proteases calpain and caspases (<xref ref-type="fig" rid="F2">Figure 2</xref>; Fairless et al., <xref ref-type="bibr" rid="B49">2014</xref>). Importantly, ROS has also a deleterious effect on nuclear factor erythroid 2-related factor 2 (Nrf2) regulation. Nrf2 is a transcription factor that has an essential role in regulating cellular redox homeostasis (Kovac et al., <xref ref-type="bibr" rid="B107">2015</xref>). Reduced levels of Nrf2 can subsequently result in mitochondrial dysfunction and apoptosis. Therefore, upregulation of Nrf2 reduces oxidative stress by promoting the expression of antioxidant enzymes (<xref ref-type="fig" rid="F2">Figure 2</xref>; Li Y. C. et al., <xref ref-type="bibr" rid="B118">2021</xref>). Besides, the Repressor element 1-silencing transcription factor (REST) regulates cell death-associated genes, including BAX, BH3 interacting domain death agonist (BID), and also PUMA, and maintains resistance to stress conditions. REST-depleted neurons are more susceptible to oxidative stress and anomalously express apoptosis-inducing genes which facilitates neuronal death in AD (Lu T. et al., <xref ref-type="bibr" rid="B128">2014</xref>). Remarkably, upregulation of the transient receptor potential melastatin-2 (TRPM2) in the SNpc of human PD brains agrees with the role of TRPM2 in ROS-induced cell death in PD pathogenesis (Malko et al., <xref ref-type="bibr" rid="B135">2021</xref>). The function of Parkin can be affected by mitochondrial dysfunction and oxidative stress. This will promote Cyt C release and caspase-9 activation, which leads to neuronal cell death and facilitating PD pathogenesis (<xref ref-type="fig" rid="F2">Figure 2</xref>; Lin and Beal, <xref ref-type="bibr" rid="B122">2006</xref>). Defect in Complex I of the mitochondrial electron transport chain by aggregation of &#x003B1;-synuclein and PTEN-induced putative kinase 1 (PINK1) mutations can be also involved in PD pathogenesis by inducing neuronal apoptosis and failure in maintaining mitochondrial membrane potential, respectively (Liu et al., <xref ref-type="bibr" rid="B125">2017</xref>; Morales-Mart&#x000ED;nez et al., <xref ref-type="bibr" rid="B147">2022</xref>).</p>
</sec>
<sec id="s3-2">
<title>Oxidative stress-associated alterations of apoptotic factors</title>
<p>Besides the oxidation of macromolecules is elevated in the brain of patients, decreased levels of antioxidants, including uric acid, vitamin C and E, superoxide dismutase (SOD), catalase, and especially the antioxidant glutathione (GSH), lead to decreased detoxification of ROS in the brain cells which has been discovered in various AD, PD, and other neurodegenerative disease patients (Singh et al., <xref ref-type="bibr" rid="B177">2019</xref>). Oxidative damage occurs before the onset of significant plaque pathology in the AD by triggering glycogen synthase kinase 3 (Lin and Beal, <xref ref-type="bibr" rid="B122">2006</xref>; Wu et al., <xref ref-type="bibr" rid="B206">2019</xref>). Overproduction of ROS and RNS in AD patients has been detected. Additionally, 8-hydroxydeoxyguanosine (8-OHdG), a biomarker of oxidative damage, was elevated in AD ventricular CSF (Niedzielska et al., <xref ref-type="bibr" rid="B150">2016</xref>). However, alterations in plasma levels of antioxidants in AD patients are paradoxical in experimental reports (Niedzielska et al., <xref ref-type="bibr" rid="B150">2016</xref>). A&#x003B2; plaques can cause Ca<sup>2+</sup> dyshomeostasis in ER leading to Ca<sup>2+</sup> influx in the cytosol. Consequently, endogenous GSH levels are reduced, and ROS can cause neurotoxic effects (Liu et al., <xref ref-type="bibr" rid="B125">2017</xref>). The alterations of transition metals, including Cu<sup>2+</sup>, Zn<sup>2+</sup>, Fe<sup>3+</sup>, have been assessed in AD samples. The results indicated that transition metals seem to be imbalanced in AD brains which contributed to oxidative damage and subsequent neuronal death (Bhat et al., <xref ref-type="bibr" rid="B16">2015</xref>). Evidence also shows reduction in nuclear REST levels in neurons of degenerated regions in AD brains, such as prefrontal cortical and hippocampal neurons, which transcriptional dysregulation in apoptotic genes and vulnerability to oxidative stress has made them susceptible to apoptosis cell death (Lu T. et al., <xref ref-type="bibr" rid="B128">2014</xref>). Elevated levels of activated JNK have been reported in post-mortem AD samples, which is probably associated with A&#x003B2; formation. JNK implicates in the upregulation of BACE1 and promotes the formation of A&#x003B2;, leading to oxidative stress and neuronal apoptosis cell death (Yao et al., <xref ref-type="bibr" rid="B210">2005</xref>; Guglielmotto et al., <xref ref-type="bibr" rid="B70">2011</xref>; Sbodio et al., <xref ref-type="bibr" rid="B173">2019</xref>).</p>
<p>HNE levels were significantly high in the CSF of AD and PD patients, which can be considered as an important reason for neuronal demise and behavioral symptoms in neurodegenerative diseases (Taso et al., <xref ref-type="bibr" rid="B190">2019</xref>). Decreased level of GSH in the Substantia Nigra (SN) of PD patients is one of the earliest biochemical alterations that facilitate the neurotoxic effects of ROS (Niedzielska et al., <xref ref-type="bibr" rid="B150">2016</xref>). Moreover, overexpression of &#x003B1;-synuclein in transgenic mice results in mitochondrial dysfunction and increased oxidative stress (Song et al., <xref ref-type="bibr" rid="B180">2004</xref>). It has been observed that aberrant activity of mutant human SOD1 in ALS patients leads to increase in the level of free radicals in CSF, serum, and urine samples of ALS patients, which exacerbates neuronal damage (Liu and Wang, <xref ref-type="bibr" rid="B123">2017</xref>). Indeed, mSOD1 accumulation in outer mitochondrial membrane (OMM) can result in mitochondrial dysfunction and promotes aberrant ROS production. In an experimental study, mice expressing mSOD1 showed more oxidative damage to mitochondrial lipids and molecules (Mattiazzi et al., <xref ref-type="bibr" rid="B140">2002</xref>; Liu et al., <xref ref-type="bibr" rid="B124">2004</xref>). P53 can regulate genes involved in oxidative stress and mitochondrial function. Environmental toxicants such as bisphenol A (BPA) play a role in inducing neurotoxicity by significantly increased oxidative stress. BPA subsequently leads to upregulation in apoptotic inducing factors, including p53, PUMA, and Drp-1 (Ishtiaq et al., <xref ref-type="bibr" rid="B95">2021</xref>). Additionally, in Huntington&#x02019;s disease pathology, mHTT can interact with p53 and increase p53 levels, and eventually upregulates apoptotic factors BAX and PUMA, which leads to apoptosis (Bae et al., <xref ref-type="bibr" rid="B12">2005</xref>; Lin and Beal, <xref ref-type="bibr" rid="B122">2006</xref>). mHTT also interacts with mitochondrial membranes, causing mitochondrial abnormalities and an increase in ROS generation, which potentially leads to neuronal degeneration and cell death (Ross and Tabrizi, <xref ref-type="bibr" rid="B169">2011</xref>; Liu et al., <xref ref-type="bibr" rid="B125">2017</xref>). Elevated levels of lipid peroxidation and decreased levels of GSH content have been indicated in the plasma of HD patients (Klepac et al., <xref ref-type="bibr" rid="B105">2007</xref>). In addition, increased levels of 8-OHdG have been observed in the serum of HD patients and post-mortem HD samples (Sbodio et al., <xref ref-type="bibr" rid="B173">2019</xref>).</p>
</sec>
<sec id="s3-3">
<title>Targeting oxidative stress-induced apoptosis cell death</title>
<p>Undoubtedly, oxidative stress has neurotoxic effects in the pathogenesis of neurodegenerative diseases. However, the exact molecular pathways remain unclear and need to be more inquired about finding a promising therapeutic strategy to decrease neuronal death in neurodegenerative diseases and extend the lifespan of patients. In this regard, the antioxidant properties of many candidate compounds have been reported. In addition, many other molecules that mediate oxidative stress-induced apoptosis have been targeted to prevent neuronal cell death and disease progression (<xref ref-type="fig" rid="F2">Figure 2</xref>). A cytoprotective polypeptide called Humanin (HN), which is encoded by mtDNA, has neuroprotective activity against cellular stress conditions, such as oxidative stress. HN regulates mitochondrial function by targeting apoptotic factors and inhibits apoptosis by upregulation of Bcl-2 and downregulation of Bid and Bax (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Hazafa et al., <xref ref-type="bibr" rid="B80">2021</xref>). Also, some amino acid derivatives have shown anti-apoptotic effects in ALS models <italic>in vitro</italic> (Sirianni et al., <xref ref-type="bibr" rid="B178">2015</xref>). N-acetyl-L-tryptophan (L-NAT) and N-acetyl-DL-tryptophan (DL-NAT) have inhibited neuronal cell death in H<sub>2</sub>O<sub>2</sub>-induced NSC-34 motor neurons (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). L-NAT inhibits the release of Cyt C/Smac/AIF from mitochondria, as well as inhibition of caspase activity, thereby preventing neuronal apoptosis cell death (Sirianni et al., <xref ref-type="bibr" rid="B178">2015</xref>). Another study by Yoo et al. (<xref ref-type="bibr" rid="B211">2017</xref>) showed that N-acetyl serotonin (NAS) has anti-apoptotic properties by activating neurotrophic signaling TrkB/CREB/BDNF pathways. NAS induces and activates the expression of antioxidant enzymes to reduce the level of ROS (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). It also regulates anti- and pro-apoptotic factors and restores mitochondrial membrane potential to prevent neuronal cell death in neurodegenerative disease models (Yoo et al., <xref ref-type="bibr" rid="B211">2017</xref>). According to evidence, mitochondrial permeability transition pore (mPTP) can increase mitochondrial calcium retention and cause cell death. CoQ10 is considered as an inhibitor of mitochondrial permeability transition pore and protects neurons from oxidative stress and apoptosis. The exact protective mechanism of CoQ10 is still indistinct and needs more experiments. CoQ10 may decrease apoptosis by maintaining the integrity of the mitochondrial membrane and inhibiting Cyt C release. CoQ10 may also decrease the Bcl-2 protein level and prevent caspase activation (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Akanji et al., <xref ref-type="bibr" rid="B4">2021</xref>). As previously mentioned, protein aggregates can potentially induce oxidative stress in neuronal cells. For instance, A&#x003B2; can interact and bind to A&#x003B2;-binding alcohol dehydrogenase (ABAD), a mitochondrial-matrix protein, and induce apoptosis and free-radical generation. Blocking the interaction of A&#x003B2; and ABAD with a &#x0201C;decoy peptide&#x0201D; suppress oxidative stress and neuronal death. In contrast overexpression of ABAD in mouse models contribute to exaggerating cellular stress and further complications (Lustbader et al., <xref ref-type="bibr" rid="B130">2004</xref>). Moreover, NADPH oxidase (NOX) catalyzes the formation of O<sub>2</sub><sup>&#x02212;</sup> and participates in elevating neurotoxicity and increasing cell death in HD. Treatment of HD models with NOX inhibitors, including diphenyleneiodonium, apocynin, and VAS2870, prevented neurons from cell death (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Sbodio et al., <xref ref-type="bibr" rid="B173">2019</xref>).</p>
<p>In several studies, it has been reported that plant iridoids have therapeutic applications in several neurodegenerative diseases by regulating apoptotic factors and neuroprotective proteins (Dinda et al., <xref ref-type="bibr" rid="B40">2019</xref>). Aucubin (AU) is an iridoid glycoside with neuroprotective properties, which significantly increases cell viability in neurons via oxidative stress reduction. AU enhances the antioxidant capacity of cells through the Nrf2 signaling pathway and decreases ROS-induced neuronal apoptosis by regulating mitochondrial membrane potential and reducing ROS generation (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Li Y. C. et al., <xref ref-type="bibr" rid="B118">2021</xref>). The pharmacological effects of other herbal compounds have also been investigated. Salidroside (Sald), is a Chinese plant-derivative compound that could detoxify neurons by suppressing the elevation of the intracellular ROS level and induction of antioxidant enzymes. Sald also participates in the downregulation of pro-apoptotic protein Bax and upregulation of anti-apoptotic protein Bcl-xl, and prevents neuronal cell death (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Zhang et al., <xref ref-type="bibr" rid="B213">2010</xref>). Some plant-derived organic oils, including a bicyclic monoterpene termed &#x0201C;Borneol&#x0201D;, indicated neuroprotective effects against H<sub>2</sub>O<sub>2</sub>-induced apoptosis <italic>in vitro</italic>. Borneol alleviates neuronal apoptosis by inhibiting Cyt C and AIF release through increase in the expression of anti-apoptotic protein Bcl-2 and decrease in expression of pro-apoptotic protein Bax (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Hur et al., <xref ref-type="bibr" rid="B93">2013</xref>). -gingerol also attenuates A&#x003B2;-induced oxidative stress. Studies revealed that -gingerol scavenges free radicals and decreases phospholipid peroxidation, as well as improves cellular redox balance (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Lee et al., <xref ref-type="bibr" rid="B114">2011</xref>). Increase in the activity of glycogen synthase kinase-3&#x003B2; (GSK-3&#x003B2;) under oxidative stress condition leads to Nrf2 dysregulation (Kumar et al., <xref ref-type="bibr" rid="B109">2012</xref>). Thus, GSK-3&#x003B2; inhibitors, including an anti-oxidative phytochemical known as Isoorientin, can have neuroprotection against oxidative damage by regulating Nrf2 antioxidant activity (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Lim et al., <xref ref-type="bibr" rid="B121">2007</xref>; Gianferrara et al., <xref ref-type="bibr" rid="B66">2022</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>Neuroinflammation-induced cell death in neurodegenerative diseases</title>
<sec id="s4-1">
<title>Mechanism of neuroinflammation-induced cell death</title>
<p>Research findings have indicated that several neurodegenerative diseases are associated with inflammation (Kwon and Koh, <xref ref-type="bibr" rid="B110">2020</xref>). Activated microglia and T lymphocytes have been detected in the SN of PD patients (Dias et al., <xref ref-type="bibr" rid="B39">2013</xref>). In parallel with this, high expression levels of chemokines, interleukins, interferons, and tumor necrosis factor-&#x003B1; (TNF-&#x003B1;) have been discovered in the striatum and substantia nigra of PD post-mortem brain samples and CSF of AD patients (Hirsch and Hunot, <xref ref-type="bibr" rid="B84">2009</xref>; Llano et al., <xref ref-type="bibr" rid="B126">2012</xref>; Gelders et al., <xref ref-type="bibr" rid="B61">2018</xref>). A neurotoxic microenvironment can be promoted by the continuous secretion of inflammatory mediators from microglia and astrocytes, thus facilitating neural degeneration, and glial cell death (Pardillo-D&#x000ED;az et al., <xref ref-type="bibr" rid="B157">2022</xref>; Song et al., <xref ref-type="bibr" rid="B181">2022</xref>). In addition to apoptosis cell death, pyroptosis, a non-apoptotic programed cell death, can also occur in the CNS, which is mainly mediated by inflammatory processes. Pyroptosis is characterized by cell swelling, formation of pores in the plasma membrane carried out by cleaved Gasdermin D, and the release of pro-inflammatory cytosolic contents into the extracellular space (<xref ref-type="fig" rid="F3">Figure 3</xref>; Walle and Lamkanfi, <xref ref-type="bibr" rid="B199">2016</xref>; Man et al., <xref ref-type="bibr" rid="B136">2017</xref>; Wang et al., <xref ref-type="bibr" rid="B201">2019</xref>). Besides, some specific caspases, including caspase-1, 4, 5, 11, are called &#x0201C;inflammatory caspases&#x0201D;, can mediate pyroptosis (Taylor et al., <xref ref-type="bibr" rid="B191">2008</xref>; Gaidt and Hornung, <xref ref-type="bibr" rid="B56">2016</xref>). Some factors are associated with initiation of inflammatory cascades and promotion of disease pathology. For instance, ER stress can cause inflammation in neurodegenerative diseases. In other words, inducing ER stress in neurons mostly initiates apoptosis, whereas intense ER stress in glial cells can potentially trigger inflammation in neurodegenerative diseases (Sprenkle et al., <xref ref-type="bibr" rid="B182">2017</xref>). The UPR can increase the production and the release of inflammatory factors, such as transcription factor &#x0201C;nuclear factor kappa-light-chain-enhancer of activated B cells&#x0201D; (NF-&#x003BA;B), interleukin 1 (IL-1), IL-6, IL-8, and TNF-&#x003B1; (Feng et al., <xref ref-type="bibr" rid="B53">2017</xref>). Furthermore, in ER stress condition, p-IRE1 can bind to the TRAF-2 protein and forms the TRAF2-IRE1 complex. The complex may bind to ASK-1 and activate the JNK signaling pathway that enhances inflammation (Vukic et al., <xref ref-type="bibr" rid="B198">2009</xref>; Mohammed-Ali et al., <xref ref-type="bibr" rid="B146">2015</xref>). In addition, p-PERK also facilitates neuroinflammation by inducing the JAK1/STAT3 signaling pathway in glial cells (Meares et al., <xref ref-type="bibr" rid="B143">2014</xref>). Moreover, neuroinflammation is a cause and a consequence of chronic oxidative stress. Studies indicate that the production of free radicals (such as ROS) are elevated in neurodegenerative diseases, which can be due to neuroinflammation (Dias et al., <xref ref-type="bibr" rid="B39">2013</xref>; Gonz&#x000E1;lez-reyes et al., <xref ref-type="bibr" rid="B67">2017</xref>). On the other hand, increased levels of ROS can contribute to pro-inflammatory gene transcription and release of cytokines, including IL-1, IL-6, and TNF-&#x003B1; (Sochocka et al., <xref ref-type="bibr" rid="B179">2013</xref>; Teleanu et al., <xref ref-type="bibr" rid="B192">2022</xref>). Debris of dead neurons may trigger glia-mediated neuroinflammation and initiate a pro-inflammatory cascade that can exacerbate disease progression (Wang et al., <xref ref-type="bibr" rid="B202">2015</xref>; Joshi et al., <xref ref-type="bibr" rid="B99">2019</xref>). Recently, it was revealed that microglial pro-inflammatory cytokines are associated with increased &#x003B1;-synuclein aggregation (Guo et al., <xref ref-type="bibr" rid="B72">2020</xref>). Thereby, protein aggregates can be involved in inducing neuroinflammation in the CNS parenchyma.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p>The possible role of inhibiting inflammatory factors to attenuate neuroinflammation-induced neuronal cell death.</p></caption>
<graphic xlink:href="fncel-17-1105247-g0003.tif"/>
</fig>
<p>It has been investigated that the failure to clear apoptotic cells and activation of glial cells by DAMPs and PAMPs can enhance inflammation response and subsequent neuronal damage and loss (Imbeault et al., <xref ref-type="bibr" rid="B94">2014</xref>; Salter and Stevens, <xref ref-type="bibr" rid="B172">2017</xref>; Voet et al., <xref ref-type="bibr" rid="B197">2019</xref>; Cheng Y. et al., <xref ref-type="bibr" rid="B29">2021</xref>). Activation of complex signaling cascades such as the NLR family pyrin domain containing 3 (NLRP3) inflammasome can be triggered by a wide range of factors including cellular stress, infection (Bader and Winklhofer, <xref ref-type="bibr" rid="B11">2020</xref>; Mahboubi Mehrabani et al., <xref ref-type="bibr" rid="B133">2022</xref>), protein aggregates, and activated microglia (Nichols et al., <xref ref-type="bibr" rid="B149">2019</xref>; Bader and Winklhofer, <xref ref-type="bibr" rid="B11">2020</xref>; Tansey et al., <xref ref-type="bibr" rid="B189">2022</xref>). This phenomenon contributes to producing more neurotoxic cytokines and chemokines such as IL-1&#x003B2;, IL-6, TNF-&#x003B1;, and CCL2 (also known as monocyte chemo-attractant protein-1 or MCP-1), that cause enhancement in neurotoxicity and cell death (Sprenkle et al., <xref ref-type="bibr" rid="B182">2017</xref>; Rocha et al., <xref ref-type="bibr" rid="B168">2018</xref>; Joshi et al., <xref ref-type="bibr" rid="B99">2019</xref>; Nichols et al., <xref ref-type="bibr" rid="B149">2019</xref>). The exact mechanism of neuronal death through activation of NLRP3 inflammasome in microglia has not been perfectly discovered yet (Lee et al., <xref ref-type="bibr" rid="B115">2019</xref>). In fact, NLRP3 inflammasome induces heteromer formation or aggregation of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which subsequently activates caspase-1. It results in the maturation of IL-1&#x003B2; and induction of pyroptosis using cleaved Gasdermin D and membrane pores (<xref ref-type="fig" rid="F3">Figure 3</xref>; Stancu et al., <xref ref-type="bibr" rid="B183">2019</xref>; Wang et al., <xref ref-type="bibr" rid="B201">2019</xref>; Bader and Winklhofer, <xref ref-type="bibr" rid="B11">2020</xref>; Feng et al., <xref ref-type="bibr" rid="B52">2020</xref>; Onyango et al., <xref ref-type="bibr" rid="B153">2021</xref>).</p>
<p>Specific receptors, including TLRs and NLRs expressing on neurons or neuroglia, can recognize extracellular neurotoxic protein aggregates (Nichols et al., <xref ref-type="bibr" rid="B149">2019</xref>; Leng and Edison, <xref ref-type="bibr" rid="B116">2021</xref>; Heidari et al., <xref ref-type="bibr" rid="B81">2022</xref>). This may facilitate neuronal cell death (Li Y. et al., <xref ref-type="bibr" rid="B120">2021</xref>) by involvement in caspase activation and secretion of pro-inflammatory factors through NF-&#x003BA;B activation (<xref ref-type="fig" rid="F3">Figure 3</xref>; Rocha et al., <xref ref-type="bibr" rid="B168">2018</xref>; Leng and Edison, <xref ref-type="bibr" rid="B116">2021</xref>). The expression of the receptors for cytokines was indicated in DA neurons, making neurons more susceptible to damage and death (Hirsch and Hunot, <xref ref-type="bibr" rid="B84">2009</xref>). Complement receptors and Fc receptors on microglia can also mediate pro-inflammatory responses independent from extracellular protein aggregates (Leng and Edison, <xref ref-type="bibr" rid="B116">2021</xref>). Activation of microglia can potentially contribute to activating astrocytes, which rapidly upregulates inflammatory signaling molecules (Sims et al., <xref ref-type="bibr" rid="B176">2022</xref>), and can potentially initiate or enhance nitrosative stress due to producing NO (Rocha et al., <xref ref-type="bibr" rid="B168">2018</xref>). In support of this claim, the presence of activated astrocytes is confirmed in post-mortem brain samples of various neurodegenerative disease patients (Hashioka et al., <xref ref-type="bibr" rid="B79">2021</xref>). DAMPs released by dying neurons may also activate microglia through the ionotropic P2X and metabotropic P2Y purinergic receptors and initiate an inflammatory response. For example, under pathological conditions, P2X7 receptors can be overexpressed in the CNS. ATP acts as a DAMP and activates P2X7 receptors, and promotes chronic inflammatory neurological disorders (Thawkar and Kaur, <xref ref-type="bibr" rid="B193">2019</xref>). Post-mortem brain samples of AD patients showed overexpression of P2X7 receptors, which can be associated with disease pathology and progression. It is also suggested that P2X4 receptor overstimulation may result in neuronal cell death (Thawkar and Kaur, <xref ref-type="bibr" rid="B193">2019</xref>). Interestingly, upregulation of P2X and P2Y receptors in ALS patients can subsequently lead to overproduction of TNF-&#x003B1; and cyclooxygenase-2 (COX2), which facilitates neurotoxicity (Liu and Wang, <xref ref-type="bibr" rid="B123">2017</xref>).</p>
</sec>
<sec id="s4-2">
<title>Targeting neuroinflammation-induced cell death</title>
<p>Even though the neuroinflammatory cascades exacerbate neurodegenerative disease progression and participate in neuronal death, the exact mechanism of this involvement and therapeutic strategies regarding targeting neuroinflammation is not well studied. According to some investigations, targeting neuroinflammation can be a promising therapeutic approach to decrease inflammation and its further complications in neurodegenerative diseases (<xref ref-type="fig" rid="F3">Figure 3</xref>). Therefore, it can improve patients&#x02019; neuronal function in mental and physical activities. Incipiently, some specific microRNAs, such as miR-155-5p, can be key regulators of inflammatory cascades in neurodegenerative diseases. Overexpression of miR-155-5p has been reported in the CSF of AD and MS patients (Lv et al., <xref ref-type="bibr" rid="B132">2020</xref>). It has been recently found that Rosmarinic acid (RA) can inhibit neuroinflammation in neurodegenerative disease samples by regulating miR-155-5p, leading to attenuation in inflammation-associated neuronal damage and loss (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Lv et al., <xref ref-type="bibr" rid="B132">2020</xref>). Calpains as non-caspase proteases participate in the execution of neuronal cell death and cooperate with key factors of neuronal cell death. Thus, targeting these proteases may result in neuroprotection. Studies have demonstrated that Alpha1-antitrypsin (A1AT) can attenuate microglial neuroinflammation as well as inhibition of calpain activity (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Feng et al., <xref ref-type="bibr" rid="B52">2020</xref>). Other novel strategies have also been recruited with a focus on neuroinflammation. A recent study by Cheng C.-Y. et al. (<xref ref-type="bibr" rid="B28">2021</xref>) targeted inflammation in the substantia nigra of lipopolysaccharide (LPS)-treated rats by liposomes carrying Epigallocatechin-3-gallate (EGCG), a natural antioxidant in green tea. It demonstrated neuroprotection by inhibiting neuroinflammation (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Cheng C.-Y. et al., <xref ref-type="bibr" rid="B28">2021</xref>). Aucubin, which showed neuroprotective effects in oxidative stress-induced neurotoxicity, can also reduce phosphorylation levels of NF-&#x003BA;B, JNK, p38, and ERK, leading to a decrease in the level of inflammatory factors (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Li Y. C. et al., <xref ref-type="bibr" rid="B118">2021</xref>). Additionally, a polyphenol named Resveratrol indicated a similar effect by down-regulation of the transcription factor NF-&#x003BA;B <italic>in vitro</italic> (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Zhong et al., <xref ref-type="bibr" rid="B217">2012</xref>; Zhang et al., <xref ref-type="bibr" rid="B214">2017</xref>). Targeting TLR4/NF-&#x003BA;B signaling pathway by Hesperetin, a Citrus flavonoid, protected neurons from neuroinflammation and apoptosis (<xref ref-type="table" rid="T2">Table 2</xref>; Muhammad et al., <xref ref-type="bibr" rid="B148">2019</xref>). Many other similar signaling pathways can be inhibited, aiming to alleviate neuroinflammation in the CNS (Hou et al., <xref ref-type="bibr" rid="B89">2021</xref>). Furthermore, targeting inflammation-associated receptors expressed on neurons can also be an approach. For example, 15d-PGJ2 is a peroxisome proliferator-activated receptor-gamma (PPAR-&#x003B3;) agonist that inhibits the production of some interleukins and suppresses inflammation in microglial cells <italic>in vitro</italic> (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Xu et al., <xref ref-type="bibr" rid="B208">2008</xref>). Suppressing neuroinflammation by targeting P2X7R has been studied, but blood-brain barrier (BBB) permeability limits candidate drugs, so more studies are needed in this case (Thawkar and Kaur, <xref ref-type="bibr" rid="B193">2019</xref>). Intriguingly, Anakinra, an IL-1 receptor antagonist (Mahboubi Mehrabani et al., <xref ref-type="bibr" rid="B133">2022</xref>), reaches CNS easily and inhibits the activity of IL-1&#x003B2; by binding to its receptor and mitigate pyroptosis in neurons (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Wang et al., <xref ref-type="bibr" rid="B201">2019</xref>).</p>
<p>As mentioned in the former section, since the NLRP3 inflammasome plays a significant role in the enhancement of neurotoxicity, inhibition of NLRP3 and its subsequent pathways might be an effective method to decrease neuroinflammation-induced cell death. MCC950 is a small-molecule NLRP3 inhibitor that has inhibited inflammasome activation in rodent PD models leading to substantial neuroprotection, mitigation in motor deficits, and accumulation of &#x003B1;-synuclein aggregates (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Gordon et al., <xref ref-type="bibr" rid="B68">2018</xref>). Noteworthy, the neurotransmitter dopamine can bind to the dopamine D1 receptor, which results in ubiquitination and degradation of NLRP3 via the binding of cAMP with NLRP3, leading to the restriction of NLRP3 activation (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Yan et al., <xref ref-type="bibr" rid="B209">2015</xref>). Some experiments revealed attenuation of NLRP3-mediated neuroinflammation in PD mouse models using peroxisome proliferator-activated receptor beta/delta (PPAR-&#x003B2;/&#x003B4;) agonist GW501516 (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). There were some limitations with this drug, such as the resistance of the BBB to pass the drug to reach the brain parenchyma. Hence, this compound cannot be considered a candidate for PD treatment until the problem is not solved (Chen et al., <xref ref-type="bibr" rid="B26">2019</xref>). A flavonoid derived from the roots of <italic>Scutellaria baicalensis Georgi</italic>, termed &#x0201C;Baicalein&#x0201D;, indicated anti-inflammatory and anti-pyroptosis properties in animal models of PD. Experiments suggest that Baicalein may play a role in preventing the loss of DA neurons by reducing the production of various pro-inflammatory cytokines. It can also inhibit NLRP3 and caspase-1 activation, and simultaneously suppress pyroptosis by targeting Gasdermin D in 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) Induced Mice Model of PD (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Rui et al., <xref ref-type="bibr" rid="B170">2020</xref>). Benzyl isothiocyanate (BITC) and dihydromyricetin (DHM) are other plant-derived compounds with anti-inflammation properties (Lee et al., <xref ref-type="bibr" rid="B113">2016</xref>; Feng et al., <xref ref-type="bibr" rid="B51">2018</xref>). BITC seems to have the neuroprotective effects by inhibition of IL-1&#x003B2; release and NLRP3 inflammasome inhibition in the BV2 microglial cells (Lee et al., <xref ref-type="bibr" rid="B113">2016</xref>). Treatment of APP/PS1 transgenic mice with DHM improved neuroinflammation and memory function, as a result of decreased NLRP3 inflammasome activation (<xref ref-type="fig" rid="F3">Figure 3</xref>, <xref ref-type="table" rid="T2">Table 2</xref>; Feng et al., <xref ref-type="bibr" rid="B51">2018</xref>). Taken together, the detrimental effects of neuroinflammation in induced neuronal cell death must not be underestimated, and more research is required to provide a better understanding of mechanisms and underlying therapeutic strategies.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>As described elaborately, neuronal cell death plays a key role in demonstrating neurodegenerative disease manifestations. Understanding the exact mechanisms and pathways leading to cell death would provide the opportunity for researchers to recommend high-efficiency neuroprotective agents. Until now, many pre-clinical studies have been done in an attempt to cure neurodegenerative diseases, targeting crucial agents involved in well-known pathways leading to neuronal cell death. The field of targeting ER stress and UPR as a therapeutic approach to treat neurodegeneration is growing and has revealed considerable results. On the other hand, ROS damage to mitochondria and homeostasis of the neuron is prominent in neurodegenerative diseases. Hence, this has led to therapeutic approaches using agents with antioxidant properties or inducing the antioxidant activity of the neuron, resulting in inhibition of ROS-mediated neuronal injury. Activation of neuroglia and initiation of neuroinflammation could also lead to a neurotoxic microenvironment for neurons. Unfortunately, the exact mechanism of neuroinflammation-induced cell death is still under debate. Thus, there are not sufficient experimental results of targeting key components of neuroinflammation to decrease neuronal loss in neurodegenerative diseases directly. However, there is strong evidence implicating the role of inhibiting neuroinflammation in attenuating ROS- and ER stress-induced neuronal cell death. Nowadays, the focus on the neuroprotective effects of phytochemicals has significantly increased; nevertheless, there is still much to research and discover to approve phytochemicals as a promising therapeutic agent. Taken together, despite advances in the field of targeting cell death to treat neurodegenerative diseases, there is not an approved compound to directly inhibit cell death yet, so it needs intensive research to find a novel therapeutic strategy for treatment of neurodegenerative diseases.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>MK, FSH, and MM provided the idea and mainly wrote the manuscript. MK and AA contributed to the search and assessment of the available literature. MK designed and illustrated the figures. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s8">
<title>Publisher&#x02019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdullah</surname> <given-names>A.</given-names></name> <name><surname>Ravanan</surname> <given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>Kaempferol mitigates Endoplasmic Reticulum Stress Induced Cell Death by targeting caspase 3/7</article-title>. <source>Sci. Rep.</source> <volume>8</volume>:<fpage>2189</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-018-20499-7</pub-id><pub-id pub-id-type="pmid">29391535</pub-id></citation></ref>
<ref id="B002"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adasme</surname> <given-names>T.</given-names></name> <name><surname>Paula-Lima</surname> <given-names>A.</given-names></name> <name><surname>Hidalgo</surname> <given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>Inhibitory ryanodine prevents ryanodine receptor-mediated Ca<sup>2+</sup> release without affecting endoplasmic reticulum Ca<sup>2+</sup> content in primary hippocampal neurons</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>458</volume>, <fpage>57</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.01.065</pub-id><pub-id pub-id-type="pmid">25623539</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aime</surname> <given-names>P.</given-names></name> <name><surname>Karuppagounder</surname> <given-names>S. S.</given-names></name> <name><surname>Rao</surname> <given-names>A.</given-names></name> <name><surname>Chen</surname> <given-names>Y.</given-names></name> <name><surname>Burke</surname> <given-names>R. E.</given-names></name> <name><surname>Ratan</surname> <given-names>R. R.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson&#x02019;s disease</article-title>. <source>Neurobiol. Dis.</source> <volume>136</volume>:<fpage>104725</fpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2019.104725</pub-id><pub-id pub-id-type="pmid">31911115</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ajoolabady</surname> <given-names>A.</given-names></name> <name><surname>Lindholm</surname> <given-names>D.</given-names></name> <name><surname>Ren</surname> <given-names>J.</given-names></name> <name><surname>Pratico</surname> <given-names>D.</given-names></name></person-group> (<year>2022</year>). <article-title>ER stress and UPR in Alzheimer&#x02019;s disease: mechanisms, pathogenesis, treatments</article-title>. <source>Cell Death Dis.</source> <volume>13</volume>:<fpage>706</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-022-05153-5</pub-id><pub-id pub-id-type="pmid">35970828</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akanji</surname> <given-names>M. A.</given-names></name> <name><surname>Rotimi</surname> <given-names>D. E.</given-names></name> <name><surname>Elebiyo</surname> <given-names>T. C.</given-names></name> <name><surname>Awakan</surname> <given-names>O. J.</given-names></name> <name><surname>Adeyemi</surname> <given-names>O. S.</given-names></name></person-group> (<year>2021</year>). <article-title>Redox homeostasis and prospects for therapeutic targeting in neurodegenerative disorders</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2021</volume>:<fpage>9971885</fpage>. <pub-id pub-id-type="doi">10.1155/2021/9971885</pub-id><pub-id pub-id-type="pmid">34394839</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname> <given-names>L. M.</given-names></name> <name><surname>Pinho</surname> <given-names>B. R.</given-names></name> <name><surname>Duchen</surname> <given-names>M. R.</given-names></name> <name><surname>Oliveira</surname> <given-names>J. M. A.</given-names></name></person-group> (<year>2022</year>). <article-title>The PERKs of mitochondria protection during stress: insights for PERK modulation in neurodegenerative and metabolic diseases</article-title>. <source>Biol. Rev. Camb. Philos. Soc.</source> <volume>97</volume>, <fpage>1737</fpage>&#x02013;<lpage>1748</lpage>. <pub-id pub-id-type="doi">10.1111/brv.12860</pub-id><pub-id pub-id-type="pmid">35475315</pub-id></citation></ref>
<ref id="B0011"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altinoz</surname> <given-names>M. A.</given-names></name> <name><surname>Elmaci</surname> <given-names>&#x00130;.</given-names></name> <name><surname>Hacimuftuoglu</surname> <given-names>A.</given-names></name> <name><surname>Ozpinar</surname> <given-names>A.</given-names></name> <name><surname>Hacker</surname> <given-names>E.</given-names></name> <name><surname>Ozpinar</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>PPAR&#x003B4; and its ligand erucic acid may act anti-tumoral, neuroprotective, and myelin protective in neuroblastoma, glioblastoma, and Parkinson&#x02019;s disease</article-title>. <source>Mol. Aspects Med.</source> <volume>78</volume>:<fpage>100871</fpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2020.100871</pub-id><pub-id pub-id-type="pmid">32703610</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andhavarapu</surname> <given-names>S.</given-names></name> <name><surname>Mubariz</surname> <given-names>F.</given-names></name> <name><surname>Arvas</surname> <given-names>M.</given-names></name> <name><surname>Bever</surname> <given-names>C.</given-names> <suffix>Jr.</suffix></name> <name><surname>Makar</surname> <given-names>T. K.</given-names></name></person-group> (<year>2019</year>). <article-title>Interplay between ER stress and autophagy: a possible mechanism in multiple sclerosis pathology</article-title>. <source>Exp. Mol. Pathol.</source> <volume>108</volume>, <fpage>183</fpage>&#x02013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexmp.2019.04.016</pub-id><pub-id pub-id-type="pmid">31047874</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreone</surname> <given-names>B. J.</given-names></name> <name><surname>Larhammar</surname> <given-names>M.</given-names></name> <name><surname>Lewcock</surname> <given-names>J. W.</given-names></name></person-group> (<year>2020</year>). <article-title>Cell Death and neurodegeneration</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>12</volume>:<fpage>a036434</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a036434</pub-id><pub-id pub-id-type="pmid">31451511</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Angelova</surname> <given-names>P. R.</given-names></name> <name><surname>Abramov</surname> <given-names>A. Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Role of mitochondrial ROS in the brain: from physiology to neurodegeneration</article-title>. <source>FEBS Lett.</source> <volume>592</volume>, <fpage>692</fpage>&#x02013;<lpage>702</lpage>. <pub-id pub-id-type="doi">10.1002/1873-3468.12964</pub-id><pub-id pub-id-type="pmid">29292494</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Avgerinos</surname> <given-names>K. I.</given-names></name> <name><surname>Ferrucci</surname> <given-names>L.</given-names></name> <name><surname>Kapogiannis</surname> <given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of monoclonal antibodies against amyloid-&#x003B2; on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer&#x02019;s disease</article-title>. <source>Ageing Res. Rev.</source> <volume>68</volume>:<fpage>101339</fpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2021.101339</pub-id><pub-id pub-id-type="pmid">33831607</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Awasthi</surname> <given-names>A.</given-names></name> <name><surname>Matsunaga</surname> <given-names>Y.</given-names></name> <name><surname>Yamada</surname> <given-names>T.</given-names></name></person-group> (<year>2005</year>). <article-title>Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides</article-title>. <source>Exp. Neurol.</source> <volume>196</volume>, <fpage>282</fpage>&#x02013;<lpage>289</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2005.08.001</pub-id><pub-id pub-id-type="pmid">16137679</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname> <given-names>V.</given-names></name> <name><surname>Winklhofer</surname> <given-names>K. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Mitochondria at the interface between neurodegeneration and neuroinflammation</article-title>. <source>Semin. Cell Dev. Biol.</source> <volume>99</volume>, <fpage>163</fpage>&#x02013;<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1016/j.semcdb.2019.05.028</pub-id><pub-id pub-id-type="pmid">31154011</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname> <given-names>B. I.</given-names></name> <name><surname>Xu</surname> <given-names>H.</given-names></name> <name><surname>Igarashi</surname> <given-names>S.</given-names></name> <name><surname>Fujimuro</surname> <given-names>M.</given-names></name> <name><surname>Agrawal</surname> <given-names>N.</given-names></name> <name><surname>Taya</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>p53 mediates cellular dysfunction and behavioral abnormalities in Huntington&#x02019;s disease</article-title>. <source>Neuron</source> <volume>47</volume>, <fpage>29</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2005.06.005</pub-id><pub-id pub-id-type="pmid">15996546</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrera</surname> <given-names>G.</given-names></name> <name><surname>Pizzimenti</surname> <given-names>S.</given-names></name> <name><surname>Daga</surname> <given-names>M.</given-names></name> <name><surname>Dianzani</surname> <given-names>C.</given-names></name> <name><surname>Arcaro</surname> <given-names>A.</given-names></name> <name><surname>Cetrangolo</surname> <given-names>G. P.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders</article-title>. <source>Antioxidants (Basel)</source> <volume>7</volume>:<fpage>102</fpage>. <pub-id pub-id-type="doi">10.3390/antiox7080102</pub-id><pub-id pub-id-type="pmid">30061536</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behl</surname> <given-names>T.</given-names></name> <name><surname>Makkar</surname> <given-names>R.</given-names></name> <name><surname>Sehgal</surname> <given-names>A.</given-names></name> <name><surname>Singh</surname> <given-names>S.</given-names></name> <name><surname>Sharma</surname> <given-names>N.</given-names></name> <name><surname>Zengin</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Current trends in neurodegeneration: cross talks between oxidative stress, cell death and inflammation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>:<fpage>7432</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22147432</pub-id><pub-id pub-id-type="pmid">34299052</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bejanin</surname> <given-names>A.</given-names></name> <name><surname>Schonhaut</surname> <given-names>D. R.</given-names></name> <name><surname>La Joie</surname> <given-names>R.</given-names></name> <name><surname>Kramer</surname> <given-names>J. H.</given-names></name> <name><surname>Baker</surname> <given-names>S. L.</given-names></name> <name><surname>Sosa</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer&#x02019;s disease</article-title>. <source>Brain</source> <volume>140</volume>, <fpage>3286</fpage>&#x02013;<lpage>3300</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awx243</pub-id><pub-id pub-id-type="pmid">29053874</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname> <given-names>A. H.</given-names></name> <name><surname>Dar</surname> <given-names>K. B.</given-names></name> <name><surname>Anees</surname> <given-names>S.</given-names></name> <name><surname>Zargar</surname> <given-names>M. A.</given-names></name> <name><surname>Masood</surname> <given-names>A.</given-names></name> <name><surname>Sofi</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight</article-title>. <source>Biomed. Pharmacother.</source> <volume>74</volume>, <fpage>101</fpage>&#x02013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2015.07.025</pub-id><pub-id pub-id-type="pmid">26349970</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blaner</surname> <given-names>W. S.</given-names></name> <name><surname>Shmarakov</surname> <given-names>I. O.</given-names></name> <name><surname>Traber</surname> <given-names>M. G.</given-names></name></person-group> (<year>2021</year>). <article-title>Vitamin A and vitamin E: will the real antioxidant please stand up?</article-title> <source>Annu. Rev. Nutr.</source> <volume>41</volume>, <fpage>105</fpage>&#x02013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-nutr-082018-124228</pub-id><pub-id pub-id-type="pmid">34115520</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bloem</surname> <given-names>B. R.</given-names></name> <name><surname>Okun</surname> <given-names>M. S.</given-names></name> <name><surname>Klein</surname> <given-names>C.</given-names></name></person-group> (<year>2021</year>). <article-title>Parkinson&#x02019;s disease</article-title>. <source>Lancet</source> <volume>397</volume>, <fpage>2284</fpage>&#x02013;<lpage>2303</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00218-X</pub-id><pub-id pub-id-type="pmid">33848468</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Breijyeh</surname> <given-names>Z.</given-names></name> <name><surname>Karaman</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Comprehensive review on Alzheimer&#x02019;s disease: causes and treatment</article-title>. <source>Molecules</source> <volume>25</volume>:<fpage>5789</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25245789</pub-id><pub-id pub-id-type="pmid">33302541</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brini</surname> <given-names>M.</given-names></name> <name><surname>Cal&#x000EC;</surname> <given-names>T.</given-names></name> <name><surname>Ottolini</surname> <given-names>D.</given-names></name> <name><surname>Carafoli</surname> <given-names>E.</given-names></name></person-group> (<year>2014</year>). <article-title>Neuronal calcium signaling: function and dysfunction</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>71</volume>, <fpage>2787</fpage>&#x02013;<lpage>2814</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-013-1550-7</pub-id><pub-id pub-id-type="pmid">24442513</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Callens</surname> <given-names>M.</given-names></name> <name><surname>Kraskovskaya</surname> <given-names>N.</given-names></name> <name><surname>Derevtsova</surname> <given-names>K.</given-names></name> <name><surname>Annaert</surname> <given-names>W.</given-names></name> <name><surname>Bultynck</surname> <given-names>G.</given-names></name> <name><surname>Bezprozvanny</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>The role of Bcl-2 proteins in modulating neuronal Ca<sup>2+</sup> signaling in health and in Alzheimer&#x02019;s disease</article-title>. <source>Biochim. Biophys. Acta Mol. Cell Res.</source> <volume>1868</volume>:<fpage>118997</fpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2021.118997</pub-id><pub-id pub-id-type="pmid">33711363</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calsolaro</surname> <given-names>V.</given-names></name> <name><surname>Edison</surname> <given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>Neuroinflammation in Alzheimer&#x02019;s disease: current evidence and future directions</article-title>. <source>Alzheimers Dement.</source> <volume>12</volume>, <fpage>719</fpage>&#x02013;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2016.02.010</pub-id><pub-id pub-id-type="pmid">27179961</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chami</surname> <given-names>M.</given-names></name> <name><surname>Checler</surname> <given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Alterations of the endoplasmic reticulum (ER) calcium signaling molecular components in Alzheimer&#x02019;s disease</article-title>. <source>Cells</source> <volume>9</volume>:<fpage>2577</fpage>. <pub-id pub-id-type="doi">10.3390/cells9122577</pub-id><pub-id pub-id-type="pmid">33271984</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname> <given-names>H. Y.</given-names></name> <name><surname>Nishitoh</surname> <given-names>H.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Ichijo</surname> <given-names>H.</given-names></name> <name><surname>Baltimore</surname> <given-names>D.</given-names></name></person-group> (<year>1998</year>). <article-title>Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx</article-title>. <source>Science</source> <volume>281</volume>, <fpage>1860</fpage>&#x02013;<lpage>1863</lpage>. <pub-id pub-id-type="doi">10.1126/science.281.5384.1860</pub-id><pub-id pub-id-type="pmid">9743501</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L.</given-names></name> <name><surname>Bi</surname> <given-names>M.</given-names></name> <name><surname>Zhang</surname> <given-names>Z.</given-names></name> <name><surname>Du</surname> <given-names>X.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <name><surname>Jiao</surname> <given-names>Q.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>The functions of IRE1&#x003B1; in neurodegenerative diseases: beyond ER stress</article-title>. <source>Ageing Res. Rev.</source> <volume>82</volume>:<fpage>101774</fpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2022.10177</pub-id><pub-id pub-id-type="pmid">36332756</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>S. D.</given-names></name> <name><surname>Chuang</surname> <given-names>Y. C.</given-names></name> <name><surname>Lin</surname> <given-names>T. K.</given-names></name> <name><surname>Yang</surname> <given-names>J. L.</given-names></name></person-group> (<year>2023</year>). <article-title>Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases</article-title>. <source>Eur. J. Pharmacol.</source> <volume>938</volume>:<fpage>175439</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.175439</pub-id><pub-id pub-id-type="pmid">36470445</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>L.</given-names></name> <name><surname>Xue</surname> <given-names>L.</given-names></name> <name><surname>Zheng</surname> <given-names>J.</given-names></name> <name><surname>Tian</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Tong</surname> <given-names>Q.</given-names></name></person-group> (<year>2019</year>). <article-title>PPAR&#x000DF;/&#x003B4; agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson&#x02019;s disease</article-title>. <source>Behav. Brain Res.</source> <volume>356</volume>, <fpage>483</fpage>&#x02013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2018.06.005</pub-id><pub-id pub-id-type="pmid">29885849</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>C.-Y.</given-names></name> <name><surname>Barro</surname> <given-names>L.</given-names></name> <name><surname>Tsai</surname> <given-names>S. T.</given-names></name> <name><surname>Feng</surname> <given-names>T. W.</given-names></name> <name><surname>Wu</surname> <given-names>X. Y.</given-names></name> <name><surname>Chao</surname> <given-names>C. W.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Epigallocatechin-3-gallate-loaded liposomes favor anti-inflammation of microglia cells and promote neuroprotection</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>:<fpage>3037</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22063037</pub-id><pub-id pub-id-type="pmid">33809762</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>Y.</given-names></name> <name><surname>Song</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>H.</given-names></name> <name><surname>Li</surname> <given-names>Q.</given-names></name> <name><surname>Gao</surname> <given-names>Y.</given-names></name> <name><surname>Lu</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Ferroptosis mediated by lipid reactive oxygen species: a possible causal link of neuroinflammation to neurological disorders</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2021</volume>:<fpage>5005136</fpage>. <pub-id pub-id-type="doi">10.1155/2021/5005136</pub-id><pub-id pub-id-type="pmid">34725564</pub-id></citation></ref>
<ref id="B007"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chocry</surname> <given-names>M.</given-names></name> <name><surname>Leloup</surname> <given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>The NADPH oxidase family and its inhibitors</article-title>. <source>Antioxid. Redox Signal.</source> <volume>33</volume>, <fpage>332</fpage>&#x02013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2019.7915</pub-id><pub-id pub-id-type="pmid">31826639</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colla</surname> <given-names>E.</given-names></name> <name><surname>Coune</surname> <given-names>P.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Pletnikova</surname> <given-names>O.</given-names></name> <name><surname>Troncoso</surname> <given-names>J. C.</given-names></name> <name><surname>Iwatsubo</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Endoplasmic reticulum stress is important for the manifestations of &#x003B1;-synucleinopathy in vivo</article-title>. <source>J. Neurosci.</source> <volume>32</volume>, <fpage>3306</fpage>&#x02013;<lpage>3320</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5367-11.2012</pub-id><pub-id pub-id-type="pmid">22399753</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname> <given-names>A. A.</given-names></name> <name><surname>Gitler</surname> <given-names>A. D.</given-names></name> <name><surname>Cashikar</surname> <given-names>A.</given-names></name> <name><surname>Haynes</surname> <given-names>C. M.</given-names></name> <name><surname>Hill</surname> <given-names>K. J.</given-names></name> <name><surname>Bhullar</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>&#x003B1;-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson&#x02019;s models</article-title>. <source>Science</source> <volume>313</volume>, <fpage>324</fpage>&#x02013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1126/science.1129462</pub-id><pub-id pub-id-type="pmid">16794039</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cristino</surname> <given-names>L.</given-names></name> <name><surname>Bisogno</surname> <given-names>T.</given-names></name> <name><surname>Di Marzo</surname> <given-names>V.</given-names></name></person-group> (<year>2020</year>). <article-title>Cannabinoids and the expanded endocannabinoid system in neurological disorders</article-title>. <source>Nat. Rev. Neurol.</source> <volume>16</volume>, <fpage>9</fpage>&#x02013;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-019-0284-z</pub-id><pub-id pub-id-type="pmid">31831863</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Culmsee</surname> <given-names>C.</given-names></name> <name><surname>Plesnila</surname> <given-names>N.</given-names></name></person-group> (<year>2006</year>). <article-title>Targeting Bid to prevent programmed cell death in neurons</article-title>. <source>Biochem. Soc. Trans.</source> <volume>34</volume>, <fpage>1334</fpage>&#x02013;<lpage>1340</lpage>. <pub-id pub-id-type="doi">10.1042/BST0341334</pub-id><pub-id pub-id-type="pmid">17073814</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Da Silva</surname> <given-names>D. C.</given-names></name> <name><surname>Valent&#x000E3;O</surname> <given-names>P.</given-names></name> <name><surname>Andrade</surname> <given-names>P. B.</given-names></name> <name><surname>Pereira</surname> <given-names>D. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Endoplasmic reticulum stress signaling in cancer and neurodegenerative disorders: tools and strategies to understand its complexity</article-title>. <source>Pharmacol. Res.</source> <volume>155</volume>:<fpage>104702</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2020.104702</pub-id><pub-id pub-id-type="pmid">32068119</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>David</surname> <given-names>S.</given-names></name> <name><surname>Jhelum</surname> <given-names>P.</given-names></name> <name><surname>Ryan</surname> <given-names>F.</given-names></name> <name><surname>Jeong</surname> <given-names>S. Y.</given-names></name> <name><surname>Kroner</surname> <given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Dysregulation of iron homeostasis in the central nervous system and the role of ferroptosis in neurodegenerative disorders</article-title>. <source>Antioxid. Redox Signal.</source> <volume>37</volume>, <fpage>150</fpage>&#x02013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2021.0218</pub-id><pub-id pub-id-type="pmid">34569265</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Decourt</surname> <given-names>B.</given-names></name> <name><surname>Boumelhem</surname> <given-names>F.</given-names></name> <name><surname>Pope</surname> <given-names>E. D.</given-names> <suffix>3rd</suffix></name> <name><surname>Shi</surname> <given-names>J.</given-names></name> <name><surname>Mari</surname> <given-names>Z.</given-names></name> <name><surname>Sabbagh</surname> <given-names>M. N.</given-names></name></person-group> (<year>2021</year>). <article-title>Critical appraisal of amyloid lowering agents in AD</article-title>. <source>Curr. Neurol. Neurosci. Rep.</source> <volume>21</volume>:<fpage>39</fpage>. <pub-id pub-id-type="doi">10.1007/s11910-021-01125-y</pub-id><pub-id pub-id-type="pmid">34110536</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demmings</surname> <given-names>M. D.</given-names></name> <name><surname>Tennyson</surname> <given-names>E. C.</given-names></name> <name><surname>Petroff</surname> <given-names>G. N.</given-names></name> <name><surname>Tarnowski-Garner</surname> <given-names>H. E.</given-names></name> <name><surname>Cregan</surname> <given-names>S. P.</given-names></name></person-group> (<year>2021</year>). <article-title>Activating transcription factor-4 promotes neuronal death induced by Parkinson&#x02019;s disease neurotoxins and &#x003B1;-synuclein aggregates</article-title>. <source>Cell Death Differ.</source> <volume>28</volume>, <fpage>1627</fpage>&#x02013;<lpage>1643</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-020-00688-6</pub-id><pub-id pub-id-type="pmid">33277577</pub-id></citation></ref>
<ref id="B0012"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deora</surname> <given-names>V.</given-names></name> <name><surname>Lee</surname> <given-names>J. D.</given-names></name> <name><surname>Albornoz</surname> <given-names>E. A.</given-names></name> <name><surname>McAlary</surname> <given-names>L.</given-names></name> <name><surname>Jagaraj</surname> <given-names>C. J.</given-names></name> <name><surname>Robertson</surname> <given-names>A. A. B.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins</article-title>. <source>Glia</source> <volume>68</volume>, <fpage>407</fpage>&#x02013;<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1002/glia.23728</pub-id><pub-id pub-id-type="pmid">31596526</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhillon</surname> <given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Aducanumab: first approval</article-title>. <source>Drugs</source> <volume>81</volume>, <fpage>1437</fpage>&#x02013;<lpage>1443</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-021-01569-z</pub-id><pub-id pub-id-type="pmid">34324167</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname> <given-names>V.</given-names></name> <name><surname>Junn</surname> <given-names>E.</given-names></name> <name><surname>Mouradian</surname> <given-names>M. M.</given-names></name></person-group> (<year>2013</year>). <article-title>The role of oxidative stress in Parkinson&#x02019;s disease</article-title>. <source>J. Parkinsons Dis.</source> <volume>3</volume>, <fpage>461</fpage>&#x02013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.3233/JPD-130230</pub-id><pub-id pub-id-type="pmid">24252804</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinda</surname> <given-names>B.</given-names></name> <name><surname>Dinda</surname> <given-names>M.</given-names></name> <name><surname>Kulsi</surname> <given-names>G.</given-names></name> <name><surname>Chakraborty</surname> <given-names>A.</given-names></name> <name><surname>Dinda</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Therapeutic potentials of plant iridoids in Alzheimer&#x02019;s and Parkinson&#x02019;s diseases: a review</article-title>. <source>Eur. J. Med. Chem.</source> <volume>169</volume>, <fpage>185</fpage>&#x02013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2019.03.009</pub-id><pub-id pub-id-type="pmid">30877973</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Djajadikerta</surname> <given-names>A.</given-names></name> <name><surname>Keshri</surname> <given-names>S.</given-names></name> <name><surname>Pavel</surname> <given-names>M.</given-names></name> <name><surname>Prestil</surname> <given-names>R.</given-names></name> <name><surname>Ryan</surname> <given-names>L.</given-names></name> <name><surname>Rubinsztein</surname> <given-names>D. C.</given-names></name></person-group> (<year>2020</year>). <article-title>Autophagy induction as a therapeutic strategy for neurodegenerative diseases</article-title>. <source>J. Mol. Biol.</source> <volume>432</volume>, <fpage>2799</fpage>&#x02013;<lpage>2821</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2019.12.035</pub-id><pub-id pub-id-type="pmid">31887286</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doroudian</surname> <given-names>M.</given-names></name> <name><surname>Azhdari</surname> <given-names>M. H.</given-names></name> <name><surname>Goodarzi</surname> <given-names>N.</given-names></name> <name><surname>O&#x02019;Sullivan</surname> <given-names>D.</given-names></name> <name><surname>Donnelly</surname> <given-names>S. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Smart nanotherapeutics and lung cancer</article-title>. <source>Pharmaceutics</source> <volume>13</volume>:<fpage>1972</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics13111972</pub-id><pub-id pub-id-type="pmid">34834387</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname> <given-names>K. M.</given-names></name> <name><surname>Kennedy</surname> <given-names>D.</given-names></name> <name><surname>Gorman</surname> <given-names>A. M.</given-names></name> <name><surname>Gupta</surname> <given-names>S.</given-names></name> <name><surname>Healy</surname> <given-names>S. J.</given-names></name> <name><surname>Samali</surname> <given-names>A.</given-names></name></person-group> (<year>2011</year>). <article-title>Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders</article-title>. <source>J. Cell. Mol. Med.</source> <volume>15</volume>, <fpage>2025</fpage>&#x02013;<lpage>2039</lpage>. <pub-id pub-id-type="doi">10.1111/j.1582-4934.2011.01374.x</pub-id><pub-id pub-id-type="pmid">21722302</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dugger</surname> <given-names>B. N.</given-names></name> <name><surname>Dickson</surname> <given-names>D. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Pathology of neurodegenerative diseases</article-title>. <source>Cold Spring Harb. Perspect. Biol.</source> <volume>9</volume>:<fpage>a028035</fpage>. <pub-id pub-id-type="doi">10.1101/cshperspect.a028035</pub-id><pub-id pub-id-type="pmid">28062563</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname> <given-names>M. F.</given-names></name> <name><surname>Kost</surname> <given-names>J.</given-names></name> <name><surname>Tariot</surname> <given-names>P. N.</given-names></name> <name><surname>Aisen</surname> <given-names>P. S.</given-names></name> <name><surname>Cummings</surname> <given-names>J. L.</given-names></name> <name><surname>Vellas</surname> <given-names>B.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Randomized trial of verubecestat for mild-to-moderate Alzheimer&#x02019;s disease</article-title>. <source>N. Engl. J. Med.</source> <volume>378</volume>, <fpage>1691</fpage>&#x02013;<lpage>1703</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1706441</pub-id><pub-id pub-id-type="pmid">29719179</pub-id></citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egan</surname> <given-names>M. F.</given-names></name> <name><surname>Kost</surname> <given-names>J.</given-names></name> <name><surname>Voss</surname> <given-names>T.</given-names></name> <name><surname>Mukai</surname> <given-names>Y.</given-names></name> <name><surname>Aisen</surname> <given-names>P. S.</given-names></name> <name><surname>Cummings</surname> <given-names>J. L.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Randomized trial of verubecestat for prodromal Alzheimer&#x02019;s disease</article-title>. <source>N. Engl. J. Med.</source> <volume>380</volume>, <fpage>1408</fpage>&#x02013;<lpage>1420</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1812840</pub-id><pub-id pub-id-type="pmid">30970186</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emerit</surname> <given-names>J.</given-names></name> <name><surname>Edeas</surname> <given-names>M.</given-names></name> <name><surname>Bricaire</surname> <given-names>F.</given-names></name></person-group> (<year>2004</year>). <article-title>Neurodegenerative diseases and oxidative stress</article-title>. <source>Biomed. Pharmacother.</source> <volume>58</volume>, <fpage>39</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2003.11.004</pub-id><pub-id pub-id-type="pmid">14739060</pub-id></citation></ref>
<ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fairless</surname> <given-names>R.</given-names></name> <name><surname>Williams</surname> <given-names>S. K.</given-names></name> <name><surname>Diem</surname> <given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Dysfunction of neuronal calcium signalling in neuroinflammation and neurodegeneration</article-title>. <source>Cell Tissue Res.</source> <volume>357</volume>, <fpage>455</fpage>&#x02013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-013-1758-8</pub-id><pub-id pub-id-type="pmid">24326615</pub-id></citation></ref>
<ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Falabella</surname> <given-names>M.</given-names></name> <name><surname>Vernon</surname> <given-names>H. J.</given-names></name> <name><surname>Hanna</surname> <given-names>M. G.</given-names></name> <name><surname>Claypool</surname> <given-names>S. M.</given-names></name> <name><surname>Pitceathly</surname> <given-names>R. D. S.</given-names></name></person-group> (<year>2021</year>). <article-title>Cardiolipin, mitochondria and neurological disease</article-title>. <source>Trends Endocrinol. Metab.</source> <volume>32</volume>, <fpage>224</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2021.01.006</pub-id><pub-id pub-id-type="pmid">33640250</pub-id></citation></ref>
<ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Zhou</surname> <given-names>W.</given-names></name> <name><surname>Lou</surname> <given-names>D.</given-names></name> <name><surname>Huang</surname> <given-names>D.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Regulation of SET gene expression by NFkB</article-title>. <source>Mol. Neurobiol.</source> <volume>54</volume>, <fpage>4477</fpage>&#x02013;<lpage>4485</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-016-9967-2</pub-id><pub-id pub-id-type="pmid">27351675</pub-id></citation></ref>
<ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>Y. S.</given-names></name> <name><surname>Tan</surname> <given-names>Z. X.</given-names></name> <name><surname>Wu</surname> <given-names>L. Y.</given-names></name> <name><surname>Dong</surname> <given-names>F.</given-names></name> <name><surname>Zhang</surname> <given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>The involvement of NLRP3 inflammasome in the treatment of Alzheimer&#x02019;s disease</article-title>. <source>Ageing Res. Rev.</source> <volume>64</volume>:<fpage>101192</fpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2020.101192</pub-id><pub-id pub-id-type="pmid">33059089</pub-id></citation></ref>
<ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>J. X.</given-names></name> <name><surname>Du</surname> <given-names>Y. H.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>W.</given-names></name> <name><surname>Chen</surname> <given-names>J. F.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice</article-title>. <source>CNS Neurosci. Ther.</source> <volume>24</volume>, <fpage>1207</fpage>&#x02013;<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.1111/cns.12983</pub-id><pub-id pub-id-type="pmid">29869390</pub-id></citation></ref>
<ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrada</surname> <given-names>L.</given-names></name> <name><surname>Barahona</surname> <given-names>M. J.</given-names></name> <name><surname>Salazar</surname> <given-names>K.</given-names></name> <name><surname>Vandenabeele</surname> <given-names>P.</given-names></name> <name><surname>Nualart</surname> <given-names>F.</given-names></name></person-group> (<year>2020</year>). <article-title>Vitamin C controls neuronal necroptosis under oxidative stress</article-title>. <source>Redox Biol.</source> <volume>29</volume>:<fpage>101408</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2019.101408</pub-id><pub-id pub-id-type="pmid">31926631</pub-id></citation></ref>
<ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fricker</surname> <given-names>M.</given-names></name> <name><surname>Tolkovsky</surname> <given-names>A. M.</given-names></name> <name><surname>Borutaite</surname> <given-names>V.</given-names></name> <name><surname>Coleman</surname> <given-names>M.</given-names></name> <name><surname>Brown</surname> <given-names>G. C.</given-names></name></person-group> (<year>2018</year>). <article-title>Neuronal cell death</article-title>. <source>Physiol. Rev.</source> <volume>98</volume>, <fpage>813</fpage>&#x02013;<lpage>880</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00011.2017</pub-id><pub-id pub-id-type="pmid">29488822</pub-id></citation></ref>
<ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaidt</surname> <given-names>M. M.</given-names></name> <name><surname>Hornung</surname> <given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Pore formation by GSDMD is the effector mechanism of pyroptosis</article-title>. <source>EMBO J.</source> <volume>35</volume>, <fpage>2167</fpage>&#x02013;<lpage>2169</lpage>. <pub-id pub-id-type="doi">10.15252/embj.201695415</pub-id><pub-id pub-id-type="pmid">27572465</pub-id></citation></ref>
<ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galehdar</surname> <given-names>Z.</given-names></name> <name><surname>Swan</surname> <given-names>P.</given-names></name> <name><surname>Fuerth</surname> <given-names>B.</given-names></name> <name><surname>Callaghan</surname> <given-names>S. M.</given-names></name> <name><surname>Park</surname> <given-names>D. S.</given-names></name> <name><surname>Cregan</surname> <given-names>S. P.</given-names></name></person-group> (<year>2010</year>). <article-title>Neuronal apoptosis induced by endoplasmic reticulum stress is regulated by ATF4-CHOP-mediated induction of the Bcl-2 homology 3-only member PUMA</article-title>. <source>J. Neurosci.</source> <volume>30</volume>, <fpage>16938</fpage>&#x02013;<lpage>16948</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1598-10.2010</pub-id><pub-id pub-id-type="pmid">21159964</pub-id></citation></ref>
<ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galvan</surname> <given-names>V.</given-names></name> <name><surname>Banwait</surname> <given-names>S.</given-names></name> <name><surname>Spilman</surname> <given-names>P.</given-names></name> <name><surname>Gorostiza</surname> <given-names>O. F.</given-names></name> <name><surname>Peel</surname> <given-names>A.</given-names></name> <name><surname>Ataie</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Interaction of ASK1 and the &#x003B2;-amyloid precursor protein in a stress-signaling complex</article-title>. <source>Neurobiol. Dis.</source> <volume>28</volume>, <fpage>65</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2007.06.017</pub-id><pub-id pub-id-type="pmid">17719230</pub-id></citation></ref>
<ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaschler</surname> <given-names>M. M.</given-names></name> <name><surname>Stockwell</surname> <given-names>B. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Lipid peroxidation in cell death</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>482</volume>, <fpage>419</fpage>&#x02013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.10.086</pub-id><pub-id pub-id-type="pmid">28212725</pub-id></citation></ref>
<ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gauthier</surname> <given-names>S.</given-names></name> <name><surname>Feldman</surname> <given-names>H. H.</given-names></name> <name><surname>Schneider</surname> <given-names>L. S.</given-names></name> <name><surname>Wilcock</surname> <given-names>G. K.</given-names></name> <name><surname>Frisoni</surname> <given-names>G. B.</given-names></name> <name><surname>Hardlund</surname> <given-names>J. H.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer&#x02019;s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial</article-title>. <source>Lancet</source> <volume>388</volume>, <fpage>2873</fpage>&#x02013;<lpage>2884</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)31275-2</pub-id><pub-id pub-id-type="pmid">27863809</pub-id></citation></ref>
<ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelders</surname> <given-names>G.</given-names></name> <name><surname>Baekelandt</surname> <given-names>V.</given-names></name> <name><surname>Van der Perren</surname> <given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Linking neuroinflammation and neurodegeneration in Parkinson&#x02019;s disease</article-title>. <source>J. Immunol. Res.</source> <volume>2018</volume>:<fpage>4784268</fpage>. <pub-id pub-id-type="doi">10.1155/2018/4784268</pub-id><pub-id pub-id-type="pmid">29850629</pub-id></citation></ref>
<ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerakis</surname> <given-names>Y.</given-names></name> <name><surname>Hetz</surname> <given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>Brain organoids: a next step for humanized Alzheimer&#x02019;s disease models?</article-title> <source>Mol. Psychiatry</source> <volume>24</volume>, <fpage>474</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1038/s41380-018-0343-7</pub-id><pub-id pub-id-type="pmid">30617271</pub-id></citation></ref>
<ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghemrawi</surname> <given-names>R.</given-names></name> <name><surname>Khair</surname> <given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Endoplasmic reticulum stress and unfolded protein response in neurodegenerative diseases</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>6127</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21176127</pub-id><pub-id pub-id-type="pmid">32854418</pub-id></citation></ref>
<ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gherardi</surname> <given-names>G.</given-names></name> <name><surname>Corbioli</surname> <given-names>G.</given-names></name> <name><surname>Ruzza</surname> <given-names>F.</given-names></name> <name><surname>Rizzuto</surname> <given-names>R.</given-names></name></person-group> (<year>2022</year>). <article-title>CoQ<sub>10</sub> and resveratrol effects to ameliorate aged-related mitochondrial dysfunctions</article-title>. <source>Nutrients</source> <volume>14</volume>:<fpage>4326</fpage>. <pub-id pub-id-type="doi">10.3390/nu14204326</pub-id><pub-id pub-id-type="pmid">36297010</pub-id></citation></ref>
<ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname> <given-names>R.</given-names></name> <name><surname>Wang</surname> <given-names>L.</given-names></name> <name><surname>Wang</surname> <given-names>E. S.</given-names></name> <name><surname>Perera</surname> <given-names>B. G.</given-names></name> <name><surname>Igbaria</surname> <given-names>A.</given-names></name> <name><surname>Morita</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Allosteric inhibition of the IRE1&#x003B1; RNase preserves cell viability and function during endoplasmic reticulum stress</article-title>. <source>Cell</source> <volume>158</volume>, <fpage>534</fpage>&#x02013;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.07.002</pub-id><pub-id pub-id-type="pmid">25018104</pub-id></citation></ref>
<ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gianferrara</surname> <given-names>T.</given-names></name> <name><surname>Cescon</surname> <given-names>E.</given-names></name> <name><surname>Grieco</surname> <given-names>I.</given-names></name> <name><surname>Spalluto</surname> <given-names>G.</given-names></name> <name><surname>Federico</surname> <given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Glycogen synthase kinase 3&#x003B2; involvement in neuroinflammation and neurodegenerative diseases</article-title>. <source>Curr. Med. Chem.</source> <volume>29</volume>, <fpage>4631</fpage>&#x02013;<lpage>4697</lpage>. <pub-id pub-id-type="doi">10.2174/0929867329666220216113517</pub-id><pub-id pub-id-type="pmid">35170406</pub-id></citation></ref>
<ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000E1;lez-reyes</surname> <given-names>R. E.</given-names></name> <name><surname>Nava-Mesa</surname> <given-names>M. O.</given-names></name> <name><surname>Vargas-S&#x000E1;nchez</surname> <given-names>K.</given-names></name> <name><surname>Ariza-Salamanca</surname> <given-names>D.</given-names></name> <name><surname>Mora-Mu&#x000F1;oz</surname> <given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Involvement of astrocytes in Alzheimer&#x02019;s disease from a neuroinflammatory and oxidative stress perspective</article-title>. <source>Front. Mol. Neurosci.</source> <volume>10</volume>:<fpage>427</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2017.00427</pub-id><pub-id pub-id-type="pmid">29311817</pub-id></citation></ref>
<ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname> <given-names>R.</given-names></name> <name><surname>Albornoz</surname> <given-names>E. A.</given-names></name> <name><surname>Christie</surname> <given-names>D. C.</given-names></name> <name><surname>Langley</surname> <given-names>M. R.</given-names></name> <name><surname>Kumar</surname> <given-names>V.</given-names></name> <name><surname>Mantovani</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Inflammasome inhibition prevents &#x003B1;-synuclein pathology and dopaminergic neurodegeneration in mice</article-title>. <source>Sci. Transl. Med.</source> <volume>10</volume>:<fpage>eaah4066</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aah4066</pub-id><pub-id pub-id-type="pmid">30381407</pub-id></citation></ref>
<ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorman</surname> <given-names>A. M.</given-names></name> <name><surname>Healy</surname> <given-names>S. J.</given-names></name> <name><surname>J&#x000E4;ger</surname> <given-names>R.</given-names></name> <name><surname>Samali</surname> <given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Stress management at the ER: regulators of ER stress-induced apoptosis</article-title>. <source>Pharmacol. Ther.</source> <volume>134</volume>, <fpage>306</fpage>&#x02013;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.02.003</pub-id><pub-id pub-id-type="pmid">22387231</pub-id></citation></ref>
<ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guglielmotto</surname> <given-names>M.</given-names></name> <name><surname>Monteleone</surname> <given-names>D.</given-names></name> <name><surname>Giliberto</surname> <given-names>L.</given-names></name> <name><surname>Fornaro</surname> <given-names>M.</given-names></name> <name><surname>Borghi</surname> <given-names>R.</given-names></name> <name><surname>Tamagno</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Amyloid-&#x003B2;<sub>42</sub> activates the expression of BACE1 through the JNK pathway</article-title>. <source>J. Alzheimers Dis.</source> <volume>27</volume>, <fpage>871</fpage>&#x02013;<lpage>883</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2011-110884</pub-id><pub-id pub-id-type="pmid">21897006</pub-id></citation></ref>
<ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gully</surname> <given-names>J. C.</given-names></name> <name><surname>Sergeyev</surname> <given-names>V. G.</given-names></name> <name><surname>Bhootada</surname> <given-names>Y.</given-names></name> <name><surname>Mendez-Gomez</surname> <given-names>H.</given-names></name> <name><surname>Meyers</surname> <given-names>C. A.</given-names></name> <name><surname>Zolotukhin</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Up-regulation of activating transcription factor 4 induces severe loss of dopamine nigral neurons in a rat model of Parkinson&#x02019;s disease</article-title>. <source>Neurosci. Lett.</source> <volume>627</volume>, <fpage>36</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2016.05.039</pub-id><pub-id pub-id-type="pmid">27233218</pub-id></citation></ref>
<ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>M.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Feng</surname> <given-names>Y.</given-names></name> <name><surname>Han</surname> <given-names>S.</given-names></name> <name><surname>Dong</surname> <given-names>Q.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Microglial exosomes facilitate &#x003B1;-synuclein transmission in Parkinson&#x02019;s disease</article-title>. <source>Brain</source> <volume>143</volume>, <fpage>1476</fpage>&#x02013;<lpage>1497</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awaa090</pub-id><pub-id pub-id-type="pmid">32355963</pub-id></citation></ref>
<ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>R.</given-names></name> <name><surname>Ambasta</surname> <given-names>R. K.</given-names></name> <name><surname>Pravir</surname> <given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Autophagy and apoptosis cascade: which is more prominent in neuronal death?</article-title> <source>Cell. Mol. Life Sci.</source> <volume>78</volume>, <fpage>8001</fpage>&#x02013;<lpage>8047</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-021-04004-4</pub-id><pub-id pub-id-type="pmid">34741624</pub-id></citation></ref>
<ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname> <given-names>S.</given-names></name> <name><surname>Mishra</surname> <given-names>A.</given-names></name> <name><surname>Singh</surname> <given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Cardinal role of eukaryotic initiation factor 2 (eIF2&#x003B1;) in progressive dopaminergic neuronal death, DNA fragmentation: implication of PERK:IRE1&#x003B1;:ATF6 axis in Parkinson&#x02019;s pathology</article-title>. <source>Cell Signal.</source> <volume>81</volume>:<fpage>109922</fpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2021.109922</pub-id></citation></ref>
<ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hajam</surname> <given-names>Y. A.</given-names></name> <name><surname>Rani</surname> <given-names>R.</given-names></name> <name><surname>Ganie</surname> <given-names>S. Y.</given-names></name> <name><surname>Sheikh</surname> <given-names>T. A.</given-names></name> <name><surname>Javaid</surname> <given-names>D.</given-names></name> <name><surname>Qadri</surname> <given-names>S. S.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Oxidative stress in human pathology and aging: molecular mechanisms and perspectives</article-title>. <source>Cells</source> <volume>11</volume>:<fpage>552</fpage>. <pub-id pub-id-type="doi">10.3390/cells11030552</pub-id><pub-id pub-id-type="pmid">35159361</pub-id></citation></ref>
<ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname> <given-names>M.</given-names></name> <name><surname>Radford</surname> <given-names>H.</given-names></name> <name><surname>Sekine</surname> <given-names>Y.</given-names></name> <name><surname>Moreno</surname> <given-names>J.</given-names></name> <name><surname>Verity</surname> <given-names>N.</given-names></name> <name><surname>Le Quesne</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity</article-title>. <source>Cell Death Dis.</source> <volume>6</volume>:<fpage>e1672</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2015.49</pub-id><pub-id pub-id-type="pmid">25741597</pub-id></citation></ref>
<ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname> <given-names>M.</given-names></name> <name><surname>Radford</surname> <given-names>H.</given-names></name> <name><surname>Zents</surname> <given-names>K. A. M.</given-names></name> <name><surname>Molloy</surname> <given-names>C.</given-names></name> <name><surname>Moreno</surname> <given-names>J. A.</given-names></name> <name><surname>Verity</surname> <given-names>N. C.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Repurposed drugs targeting eIF2&#x003B1;-P-mediated translational repression prevent neurodegeneration in mice</article-title>. <source>Brain</source> <volume>140</volume>, <fpage>1768</fpage>&#x02013;<lpage>1783</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awx074</pub-id><pub-id pub-id-type="pmid">28430857</pub-id></citation></ref>
<ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halperin</surname> <given-names>L.</given-names></name> <name><surname>Jung</surname> <given-names>J.</given-names></name> <name><surname>Michalak</surname> <given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>The many functions of the endoplasmic reticulum chaperones and folding enzymes</article-title>. <source>IUBMB Life</source> <volume>66</volume>, <fpage>318</fpage>&#x02013;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1002/iub.1272</pub-id><pub-id pub-id-type="pmid">24839203</pub-id></citation></ref>
<ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashioka</surname> <given-names>S.</given-names></name> <name><surname>Wu</surname> <given-names>Z.</given-names></name> <name><surname>Klegeris</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Glia-driven neuroinflammation and systemic inflammation in Alzheimer&#x02019;s disease</article-title>. <source>Curr. Neuropharmacol.</source> <volume>19</volume>, <fpage>908</fpage>&#x02013;<lpage>924</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X18666201111104509</pub-id><pub-id pub-id-type="pmid">33176652</pub-id></citation></ref>
<ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hazafa</surname> <given-names>A.</given-names></name> <name><surname>Batool</surname> <given-names>A.</given-names></name> <name><surname>Ahmad</surname> <given-names>S.</given-names></name> <name><surname>Amjad</surname> <given-names>M.</given-names></name> <name><surname>Chaudhry</surname> <given-names>S. N.</given-names></name> <name><surname>Asad</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Humanin: a mitochondrial-derived peptide in the treatment of apoptosis-related diseases</article-title>. <source>Life Sci.</source> <volume>264</volume>:<fpage>118679</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.118679</pub-id><pub-id pub-id-type="pmid">33130077</pub-id></citation></ref>
<ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heidari</surname> <given-names>A.</given-names></name> <name><surname>Yazdanpanah</surname> <given-names>N.</given-names></name> <name><surname>Rezaei</surname> <given-names>N.</given-names></name></person-group> (<year>2022</year>). <article-title>The role of toll-like receptors and neuroinflammation in Parkinson&#x02019;s disease</article-title>. <source>J. Neuroinflammation</source> <volume>19</volume>:<fpage>135</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-022-02496-w</pub-id><pub-id pub-id-type="pmid">35668422</pub-id></citation></ref>
<ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hetz</surname> <given-names>C.</given-names></name> <name><surname>Saxena</surname> <given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>ER stress and the unfolded protein response in neurodegeneration</article-title>. <source>Nat. Rev. Neurol.</source> <volume>13</volume>, <fpage>477</fpage>&#x02013;<lpage>491</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2017.99</pub-id><pub-id pub-id-type="pmid">28731040</pub-id></citation></ref>
<ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirota</surname> <given-names>M.</given-names></name> <name><surname>Kitagaki</surname> <given-names>M.</given-names></name> <name><surname>Itagaki</surname> <given-names>H.</given-names></name> <name><surname>Aiba</surname> <given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Quantitative measurement of spliced XBP1 mRNA as an indicator of endoplasmic reticulum stress</article-title>. <source>J. Toxicol. Sci.</source> <volume>31</volume>, <fpage>149</fpage>&#x02013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.2131/jts.31.149</pub-id><pub-id pub-id-type="pmid">16772704</pub-id></citation></ref>
<ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname> <given-names>E. C.</given-names></name> <name><surname>Hunot</surname> <given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Neuroinflammation in Parkinson&#x02019;s disease: a target for neuroprotection?</article-title> <source>Lancet Neurol.</source> <volume>8</volume>, <fpage>382</fpage>&#x02013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(09)70062-6</pub-id><pub-id pub-id-type="pmid">19296921</pub-id></citation></ref>
<ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname> <given-names>L.</given-names></name> <name><surname>Waclawczyk</surname> <given-names>M. S.</given-names></name> <name><surname>Tang</surname> <given-names>S.</given-names></name> <name><surname>Hanschmann</surname> <given-names>E. M.</given-names></name> <name><surname>Gellert</surname> <given-names>M.</given-names></name> <name><surname>Rust</surname> <given-names>M. B.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Cofilin1 oxidation links oxidative distress to mitochondrial demise and neuronal cell death</article-title>. <source>Cell Death Dis.</source> <volume>12</volume>:<fpage>953</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-021-04242-1</pub-id><pub-id pub-id-type="pmid">34657120</pub-id></citation></ref>
<ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>H&#x000F6;hn</surname> <given-names>A.</given-names></name> <name><surname>Tramutola</surname> <given-names>A.</given-names></name> <name><surname>Cascella</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Proteostasis failure in neurodegenerative diseases: focus on oxidative stress</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2020</volume>:<fpage>5497046</fpage>. <pub-id pub-id-type="doi">10.1155/2020/5497046</pub-id><pub-id pub-id-type="pmid">32308803</pub-id></citation></ref>
<ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holubiec</surname> <given-names>M. I.</given-names></name> <name><surname>Gellert</surname> <given-names>M.</given-names></name> <name><surname>Hanschmann</surname> <given-names>E. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Redox signaling and metabolism in Alzheimer&#x02019;s disease</article-title>. <source>Front. Aging Neurosci.</source> <volume>14</volume>:<fpage>1003721</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2022.1003721</pub-id><pub-id pub-id-type="pmid">36408110</pub-id></citation></ref>
<ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname> <given-names>K.</given-names></name> <name><surname>Katagiri</surname> <given-names>K.</given-names></name> <name><surname>Nishitoh</surname> <given-names>H.</given-names></name> <name><surname>Ichijo</surname> <given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Targeting ASK1 in ER stress-related neurodegenerative diseases</article-title>. <source>Expert Opin. Ther. Targets</source> <volume>13</volume>, <fpage>653</fpage>&#x02013;<lpage>664</lpage>. <pub-id pub-id-type="doi">10.1517/14728220902980249</pub-id><pub-id pub-id-type="pmid">19456270</pub-id></citation></ref>
<ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname> <given-names>Y.</given-names></name> <name><surname>Wei</surname> <given-names>Y.</given-names></name> <name><surname>Lautrup</surname> <given-names>S.</given-names></name> <name><surname>Yang</surname> <given-names>B.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Cordonnier</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>NAD<sup>+</sup> supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer&#x02019;s disease via cGAS-STING</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>118</volume>:<fpage>e2011226118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2011226118</pub-id><pub-id pub-id-type="pmid">34497121</pub-id></citation></ref>
<ref id="B0013"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>J.</given-names></name> <name><surname>Huang</surname> <given-names>N.</given-names></name> <name><surname>Xu</surname> <given-names>S.</given-names></name> <name><surname>Luo</surname> <given-names>Y.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Jin</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Signaling mechanisms underlying inhibition of neuroinflammation by resveratrol in neurodegenerative diseases</article-title>. <source>J. Nutr. Biochem.</source> <volume>88</volume>:<fpage>108552</fpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2020.108552</pub-id><pub-id pub-id-type="pmid">33220405</pub-id></citation></ref>
<ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>L.</given-names></name> <name><surname>Xue</surname> <given-names>Y.</given-names></name> <name><surname>Feng</surname> <given-names>D.</given-names></name> <name><surname>Yang</surname> <given-names>R.</given-names></name> <name><surname>Nie</surname> <given-names>T.</given-names></name> <name><surname>Zhu</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Blockade of RyRs in the ER attenuates 6-OHDA-induced calcium overload, cellular hypo-excitability and apoptosis in dopaminergic neurons</article-title>. <source>Front. Cell Neurosci.</source> <volume>11</volume>:<fpage>52</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00052</pub-id><pub-id pub-id-type="pmid">28316566</pub-id></citation></ref>
<ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hung</surname> <given-names>S. Y.</given-names></name> <name><surname>Fu</surname> <given-names>W. M.</given-names></name></person-group> (<year>2017</year>). <article-title>Drug candidates in clinical trials for Alzheimer&#x02019;s disease</article-title>. <source>J. Biomed. Sci.</source> <volume>24</volume>:<fpage>47</fpage>. <pub-id pub-id-type="doi">10.1186/s12929-017-0355-7</pub-id><pub-id pub-id-type="pmid">28720101</pub-id></citation></ref>
<ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname> <given-names>J.</given-names></name> <name><surname>Pak</surname> <given-names>S. C.</given-names></name> <name><surname>Koo</surname> <given-names>B. S.</given-names></name> <name><surname>Jeon</surname> <given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Borneol alleviates oxidative stress via upregulation of Nrf2 and Bcl-2 in SH-SY5Y cells</article-title>. <source>Pharm. Biol.</source> <volume>51</volume>, <fpage>30</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.3109/13880209.2012.700718</pub-id><pub-id pub-id-type="pmid">23134284</pub-id></citation></ref>
<ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imbeault</surname> <given-names>E.</given-names></name> <name><surname>Mahvelati</surname> <given-names>T. M.</given-names></name> <name><surname>Braun</surname> <given-names>R.</given-names></name> <name><surname>Gris</surname> <given-names>P.</given-names></name> <name><surname>Gris</surname> <given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Nlrx1 regulates neuronal cell death</article-title>. <source>Mol. Brain</source> <volume>7</volume>:<fpage>90</fpage>. <pub-id pub-id-type="doi">10.1186/s13041-014-0090-x</pub-id><pub-id pub-id-type="pmid">25540124</pub-id></citation></ref>
<ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishtiaq</surname> <given-names>A.</given-names></name> <name><surname>Ali</surname> <given-names>T.</given-names></name> <name><surname>Bakhtiar</surname> <given-names>A.</given-names></name> <name><surname>Bibi</surname> <given-names>R.</given-names></name> <name><surname>Bibi</surname> <given-names>K.</given-names></name> <name><surname>Mushtaq</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Melatonin abated bisphenol A-induced neurotoxicity via p53/PUMA/Drp-1 signaling</article-title>. <source>Environ. Sci. Pollut. Res. Int.</source> <volume>28</volume>, <fpage>17789</fpage>&#x02013;<lpage>17801</lpage>. <pub-id pub-id-type="doi">10.1007/s11356-020-12129-5</pub-id><pub-id pub-id-type="pmid">33398767</pub-id></citation></ref>
<ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname> <given-names>D.</given-names></name> <name><surname>Li</surname> <given-names>X.</given-names></name> <name><surname>Williams</surname> <given-names>R.</given-names></name> <name><surname>Patel</surname> <given-names>S.</given-names></name> <name><surname>Men</surname> <given-names>L.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Ternary complexes of iron, amyloid-&#x003B2;, and nitrilotriacetic acid: binding affinities, redox properties and relevance to iron-induced oxidative stress in Alzheimer&#x02019;s disease</article-title>. <source>Biochemistry</source> <volume>48</volume>, <fpage>7939</fpage>&#x02013;<lpage>7947</lpage>. <pub-id pub-id-type="doi">10.1021/bi900907a</pub-id><pub-id pub-id-type="pmid">19601593</pub-id></citation></ref>
<ref id="B0010"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname> <given-names>S. H.</given-names></name> <name><surname>Kim</surname> <given-names>M. E.</given-names></name> <name><surname>Cho</surname> <given-names>J. H.</given-names></name> <name><surname>Lee</surname> <given-names>Y.</given-names></name> <name><surname>Lee</surname> <given-names>J.</given-names></name> <name><surname>Park</surname> <given-names>Y. D.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Hesperetin inhibits neuroinflammation on microglia by suppressing inflammatory cytokines and MAPK pathways</article-title>. <source>Arch. Pharm. Res.</source> <volume>42</volume>, <fpage>695</fpage>&#x02013;<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-019-01174-5</pub-id><pub-id pub-id-type="pmid">31327152</pub-id></citation></ref>
<ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>J.</given-names></name> <name><surname>Mercado-Ayon</surname> <given-names>E.</given-names></name> <name><surname>Mercado-Ayon</surname> <given-names>Y.</given-names></name> <name><surname>Dong</surname> <given-names>Y. N.</given-names></name> <name><surname>Halawani</surname> <given-names>S.</given-names></name> <name><surname>Ngaba</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Mitochondrial dysfunction in the development and progression of neurodegenerative diseases</article-title>. <source>Arch. Biochem. Biophys.</source> <volume>702</volume>:<fpage>108698</fpage>. <pub-id pub-id-type="doi">10.1016/j.abb.2020.108698</pub-id><pub-id pub-id-type="pmid">33259796</pub-id></citation></ref>
<ref id="B98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johri</surname> <given-names>A.</given-names></name> <name><surname>Beal</surname> <given-names>M. F.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitochondrial dysfunction in neurodegenerative diseases</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>342</volume>, <fpage>619</fpage>&#x02013;<lpage>630</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.112.192138</pub-id><pub-id pub-id-type="pmid">22700435</pub-id></citation></ref>
<ref id="B99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname> <given-names>A. U.</given-names></name> <name><surname>Minhas</surname> <given-names>P. S.</given-names></name> <name><surname>Liddelow</surname> <given-names>S. A.</given-names></name> <name><surname>Haileselassie</surname> <given-names>B.</given-names></name> <name><surname>Andreasson</surname> <given-names>K. I.</given-names></name> <name><surname>Dorn</surname> <given-names>G. W.</given-names> <suffix>2nd</suffix></name> <etal/></person-group>. (<year>2019</year>). <article-title>Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration</article-title>. <source>Nat. Neurosci.</source> <volume>22</volume>, <fpage>1635</fpage>&#x02013;<lpage>1648</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-019-0486-0</pub-id><pub-id pub-id-type="pmid">31551592</pub-id></citation></ref>
<ref id="B100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaminskyy</surname> <given-names>V. O.</given-names></name> <name><surname>Zhivotovsky</surname> <given-names>B.</given-names></name></person-group> (<year>2014</year>). <article-title>Free radicals in cross talk between autophagy and apoptosis</article-title>. <source>Antioxid. Redox Signal.</source> <volume>21</volume>, <fpage>86</fpage>&#x02013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2013.5746</pub-id><pub-id pub-id-type="pmid">24359220</pub-id></citation></ref>
<ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karimi-Haghighi</surname> <given-names>S.</given-names></name> <name><surname>Razavi</surname> <given-names>Y.</given-names></name> <name><surname>Iezzi</surname> <given-names>D.</given-names></name> <name><surname>Scheyer</surname> <given-names>A. F.</given-names></name> <name><surname>Manzoni</surname> <given-names>O.</given-names></name> <name><surname>Haghparast</surname> <given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Cannabidiol and substance use disorder: dream or reality</article-title>. <source>Neuropharmacology</source> <volume>207</volume>:<fpage>108948</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.108948</pub-id><pub-id pub-id-type="pmid">35032495</pub-id></citation></ref>
<ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karuppagounder</surname> <given-names>S. S.</given-names></name> <name><surname>Alim</surname> <given-names>I.</given-names></name> <name><surname>Khim</surname> <given-names>S. J.</given-names></name> <name><surname>Bourassa</surname> <given-names>M. W.</given-names></name> <name><surname>Sleiman</surname> <given-names>S. F.</given-names></name> <name><surname>John</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models</article-title>. <source>Sci. Transl. Med.</source> <volume>8</volume>:<fpage>328ra29</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aac6008</pub-id><pub-id pub-id-type="pmid">26936506</pub-id></citation></ref>
<ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname> <given-names>P.</given-names></name> <name><surname>Thompson</surname> <given-names>J. L.</given-names></name> <name><surname>Levy</surname> <given-names>G.</given-names></name> <name><surname>Buchsbaum</surname> <given-names>R.</given-names></name> <name><surname>Shefner</surname> <given-names>J.</given-names></name> <name><surname>Krivickas</surname> <given-names>L. S.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III</article-title>. <source>Ann. Neurol.</source> <volume>66</volume>, <fpage>235</fpage>&#x02013;<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21743</pub-id><pub-id pub-id-type="pmid">19743457</pub-id></citation></ref>
<ref id="B001"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>J. S.</given-names></name> <name><surname>Heo</surname> <given-names>R. W.</given-names></name> <name><surname>Kim</surname> <given-names>H.</given-names></name> <name><surname>Yi</surname> <given-names>C. O.</given-names></name> <name><surname>Shin</surname> <given-names>H. J.</given-names></name> <name><surname>Han</surname> <given-names>J. W.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Salubrinal, ER stress inhibitor, attenuates kainic acid-induced hippocampal cell death</article-title>. <source>J. Neural Transm. (Vienna)</source> <volume>121</volume>, <fpage>1233</fpage>&#x02013;<lpage>1243</lpage>. <pub-id pub-id-type="doi">10.1007/s00702-014-1208-0</pub-id><pub-id pub-id-type="pmid">24728926</pub-id></citation></ref>
<ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname> <given-names>G.</given-names></name> <name><surname>Delmar</surname> <given-names>P.</given-names></name> <name><surname>Voyle</surname> <given-names>N.</given-names></name> <name><surname>Rehal</surname> <given-names>S.</given-names></name> <name><surname>Hofmann</surname> <given-names>C.</given-names></name> <name><surname>Abi-Saab</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Gantenerumab reduces amyloid-&#x003B2; plaques in patients with prodromal to moderate Alzheimer&#x02019;s disease: a PET substudy interim analysis</article-title>. <source>Alzheimers Res. Ther.</source> <volume>11</volume>:<fpage>101</fpage>. <pub-id pub-id-type="doi">10.1186/s13195-019-0559-z</pub-id></citation></ref>
<ref id="B105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klepac</surname> <given-names>N.</given-names></name> <name><surname>Relja</surname> <given-names>M.</given-names></name> <name><surname>Klepac</surname> <given-names>R.</given-names></name> <name><surname>He&#x00107;imovi&#x00107;</surname> <given-names>S.</given-names></name> <name><surname>Babi&#x00107;</surname> <given-names>T.</given-names></name> <name><surname>Trkulja</surname> <given-names>V.</given-names></name></person-group> (<year>2007</year>). <article-title>Oxidative stress parameters in plasma of Huntington&#x02019;s disease patients, asymptomatic Huntington&#x02019;s disease gene carriers and healthy subjects: a cross-sectional study</article-title>. <source>J. Neurol.</source> <volume>254</volume>, <fpage>1676</fpage>&#x02013;<lpage>1683</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-007-0611-y</pub-id><pub-id pub-id-type="pmid">17990062</pub-id></citation></ref>
<ref id="B106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korovesis</surname> <given-names>D.</given-names></name> <name><surname>Rubio-Tom&#x000E1;s</surname> <given-names>T.</given-names></name> <name><surname>Tavernarakis</surname> <given-names>N.</given-names></name></person-group> (<year>2023</year>). <article-title>Oxidative stress in age-related neurodegenerative diseases: an overview of recent tools and findings</article-title>. <source>Antioxidants (Basel)</source> <volume>12</volume>:<fpage>131</fpage>. <pub-id pub-id-type="doi">10.3390/antiox12010131</pub-id><pub-id pub-id-type="pmid">36670993</pub-id></citation></ref>
<ref id="B107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovac</surname> <given-names>S.</given-names></name> <name><surname>Angelova</surname> <given-names>P. R.</given-names></name> <name><surname>Holmstr&#x000F6;m</surname> <given-names>K. M.</given-names></name> <name><surname>Zhang</surname> <given-names>Y.</given-names></name> <name><surname>Dinkova-Kostova</surname> <given-names>A. T.</given-names></name> <name><surname>Abramov</surname> <given-names>A. Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Nrf2 regulates ROS production by mitochondria and NADPH oxidase</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1850</volume>, <fpage>794</fpage>&#x02013;<lpage>801</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2014.11.021</pub-id><pub-id pub-id-type="pmid">25484314</pub-id></citation></ref>
<ref id="B108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname> <given-names>S. B.</given-names></name> <name><surname>Miao</surname> <given-names>E. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Gasdermins: effectors of pyroptosis</article-title>. <source>Trends Cell. Biol.</source> <volume>27</volume>, <fpage>673</fpage>&#x02013;<lpage>684</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2017.05.005</pub-id><pub-id pub-id-type="pmid">28619472</pub-id></citation></ref>
<ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>H.</given-names></name> <name><surname>Lim</surname> <given-names>H. W.</given-names></name> <name><surname>More</surname> <given-names>S. V.</given-names></name> <name><surname>Kim</surname> <given-names>B. W.</given-names></name> <name><surname>Koppula</surname> <given-names>S.</given-names></name> <name><surname>Kim</surname> <given-names>I. S.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>The role of free radicals in the aging brain and Parkinson&#x02019;s disease: convergence and parallelism</article-title>. <source>Int. J. Mol. Sci.</source> <volume>13</volume>, <fpage>10478</fpage>&#x02013;<lpage>10504</lpage>. <pub-id pub-id-type="doi">10.3390/ijms130810478</pub-id><pub-id pub-id-type="pmid">22949875</pub-id></citation></ref>
<ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname> <given-names>H. S.</given-names></name> <name><surname>Koh</surname> <given-names>S. H.</given-names></name></person-group> (<year>2020</year>). <article-title>Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes</article-title>. <source>Transl. Neurodegener.</source> <volume>9</volume>:<fpage>42</fpage>. <pub-id pub-id-type="doi">10.1186/s40035-020-00221-2</pub-id><pub-id pub-id-type="pmid">33239064</pub-id></citation></ref>
<ref id="B111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname> <given-names>F. M.</given-names></name> <name><surname>Mo</surname> <given-names>Y.</given-names></name> <name><surname>Sabbagh</surname> <given-names>M.</given-names></name> <name><surname>Solomon</surname> <given-names>P.</given-names></name> <name><surname>Boada</surname> <given-names>M.</given-names></name> <name><surname>Jones</surname> <given-names>R. W.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer&#x02019;s disease: a randomized, placebo-controlled, phase 3 clinical trial (MINDSET)</article-title>. <source>Alzheimers Dement. (N Y)</source> <volume>7</volume>:<fpage>e12136</fpage>. <pub-id pub-id-type="doi">10.1002/trc2.12136</pub-id><pub-id pub-id-type="pmid">34095437</pub-id></citation></ref>
<ref id="B112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>A.-H.</given-names></name> <name><surname>Iwakoshi</surname> <given-names>N. N.</given-names></name> <name><surname>Glimcher</surname> <given-names>L. H.</given-names></name></person-group> (<year>2003</year>). <article-title>XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response</article-title>. <source>Mol. Cell Biol.</source> <volume>23</volume>, <fpage>7448</fpage>&#x02013;<lpage>7459</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.23.21.7448-7459.2003</pub-id><pub-id pub-id-type="pmid">14559994</pub-id></citation></ref>
<ref id="B113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>C.-M.</given-names></name> <name><surname>Lee</surname> <given-names>D.-S.</given-names></name> <name><surname>Jung</surname> <given-names>W.-K.</given-names></name> <name><surname>Yoo</surname> <given-names>J. S.</given-names></name> <name><surname>Yim</surname> <given-names>M.-J.</given-names></name> <name><surname>Choi</surname> <given-names>Y. H.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Benzyl isothiocyanate inhibits inflammasome activation in <italic>E. coli</italic> LPS-stimulated BV2 cells</article-title>. <source>Int. J. Mol. Med.</source> <volume>38</volume>, <fpage>912</fpage>&#x02013;<lpage>918</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2016.2667</pub-id><pub-id pub-id-type="pmid">27430883</pub-id></citation></ref>
<ref id="B114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>C.</given-names></name> <name><surname>Park</surname> <given-names>G. H.</given-names></name> <name><surname>Kim</surname> <given-names>C.-Y.</given-names></name> <name><surname>Jang</surname> <given-names>J.-H.</given-names></name></person-group> (<year>2011</year>). <article-title>-Gingerol attenuates &#x003B2;-amyloid-induced oxidative cell death via fortifying cellular antioxidant defense system</article-title>. <source>Food Chem. Toxicol.</source> <volume>49</volume>, <fpage>1261</fpage>&#x02013;<lpage>1269</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2011.03.005</pub-id><pub-id pub-id-type="pmid">21396424</pub-id></citation></ref>
<ref id="B115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>E.</given-names></name> <name><surname>Hwang</surname> <given-names>I.</given-names></name> <name><surname>Park</surname> <given-names>S.</given-names></name> <name><surname>Hong</surname> <given-names>S.</given-names></name> <name><surname>Hwang</surname> <given-names>B.</given-names></name> <name><surname>Cho</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration</article-title>. <source>Cell Death Differ.</source> <volume>26</volume>, <fpage>213</fpage>&#x02013;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-018-0124-5</pub-id><pub-id pub-id-type="pmid">29786072</pub-id></citation></ref>
<ref id="B116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname> <given-names>F.</given-names></name> <name><surname>Edison</surname> <given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?</article-title> <source>Nat. Rev. Neurol.</source> <volume>17</volume>, <fpage>157</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1038/s41582-020-00435-y</pub-id><pub-id pub-id-type="pmid">33318676</pub-id></citation></ref>
<ref id="B117"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lezi</surname> <given-names>E.</given-names></name> <name><surname>Swerdlow</surname> <given-names>R. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Mitochondria in neurodegeneration</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>942</volume>, <fpage>269</fpage>&#x02013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1007/978-94-007-2869-1_12</pub-id><pub-id pub-id-type="pmid">22399427</pub-id></citation></ref>
<ref id="B005"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>W.</given-names></name> <name><surname>Fotinos</surname> <given-names>A.</given-names></name> <name><surname>Wu</surname> <given-names>Q.</given-names></name> <name><surname>Chen</surname> <given-names>Y.</given-names></name> <name><surname>Zhu</surname> <given-names>Y.</given-names></name> <name><surname>Baranov</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>N-acetyl-L-tryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model</article-title>. <source>Neurobiol. Dis.</source> <volume>80</volume>, <fpage>93</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2015.05.002</pub-id><pub-id pub-id-type="pmid">25986728</pub-id></citation></ref>
<ref id="B118"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y. C.</given-names></name> <name><surname>Hao</surname> <given-names>J. C.</given-names></name> <name><surname>Shang</surname> <given-names>B.</given-names></name> <name><surname>Zhao</surname> <given-names>C.</given-names></name> <name><surname>Wang</surname> <given-names>L. J.</given-names></name> <name><surname>Yang</surname> <given-names>K. L.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Neuroprotective effects of aucubin on hydrogen peroxide-induced toxicity in human neuroblastoma SH-SY5Y cells via the Nrf2/HO-1 pathway</article-title>. <source>Phytomedicine</source> <volume>87</volume>:<fpage>153577</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2021.153577</pub-id><pub-id pub-id-type="pmid">33994055</pub-id></citation></ref>
<ref id="B119"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Vaughan</surname> <given-names>K. L.</given-names></name> <name><surname>Tweedie</surname> <given-names>D.</given-names></name> <name><surname>Jung</surname> <given-names>J.</given-names></name> <name><surname>Kim</surname> <given-names>H. K.</given-names></name> <name><surname>Choi</surname> <given-names>H. I.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon</article-title>. <source>Sci. Rep.</source> <volume>9</volume>:<fpage>17208</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-019-53356-2</pub-id><pub-id pub-id-type="pmid">31748513</pub-id></citation></ref>
<ref id="B120"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Xia</surname> <given-names>Y.</given-names></name> <name><surname>Yin</surname> <given-names>S.</given-names></name> <name><surname>Wan</surname> <given-names>F.</given-names></name> <name><surname>Hu</surname> <given-names>J.</given-names></name> <name><surname>Kou</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Targeting microglial &#x003B1;-synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in Parkinson&#x02019;s disease</article-title>. <source>Front Immunol.</source> <volume>12</volume>:<fpage>719807</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.719807</pub-id><pub-id pub-id-type="pmid">34691027</pub-id></citation></ref>
<ref id="B009"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>Z.</given-names></name> <name><surname>Zhang</surname> <given-names>B.</given-names></name> <name><surname>Su</surname> <given-names>W. W.</given-names></name> <name><surname>Williams</surname> <given-names>P. G.</given-names></name> <name><surname>Li</surname> <given-names>Q. X.</given-names></name></person-group> (<year>2016</year>). <article-title>C-Glycosylflavones alleviate tau phosphorylation and amyloid neurotoxicity through GSK3&#x003B2; inhibition</article-title>. <source>ACS Chem. Neurosci.</source> <volume>7</volume>, <fpage>912</fpage>&#x02013;<lpage>923</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.6b00059</pub-id><pub-id pub-id-type="pmid">27213824</pub-id></citation></ref>
<ref id="B121"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>J. H.</given-names></name> <name><surname>Park</surname> <given-names>H. S.</given-names></name> <name><surname>Choi</surname> <given-names>J. K.</given-names></name> <name><surname>Lee</surname> <given-names>I. S.</given-names></name> <name><surname>Choi</surname> <given-names>H. J.</given-names></name></person-group> (<year>2007</year>). <article-title>Isoorientin induces Nrf2 pathway-driven antioxidant response through phosphatidylinositol 3-kinase signaling</article-title>. <source>Arch. Pharm. Res.</source> <volume>30</volume>, <fpage>1590</fpage>&#x02013;<lpage>1598</lpage>. <pub-id pub-id-type="doi">10.1007/BF02977329</pub-id><pub-id pub-id-type="pmid">18254247</pub-id></citation></ref>
<ref id="B122"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname> <given-names>M. T.</given-names></name> <name><surname>Beal</surname> <given-names>M. F.</given-names></name></person-group> (<year>2006</year>). <article-title>Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases</article-title>. <source>Nature</source> <volume>443</volume>, <fpage>787</fpage>&#x02013;<lpage>795</lpage>. <pub-id pub-id-type="doi">10.1038/nature05292</pub-id><pub-id pub-id-type="pmid">17051205</pub-id></citation></ref>
<ref id="B124"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Lillo</surname> <given-names>C.</given-names></name> <name><surname>Jonsson</surname> <given-names>P. A.</given-names></name> <name><surname>Vande Velde</surname> <given-names>C.</given-names></name> <name><surname>Ward</surname> <given-names>C. M.</given-names></name> <name><surname>Miller</surname> <given-names>T. M.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>Toxicity of familial ALS-linked SOD1 mutants from selective recruitment to spinal mitochondria</article-title>. <source>Neuron</source> <volume>43</volume>, <fpage>5</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2004.06.016</pub-id><pub-id pub-id-type="pmid">15233913</pub-id></citation></ref>
<ref id="B123"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title>Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications</article-title>. <source>Front. Immunol.</source> <volume>8</volume>:<fpage>1005</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.01005</pub-id><pub-id pub-id-type="pmid">28871262</pub-id></citation></ref>
<ref id="B125"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>Z.</given-names></name> <name><surname>Zhou</surname> <given-names>T.</given-names></name> <name><surname>Ziegler</surname> <given-names>A. C.</given-names></name> <name><surname>Dimitrion</surname> <given-names>P.</given-names></name> <name><surname>Zuo</surname> <given-names>L.</given-names></name></person-group> (<year>2017</year>). <article-title>Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2017</volume>:<fpage>2525967</fpage>. <pub-id pub-id-type="doi">10.1155/2017/2525967</pub-id><pub-id pub-id-type="pmid">28785371</pub-id></citation></ref>
<ref id="B126"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llano</surname> <given-names>D. A.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Waring</surname> <given-names>J. F.</given-names></name> <name><surname>Ellis</surname> <given-names>T.</given-names></name> <name><surname>Devanarayan</surname> <given-names>V.</given-names></name> <name><surname>Witte</surname> <given-names>D. G.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls</article-title>. <source>Alzheimer Dis. Assoc. Disord.</source> <volume>26</volume>, <fpage>322</fpage>&#x02013;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1097/WAD.0b013e31823b2728</pub-id><pub-id pub-id-type="pmid">22089638</pub-id></citation></ref>
<ref id="B127"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>L&#x000F3;pez-Send&#x000F3;n Moreno</surname> <given-names>J. L.</given-names></name> <name><surname>Garc&#x000ED;a Caldentey</surname> <given-names>J.</given-names></name> <name><surname>Trigo Cubillo</surname> <given-names>P.</given-names></name> <name><surname>Ruiz Romero</surname> <given-names>C.</given-names></name> <name><surname>Garc&#x000ED;a Ribas</surname> <given-names>G.</given-names></name> <name><surname>Alonso Arias</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington&#x02019;s disease</article-title>. <source>J. Neurol.</source> <volume>263</volume>, <fpage>1390</fpage>&#x02013;<lpage>1400</lpage>. <pub-id pub-id-type="doi">10.1007/s00415-016-8145-9</pub-id><pub-id pub-id-type="pmid">27159993</pub-id></citation></ref>
<ref id="B128"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>T.</given-names></name> <name><surname>Aron</surname> <given-names>L.</given-names></name> <name><surname>Zullo</surname> <given-names>J.</given-names></name> <name><surname>Pan</surname> <given-names>Y.</given-names></name> <name><surname>Kim</surname> <given-names>H.</given-names></name> <name><surname>Chen</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>REST and stress resistance in ageing and Alzheimer&#x02019;s disease</article-title>. <source>Nature</source> <volume>507</volume>, <fpage>448</fpage>&#x02013;<lpage>454</lpage>. <pub-id pub-id-type="doi">10.1038/nature13163</pub-id><pub-id pub-id-type="pmid">24670762</pub-id></citation></ref>
<ref id="B129"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>W.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Liu</surname> <given-names>T.</given-names></name> <name><surname>Jia</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>3 &#x003B2;-hydroxysteroid-&#x00394; 24 reductase (DHCR24) protects neuronal cells from apoptotic cell death induced by endoplasmic reticulum (ER) stress</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e86753</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0086753</pub-id><pub-id pub-id-type="pmid">24489783</pub-id></citation></ref>
<ref id="B130"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lustbader</surname> <given-names>J. W.</given-names></name> <name><surname>Cirilli</surname> <given-names>M.</given-names></name> <name><surname>Lin</surname> <given-names>C.</given-names></name> <name><surname>Xu</surname> <given-names>H. W.</given-names></name> <name><surname>Takuma</surname> <given-names>K.</given-names></name> <name><surname>Wang</surname> <given-names>N.</given-names></name> <etal/></person-group>. (<year>2004</year>). <article-title>ABAD directly links A&#x003B2; to mitochondrial toxicity in Alzheimer&#x02019;s disease</article-title>. <source>Science</source> <volume>304</volume>, <fpage>448</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1126/science.1091230</pub-id><pub-id pub-id-type="pmid">15087549</pub-id></citation></ref>
<ref id="B132"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname> <given-names>R.</given-names></name> <name><surname>Du</surname> <given-names>L.</given-names></name> <name><surname>Zhou</surname> <given-names>F.</given-names></name> <name><surname>Yuan</surname> <given-names>X.</given-names></name> <name><surname>Liu</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>Rosmarinic acid alleviates inflammation, apoptosis and oxidative stress through regulating miR-155-5p in a Mice Model of Parkinson&#x02019;s disease</article-title>. <source>ACS Chem. Neurosci.</source> <volume>11</volume>, <fpage>3259</fpage>&#x02013;<lpage>3266</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.0c00375</pub-id><pub-id pub-id-type="pmid">32946211</pub-id></citation></ref>
<ref id="B131"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname> <given-names>M.</given-names></name> <name><surname>Xue</surname> <given-names>G.</given-names></name> <name><surname>Cheng</surname> <given-names>H.</given-names></name> <name><surname>Meng</surname> <given-names>P.</given-names></name> <name><surname>Lian</surname> <given-names>X.</given-names></name> <name><surname>H&#x000F6;Lscher</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-&#x003BA;B inflammatory pathway in the MPTP mouse model of Parkinson&#x02019;s disease more effectively than the GLP-1 single-receptor agonist NLY01</article-title>. <source>Brain Behav.</source> <volume>11</volume>:<fpage>e2231</fpage>. <pub-id pub-id-type="doi">10.1002/brb3.2231</pub-id><pub-id pub-id-type="pmid">34125470</pub-id></citation></ref>
<ref id="B004"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>Z. W.</given-names></name> <name><surname>Liu</surname> <given-names>D. X.</given-names></name></person-group> (<year>2018</year>). <article-title>Humanin decreases mitochondrial membrane permeability by inhibiting the membrane association and oligomerization of Bax and Bid proteins</article-title>. <source>Acta. Pharmacol. Sin.</source> <volume>39</volume>, <fpage>1012</fpage>&#x02013;<lpage>1021</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2017.169</pub-id><pub-id pub-id-type="pmid">29265109</pub-id></citation></ref>
<ref id="B133"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahboubi Mehrabani</surname> <given-names>M.</given-names></name> <name><surname>Karvandi</surname> <given-names>M. S.</given-names></name> <name><surname>Maafi</surname> <given-names>P.</given-names></name> <name><surname>Doroudian</surname> <given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches</article-title>. <source>Rev. Med. Virol.</source> <volume>32</volume>:<fpage>e2334</fpage>. <pub-id pub-id-type="doi">10.1002/rmv.2334</pub-id><pub-id pub-id-type="pmid">35138001</pub-id></citation></ref>
<ref id="B134"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maity</surname> <given-names>S.</given-names></name> <name><surname>Komal</surname> <given-names>P.</given-names></name> <name><surname>Kumar</surname> <given-names>V.</given-names></name> <name><surname>Saxena</surname> <given-names>A.</given-names></name> <name><surname>Tungekar</surname> <given-names>A.</given-names></name> <name><surname>Chandrasekar</surname> <given-names>V.</given-names></name></person-group> (<year>2022</year>). <article-title>Impact of ER stress and ER-mitochondrial crosstalk in Huntington&#x02019;s disease</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>:<fpage>780</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23020780</pub-id><pub-id pub-id-type="pmid">35054963</pub-id></citation></ref>
<ref id="B135"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malko</surname> <given-names>P.</given-names></name> <name><surname>Ding</surname> <given-names>R.</given-names></name> <name><surname>Jiang</surname> <given-names>L.-H.</given-names></name></person-group> (<year>2021</year>). <article-title>TRPM2 channel in oxidative stress-induced mitochondrial dysfunction and apoptotic cell death</article-title>. <source>Adv. Protein Chem. Struct. Biol.</source> <volume>125</volume>, <fpage>51</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/bs.apcsb.2020.12.001</pub-id><pub-id pub-id-type="pmid">33931144</pub-id></citation></ref>
<ref id="B136"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Man</surname> <given-names>S. M.</given-names></name> <name><surname>Karki</surname> <given-names>R.</given-names></name> <name><surname>Kanneganti</surname> <given-names>T. D.</given-names></name></person-group> (<year>2017</year>). <article-title>Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases</article-title>. <source>Immunol. Rev.</source> <volume>277</volume>, <fpage>61</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12534</pub-id><pub-id pub-id-type="pmid">28462526</pub-id></citation></ref>
<ref id="B137"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mangalmurti</surname> <given-names>A.</given-names></name> <name><surname>Lukens</surname> <given-names>J. R.</given-names></name></person-group> (<year>2022</year>). <article-title>How neurons die in Alzheimer&#x02019;s disease: implications for neuroinflammation</article-title>. <source>Curr. Opin. Neurobiol.</source> <volume>75</volume>:<fpage>102575</fpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2022.102575</pub-id><pub-id pub-id-type="pmid">35691251</pub-id></citation></ref>
<ref id="B138"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Markovinovic</surname> <given-names>A.</given-names></name> <name><surname>Greig</surname> <given-names>J.</given-names></name> <name><surname>Mart&#x000ED;n-Guerrero</surname> <given-names>S. M.</given-names></name> <name><surname>Salam</surname> <given-names>S.</given-names></name> <name><surname>Paillusson</surname> <given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Endoplasmic reticulum-mitochondria signaling in neurons and neurodegenerative diseases</article-title>. <source>J. Cell Sci.</source> <volume>135</volume>:<fpage>jcs248534</fpage>. <pub-id pub-id-type="doi">10.1242/jcs.248534</pub-id><pub-id pub-id-type="pmid">35129196</pub-id></citation></ref>
<ref id="B139"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marucci</surname> <given-names>G.</given-names></name> <name><surname>Buccioni</surname> <given-names>M.</given-names></name> <name><surname>Ben</surname> <given-names>D. D.</given-names></name> <name><surname>Lambertucci</surname> <given-names>C.</given-names></name> <name><surname>Volpini</surname> <given-names>R.</given-names></name> <name><surname>Amenta</surname> <given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>Efficacy of acetylcholinesterase inhibitors in Alzheimer&#x02019;s disease</article-title>. <source>Neuropharmacology</source> <volume>190</volume>:<fpage>108352</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108352</pub-id><pub-id pub-id-type="pmid">33035532</pub-id></citation></ref>
<ref id="B140"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattiazzi</surname> <given-names>M.</given-names></name> <name><surname>D&#x02019;aurelio</surname> <given-names>M.</given-names></name> <name><surname>Gajewski</surname> <given-names>C. D.</given-names></name> <name><surname>Martushova</surname> <given-names>K.</given-names></name> <name><surname>Kiaei</surname> <given-names>M.</given-names></name> <name><surname>Beal</surname> <given-names>M. F.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice</article-title>. <source>J. Biol. Chem.</source> <volume>277</volume>, <fpage>29626</fpage>&#x02013;<lpage>29633</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M203065200</pub-id><pub-id pub-id-type="pmid">12050154</pub-id></citation></ref>
<ref id="B141"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matus</surname> <given-names>S.</given-names></name> <name><surname>Lopez</surname> <given-names>E.</given-names></name> <name><surname>Valenzuela</surname> <given-names>V.</given-names></name> <name><surname>Nassif</surname> <given-names>M.</given-names></name> <name><surname>Hetz</surname> <given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Functional contribution of the transcription factor ATF4 to the pathogenesis of amyotrophic lateral sclerosis</article-title>. <source>PLoS One</source> <volume>8</volume>:<fpage>e66672</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0066672</pub-id><pub-id pub-id-type="pmid">23874395</pub-id></citation></ref>
<ref id="B142"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mcgarry</surname> <given-names>A.</given-names></name> <name><surname>Mcdermott</surname> <given-names>M.</given-names></name> <name><surname>Kieburtz</surname> <given-names>K.</given-names></name> <name><surname>De Blieck</surname> <given-names>E. A.</given-names></name> <name><surname>Beal</surname> <given-names>F.</given-names></name> <name><surname>Marder</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease</article-title>. <source>Neurology</source> <volume>88</volume>, <fpage>152</fpage>&#x02013;<lpage>159</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000003478</pub-id><pub-id pub-id-type="pmid">27913695</pub-id></citation></ref>
<ref id="B143"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meares</surname> <given-names>G. P.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Rajbhandari</surname> <given-names>R.</given-names></name> <name><surname>Qin</surname> <given-names>H.</given-names></name> <name><surname>Nozell</surname> <given-names>S. E.</given-names></name> <name><surname>Mobley</surname> <given-names>J. A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation</article-title>. <source>Mol. Cell. Biol.</source> <volume>34</volume>, <fpage>3911</fpage>&#x02013;<lpage>3925</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00980-14</pub-id><pub-id pub-id-type="pmid">25113558</pub-id></citation></ref>
<ref id="B144"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mercado</surname> <given-names>G.</given-names></name> <name><surname>Castillo</surname> <given-names>V.</given-names></name> <name><surname>Soto</surname> <given-names>P.</given-names></name> <name><surname>L&#x000F3;pez</surname> <given-names>N.</given-names></name> <name><surname>Axten</surname> <given-names>J. M.</given-names></name> <name><surname>Sardi</surname> <given-names>S. P.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson&#x02019;s disease</article-title>. <source>Neurobiol. Dis.</source> <volume>112</volume>, <fpage>136</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2018.01.004</pub-id><pub-id pub-id-type="pmid">29355603</pub-id></citation></ref>
<ref id="B145"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milo&#x00161;evi&#x00107;</surname> <given-names>M.</given-names></name> <name><surname>Arsi&#x00107;</surname> <given-names>A.</given-names></name> <name><surname>Cvetkovi&#x00107;</surname> <given-names>Z.</given-names></name> <name><surname>Vu&#x0010D;i&#x00107;</surname> <given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>Memorable food: fighting age-related neurodegeneration by precision nutrition</article-title>. <source>Front. Nutr.</source> <volume>8</volume>:<fpage>688086</fpage>. <pub-id pub-id-type="doi">10.3389/fnut.2021.688086</pub-id><pub-id pub-id-type="pmid">34422879</pub-id></citation></ref>
<ref id="B146"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mohammed-Ali</surname> <given-names>Z.</given-names></name> <name><surname>Cruz</surname> <given-names>G. L.</given-names></name> <name><surname>Dickhout</surname> <given-names>J. G.</given-names></name></person-group> (<year>2015</year>). <article-title>Crosstalk between the unfolded protein response and NF-&#x003BA;B-mediated inflammation in the progression of chronic kidney disease</article-title>. <source>J. Immunol. Res.</source> <volume>2015</volume>:<fpage>428508</fpage>. <pub-id pub-id-type="doi">10.1155/2015/428508</pub-id><pub-id pub-id-type="pmid">25977931</pub-id></citation></ref>
<ref id="B147"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morales-Mart&#x000ED;nez</surname> <given-names>A.</given-names></name> <name><surname>Mart&#x000ED;nez-G&#x000F3;mez</surname> <given-names>P. A.</given-names></name> <name><surname>Martinez-Fong</surname> <given-names>D.</given-names></name> <name><surname>Villegas-Rojas</surname> <given-names>M. M.</given-names></name> <name><surname>Perez-Severiano</surname> <given-names>F.</given-names></name> <name><surname>Del Toro-Col&#x000ED;n</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Oxidative stress and mitochondrial complex I dysfunction correlate with neurodegeneration in an &#x003B1;-synucleinopathy animal model</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>:<fpage>11394</fpage>. <pub-id pub-id-type="doi">10.3390/ijms231911394</pub-id><pub-id pub-id-type="pmid">36232716</pub-id></citation></ref>
<ref id="B148"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muhammad</surname> <given-names>T.</given-names></name> <name><surname>Ikram</surname> <given-names>M.</given-names></name> <name><surname>Ullah</surname> <given-names>R.</given-names></name> <name><surname>Rehman</surname> <given-names>S. U.</given-names></name> <name><surname>Kim</surname> <given-names>M. O.</given-names></name></person-group> (<year>2019</year>). <article-title>Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-&#x003BA;B signaling</article-title>. <source>Nutrients</source> <volume>11</volume>:<fpage>648</fpage>. <pub-id pub-id-type="doi">10.3390/nu11030648</pub-id><pub-id pub-id-type="pmid">30884890</pub-id></citation></ref>
<ref id="B149"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname> <given-names>M. R.</given-names></name> <name><surname>St-Pierre</surname> <given-names>M.-K.</given-names></name> <name><surname>Wendeln</surname> <given-names>A.-C.</given-names></name> <name><surname>Makoni</surname> <given-names>N. J.</given-names></name> <name><surname>Gouwens</surname> <given-names>L. K.</given-names></name> <name><surname>Garrad</surname> <given-names>E. C.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Inflammatory mechanisms in neurodegeneration</article-title>. <source>J. Neurochem.</source> <volume>149</volume>, <fpage>562</fpage>&#x02013;<lpage>581</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14674</pub-id><pub-id pub-id-type="pmid">30702751</pub-id></citation></ref>
<ref id="B150"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niedzielska</surname> <given-names>E.</given-names></name> <name><surname>Smaga</surname> <given-names>I.</given-names></name> <name><surname>Gawlik</surname> <given-names>M.</given-names></name> <name><surname>Moniczewski</surname> <given-names>A.</given-names></name> <name><surname>Stankowicz</surname> <given-names>P.</given-names></name> <name><surname>Pera</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Oxidative stress in neurodegenerative diseases</article-title>. <source>Mol. Neurobiol.</source> <volume>53</volume>, <fpage>4094</fpage>&#x02013;<lpage>4125</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-015-9337-5</pub-id><pub-id pub-id-type="pmid">26198567</pub-id></citation></ref>
<ref id="B151"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niso-Santano</surname> <given-names>M.</given-names></name> <name><surname>Bravo-San Pedro</surname> <given-names>J. M.</given-names></name> <name><surname>G&#x000F3;mez-S&#x000E1;nchez</surname> <given-names>R.</given-names></name> <name><surname>Climent</surname> <given-names>V.</given-names></name> <name><surname>Soler</surname> <given-names>G.</given-names></name> <name><surname>Fuentes</surname> <given-names>J. M.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>ASK1 overexpression accelerates paraquat-induced autophagy via endoplasmic reticulum stress</article-title>. <source>Toxicol Sci.</source> <volume>119</volume>, <fpage>156</fpage>&#x02013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1093/toxsci/kfq313</pub-id><pub-id pub-id-type="pmid">20929985</pub-id></citation></ref>
<ref id="B152"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nunomura</surname> <given-names>A.</given-names></name> <name><surname>Moreira</surname> <given-names>P. I.</given-names></name> <name><surname>Lee</surname> <given-names>H. G.</given-names></name> <name><surname>Zhu</surname> <given-names>X.</given-names></name> <name><surname>Castellani</surname> <given-names>R. J.</given-names></name> <name><surname>Smith</surname> <given-names>M. A.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases</article-title>. <source>CNS Neurol. Disord. Drug Targets</source> <volume>6</volume>, <fpage>411</fpage>&#x02013;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.2174/187152707783399201</pub-id><pub-id pub-id-type="pmid">18220780</pub-id></citation></ref>
<ref id="B153"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onyango</surname> <given-names>I. G.</given-names></name> <name><surname>Jauregui</surname> <given-names>G. V.</given-names></name> <name><surname>&#x0010C;arn&#x000E1;</surname> <given-names>M.</given-names></name> <name><surname>Bennett</surname> <given-names>J. P.</given-names> <suffix>Jr.</suffix></name> <name><surname>Stokin</surname> <given-names>G. B.</given-names></name></person-group> (<year>2021</year>). <article-title>Neuroinflammation in Alzheimer&#x02019;s disease</article-title>. <source>Biomedicines</source> <volume>9</volume>:<fpage>524</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines9050524</pub-id><pub-id pub-id-type="pmid">34067173</pub-id></citation></ref>
<ref id="B154"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Opazo</surname> <given-names>C.</given-names></name> <name><surname>Huang</surname> <given-names>X.</given-names></name> <name><surname>Cherny</surname> <given-names>R. A.</given-names></name> <name><surname>Moir</surname> <given-names>R. D.</given-names></name> <name><surname>Roher</surname> <given-names>A. E.</given-names></name> <name><surname>White</surname> <given-names>A. R.</given-names></name> <etal/></person-group>. (<year>2002</year>). <article-title>Metalloenzyme-like Activity of Alzheimer&#x02019;s disease &#x003B2;-amyloid: CU-Dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H<sub>2</sub>O<sub>2</sub>*</article-title>. <source>J. Biol. Chem.</source> <volume>277</volume>, <fpage>40302</fpage>&#x02013;<lpage>40308</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M206428200</pub-id><pub-id pub-id-type="pmid">12192006</pub-id></citation></ref>
<ref id="B155"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostrowitzki</surname> <given-names>S.</given-names></name> <name><surname>Bittner</surname> <given-names>T.</given-names></name> <name><surname>Sink</surname> <given-names>K. M.</given-names></name> <name><surname>Mackey</surname> <given-names>H.</given-names></name> <name><surname>Rabe</surname> <given-names>C.</given-names></name> <name><surname>Honig</surname> <given-names>L. S.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Evaluating the safety and efficacy of crenezumab vs. placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials</article-title>. <source>JAMA Neurol.</source> <volume>79</volume>, <fpage>1113</fpage>&#x02013;<lpage>1121</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2022.2909</pub-id><pub-id pub-id-type="pmid">36121669</pub-id></citation></ref>
<ref id="B156"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname> <given-names>G.</given-names></name> <name><surname>Taylor</surname> <given-names>K. I.</given-names></name> <name><surname>Anzures-Cabrera</surname> <given-names>J.</given-names></name> <name><surname>Marchesi</surname> <given-names>M.</given-names></name> <name><surname>Simuni</surname> <given-names>T.</given-names></name> <name><surname>Marek</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Trial of prasinezumab in early-stage Parkinson&#x02019;s disease</article-title>. <source>N Engl. J. Med.</source> <volume>387</volume>, <fpage>421</fpage>&#x02013;<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2202867</pub-id><pub-id pub-id-type="pmid">35921451</pub-id></citation></ref>
<ref id="B003"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname> <given-names>H. P.</given-names></name> <name><surname>Liao</surname> <given-names>W. I.</given-names></name> <name><surname>Tang</surname> <given-names>S. E.</given-names></name> <name><surname>Wu</surname> <given-names>S. Y.</given-names></name> <name><surname>Huang</surname> <given-names>K. L.</given-names></name> <name><surname>Chu</surname> <given-names>S. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Suppression of endoplasmic reticulum stress by 4-PBA protects against hyperoxia-induced acute lung injury via up-regulating claudin-4 expression</article-title>. <source>Front. Immunol.</source> <volume>12</volume>:<fpage>674316</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.674316</pub-id><pub-id pub-id-type="pmid">34122432</pub-id></citation></ref>
<ref id="B157"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pardillo-D&#x000ED;az</surname> <given-names>R.</given-names></name> <name><surname>Perez-Garc&#x000ED;A</surname> <given-names>P.</given-names></name> <name><surname>Castro</surname> <given-names>C.</given-names></name> <name><surname>Nunez-Abades</surname> <given-names>P.</given-names></name> <name><surname>Carrascal</surname> <given-names>L.</given-names></name></person-group> (<year>2022</year>). <article-title>Oxidative stress as a potential mechanism underlying membrane hyperexcitability in neurodegenerative diseases</article-title>. <source>Antioxidants (Basel)</source> <volume>11</volume>:<fpage>1511</fpage>. <pub-id pub-id-type="doi">10.3390/antiox11081511</pub-id><pub-id pub-id-type="pmid">36009230</pub-id></citation></ref>
<ref id="B158"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>S.</given-names></name> <name><surname>Bansoad</surname> <given-names>A. V.</given-names></name> <name><surname>Singh</surname> <given-names>R.</given-names></name> <name><surname>Khatik</surname> <given-names>G. L.</given-names></name></person-group> (<year>2022</year>). <article-title>BACE1: a key regulator in Alzheimer&#x02019;s disease progression and current development of its inhibitors</article-title>. <source>Curr. Neuropharmacol.</source> <volume>20</volume>, <fpage>1174</fpage>&#x02013;<lpage>1193</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X19666211201094031</pub-id><pub-id pub-id-type="pmid">34852746</pub-id></citation></ref>
<ref id="B159"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pintado</surname> <given-names>C.</given-names></name> <name><surname>Mac&#x000ED;as</surname> <given-names>S.</given-names></name> <name><surname>Dom&#x000ED;nguez-Mart&#x000ED;n</surname> <given-names>H.</given-names></name> <name><surname>Casta&#x000F1;o</surname> <given-names>A.</given-names></name> <name><surname>Ruano</surname> <given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuroinflammation alters cellular proteostasis by producing endoplasmic reticulum stress, autophagy activation and disrupting ERAD activation</article-title>. <source>Sci. Rep.</source> <volume>7</volume>:<fpage>8100</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-08722-3</pub-id><pub-id pub-id-type="pmid">28808322</pub-id></citation></ref>
<ref id="B160"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piscianz</surname> <given-names>E.</given-names></name> <name><surname>Tesser</surname> <given-names>A.</given-names></name> <name><surname>Rimondi</surname> <given-names>E.</given-names></name> <name><surname>Melloni</surname> <given-names>E.</given-names></name> <name><surname>Celeghini</surname> <given-names>C.</given-names></name> <name><surname>Marcuzzi</surname> <given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>MitoQ is able to modulate apoptosis and inflammation</article-title>. <source>Int. J. Mol. Sci.</source> <volume>22</volume>:<fpage>4753</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22094753</pub-id><pub-id pub-id-type="pmid">33946176</pub-id></citation></ref>
<ref id="B161"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pohl</surname> <given-names>F.</given-names></name> <name><surname>Kong Thoo Lin</surname> <given-names>P.</given-names></name></person-group> (<year>2018</year>). <article-title>The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: <italic>in vitro</italic>, <italic>in vivo</italic> and clinical trials</article-title>. <source>Molecules</source> <volume>23</volume>:<fpage>3283</fpage>. <pub-id pub-id-type="doi">10.3390/molecules23123283</pub-id><pub-id pub-id-type="pmid">30544977</pub-id></citation></ref>
<ref id="B162"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poulter</surname> <given-names>M. O.</given-names></name> <name><surname>Payne</surname> <given-names>K. B.</given-names></name> <name><surname>Steiner</surname> <given-names>J. P.</given-names></name></person-group> (<year>2004</year>). <article-title>Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease?</article-title> <source>Neuroscience</source> <volume>128</volume>, <fpage>1</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2004.06.016</pub-id><pub-id pub-id-type="pmid">15450348</pub-id></citation></ref>
<ref id="B163"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Moreno</surname> <given-names>M. J.</given-names></name> <name><surname>Duarte-Jurado</surname> <given-names>A. P.</given-names></name> <name><surname>Gopar-Cuevas</surname> <given-names>Y.</given-names></name> <name><surname>Gonzalez-Alcocer</surname> <given-names>A.</given-names></name> <name><surname>Loera-Arias</surname> <given-names>M. J.</given-names></name> <name><surname>Saucedo-Cardenas</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Autophagy stimulation decreases dopaminergic neuronal death mediated by oxidative stress</article-title>. <source>Mol. Neurobiol.</source> <volume>56</volume>, <fpage>8136</fpage>&#x02013;<lpage>8156</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-019-01654-1</pub-id><pub-id pub-id-type="pmid">31197654</pub-id></citation></ref>
<ref id="B164"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Read</surname> <given-names>A.</given-names></name> <name><surname>Schr&#x000F6;der</surname> <given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>The unfolded protein response: an overview</article-title>. <source>Biology (Basel)</source> <volume>10</volume>:<fpage>384</fpage>. <pub-id pub-id-type="doi">10.3390/biology10050384</pub-id><pub-id pub-id-type="pmid">33946669</pub-id></citation></ref>
<ref id="B165"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reichert</surname> <given-names>C. O.</given-names></name> <name><surname>De Freitas</surname> <given-names>F. A.</given-names></name> <name><surname>Sampaio-Silva</surname> <given-names>J.</given-names></name> <name><surname>Rokita-Rosa</surname> <given-names>L.</given-names></name> <name><surname>Barros</surname> <given-names>P. L.</given-names></name> <name><surname>Levy</surname> <given-names>D. L.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Ferroptosis mechanisms involved in neurodegenerative diseases</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>8765</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21228765</pub-id><pub-id pub-id-type="pmid">33233496</pub-id></citation></ref>
<ref id="B166"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Remondelli</surname> <given-names>P.</given-names></name> <name><surname>Renna</surname> <given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>The endoplasmic reticulum unfolded protein response in neurodegenerative disorders and its potential therapeutic significance</article-title>. <source>Front. Mol. Neurosci.</source> <volume>10</volume>:<fpage>187</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2017.00187</pub-id><pub-id pub-id-type="pmid">28670265</pub-id></citation></ref>
<ref id="B167"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname> <given-names>H.</given-names></name> <name><surname>Zhai</surname> <given-names>W.</given-names></name> <name><surname>Lu</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>The cross-links of endoplasmic reticulum stress, autophagy and neurodegeneration in Parkinson&#x02019;s disease</article-title>. <source>Front. Aging Neurosci.</source> <volume>13</volume>:<fpage>691881</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2021.691881</pub-id><pub-id pub-id-type="pmid">34168552</pub-id></citation></ref>
<ref id="B168"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname> <given-names>E. M.</given-names></name> <name><surname>De Miranda</surname> <given-names>B.</given-names></name> <name><surname>Sanders</surname> <given-names>L. H.</given-names></name></person-group> (<year>2018</year>). <article-title>Alpha-synuclein: pathology, mitochondrial dysfunction and neuroinflammation in Parkinson&#x02019;s disease</article-title>. <source>Neurobiol. Dis.</source> <volume>109</volume>, <fpage>249</fpage>&#x02013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2017.04.004</pub-id><pub-id pub-id-type="pmid">28400134</pub-id></citation></ref>
<ref id="B169"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>C. A.</given-names></name> <name><surname>Tabrizi</surname> <given-names>S. J.</given-names></name></person-group> (<year>2011</year>). <article-title>Huntington&#x02019;s disease: from molecular pathogenesis to clinical treatment</article-title>. <source>Lancet Neurol.</source> <volume>10</volume>, <fpage>83</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(10)70245-3</pub-id><pub-id pub-id-type="pmid">21163446</pub-id></citation></ref>
<ref id="B170"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rui</surname> <given-names>W.</given-names></name> <name><surname>Li</surname> <given-names>S.</given-names></name> <name><surname>Xiao</surname> <given-names>H.</given-names></name> <name><surname>Xiao</surname> <given-names>M.</given-names></name> <name><surname>Shi</surname> <given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Baicalein attenuates neuroinflammation by inhibiting NLRP3/caspase-1/GSDMD pathway in MPTP induced mice model of Parkinson&#x02019;s disease</article-title>. <source>Int. J. Neuropsychopharmacol.</source> <volume>23</volume>, <fpage>762</fpage>&#x02013;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1093/ijnp/pyaa060</pub-id><pub-id pub-id-type="pmid">32761175</pub-id></citation></ref>
<ref id="B171"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salminen</surname> <given-names>A.</given-names></name> <name><surname>Kauppinen</surname> <given-names>A.</given-names></name> <name><surname>Suuronen</surname> <given-names>T.</given-names></name> <name><surname>Kaarniranta</surname> <given-names>K.</given-names></name> <name><surname>Ojala</surname> <given-names>J.</given-names></name></person-group> (<year>2009</year>). <article-title>ER stress in Alzheimer&#x02019;s disease: a novel neuronal trigger for inflammation and Alzheimer&#x02019;s pathology</article-title>. <source>J. Neuroinflammation</source> <volume>6</volume>:<fpage>41</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-6-41</pub-id><pub-id pub-id-type="pmid">20035627</pub-id></citation></ref>
<ref id="B172"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salter</surname> <given-names>M. W.</given-names></name> <name><surname>Stevens</surname> <given-names>B.</given-names></name></person-group> (<year>2017</year>). <article-title>Microglia emerge as central players in brain disease</article-title>. <source>Nat. Med.</source> <volume>23</volume>, <fpage>1018</fpage>&#x02013;<lpage>1027</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4397</pub-id><pub-id pub-id-type="pmid">28886007</pub-id></citation></ref>
<ref id="B173"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sbodio</surname> <given-names>J. I.</given-names></name> <name><surname>Snyder</surname> <given-names>S. H.</given-names></name> <name><surname>Paul</surname> <given-names>B. D.</given-names></name></person-group> (<year>2019</year>). <article-title>Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities</article-title>. <source>Antioxid. Redox. Signal.</source> <volume>30</volume>, <fpage>1450</fpage>&#x02013;<lpage>1499</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2017.7321</pub-id><pub-id pub-id-type="pmid">29634350</pub-id></citation></ref>
<ref id="B174"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname> <given-names>D. S.</given-names></name> <name><surname>Blower</surname> <given-names>M. D.</given-names></name></person-group> (<year>2016</year>). <article-title>The endoplasmic reticulum: structure, function and response to cellular signaling</article-title>. <source>Cell. Mol. Life Sci.</source> <volume>73</volume>, <fpage>79</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-015-2052-6</pub-id><pub-id pub-id-type="pmid">26433683</pub-id></citation></ref>
<ref id="B175"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>M.</given-names></name> <name><surname>Chai</surname> <given-names>Y.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name></person-group> (<year>2022</year>). <article-title>Endoplasmic reticulum stress-associated neuronal death and innate immune response in neurological diseases</article-title>. <source>Front. Immunol.</source> <volume>12</volume>:<fpage>794580</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.794580</pub-id><pub-id pub-id-type="pmid">35082783</pub-id></citation></ref>
<ref id="B176"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname> <given-names>S. G.</given-names></name> <name><surname>Cisney</surname> <given-names>R. N.</given-names></name> <name><surname>Lipscomb</surname> <given-names>M. M.</given-names></name> <name><surname>Meares</surname> <given-names>G. P.</given-names></name></person-group> (<year>2022</year>). <article-title>The role of endoplasmic reticulum stress in astrocytes</article-title>. <source>Glia</source> <volume>70</volume>, <fpage>5</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1002/glia.24082</pub-id><pub-id pub-id-type="pmid">34462963</pub-id></citation></ref>
<ref id="B177"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>A.</given-names></name> <name><surname>Kukreti</surname> <given-names>R.</given-names></name> <name><surname>Saso</surname> <given-names>L.</given-names></name> <name><surname>Kukreti</surname> <given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Oxidative stress: a key modulator in neurodegenerative diseases</article-title>. <source>Molecules</source> <volume>24</volume>:<fpage>1583</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24081583</pub-id><pub-id pub-id-type="pmid">31013638</pub-id></citation></ref>
<ref id="B178"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sirianni</surname> <given-names>A. C.</given-names></name> <name><surname>Jiang</surname> <given-names>J.</given-names></name> <name><surname>Zeng</surname> <given-names>J.</given-names></name> <name><surname>Mao</surname> <given-names>L. L.</given-names></name> <name><surname>Zhou</surname> <given-names>S.</given-names></name> <name><surname>Sugarbaker</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>N-acetyl-l-tryptophan, but not N-acetyl-d-tryptophan, rescues neuronal cell death in models of amyotrophic lateral sclerosis</article-title>. <source>J. Neurochem.</source> <volume>134</volume>, <fpage>956</fpage>&#x02013;<lpage>968</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13190</pub-id><pub-id pub-id-type="pmid">26031348</pub-id></citation></ref>
<ref id="B179"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sochocka</surname> <given-names>M.</given-names></name> <name><surname>Koutsouraki</surname> <given-names>E. S.</given-names></name> <name><surname>Gasiorowski</surname> <given-names>K.</given-names></name> <name><surname>Leszek</surname> <given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer&#x02019;s disease: a new approach to therapy</article-title>. <source>CNS Neurol. Disord. Drug Targets</source> <volume>12</volume>, <fpage>870</fpage>&#x02013;<lpage>881</lpage>. <pub-id pub-id-type="doi">10.2174/18715273113129990072</pub-id><pub-id pub-id-type="pmid">23469836</pub-id></citation></ref>
<ref id="B181"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>J.</given-names></name> <name><surname>Han</surname> <given-names>K.</given-names></name> <name><surname>Wang</surname> <given-names>Y.</given-names></name> <name><surname>Qu</surname> <given-names>R.</given-names></name> <name><surname>Liu</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Microglial activation and oxidative stress in PM<sub>2.5</sub>-induced neurodegenerative disorders</article-title>. <source>Antioxidants (Basel)</source> <volume>11</volume>:<fpage>1482</fpage>. <pub-id pub-id-type="doi">10.3390/antiox11081482</pub-id><pub-id pub-id-type="pmid">36009201</pub-id></citation></ref>
<ref id="B180"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>D. D.</given-names></name> <name><surname>Shults</surname> <given-names>C. W.</given-names></name> <name><surname>Sisk</surname> <given-names>A.</given-names></name> <name><surname>Rockenstein</surname> <given-names>E.</given-names></name> <name><surname>Masliah</surname> <given-names>E.</given-names></name></person-group> (<year>2004</year>). <article-title>Enhanced substantia nigra mitochondrial pathology in human &#x003B1;-synuclein transgenic mice after treatment with MPTP</article-title>. <source>Exp. Neurol.</source> <volume>186</volume>, <fpage>158</fpage>&#x02013;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-4886(03)00342-X</pub-id><pub-id pub-id-type="pmid">15026254</pub-id></citation></ref>
<ref id="B182"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sprenkle</surname> <given-names>N. T.</given-names></name> <name><surname>Sims</surname> <given-names>S. G.</given-names></name> <name><surname>S&#x000E1;nchez</surname> <given-names>C. L.</given-names></name> <name><surname>Meares</surname> <given-names>G. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Endoplasmic reticulum stress and inflammation in the central nervous system</article-title>. <source>Mol. Neurodegener.</source> <volume>12</volume>:<fpage>42</fpage>. <pub-id pub-id-type="doi">10.1186/s13024-017-0183-y</pub-id><pub-id pub-id-type="pmid">28545479</pub-id></citation></ref>
<ref id="B183"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stancu</surname> <given-names>I. C.</given-names></name> <name><surname>Cremers</surname> <given-names>N.</given-names></name> <name><surname>Vanrusselt</surname> <given-names>H.</given-names></name> <name><surname>Couturier</surname> <given-names>J.</given-names></name> <name><surname>Vanoosthuyse</surname> <given-names>A.</given-names></name> <name><surname>Kessels</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology <italic>in vivo</italic></article-title>. <source>Acta Neuropathol.</source> <volume>137</volume>, <fpage>599</fpage>&#x02013;<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-018-01957-y</pub-id><pub-id pub-id-type="pmid">30721409</pub-id></citation></ref>
<ref id="B184"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stefani</surname> <given-names>I. C.</given-names></name> <name><surname>Wright</surname> <given-names>D.</given-names></name> <name><surname>Polizzi</surname> <given-names>K. M.</given-names></name> <name><surname>Kontoravdi</surname> <given-names>C.</given-names></name></person-group> (<year>2012</year>). <article-title>The role of ER stress-induced apoptosis in neurodegeneration</article-title>. <source>Curr. Alzheimer Res.</source> <volume>9</volume>, <fpage>373</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.2174/156720512800107618</pub-id><pub-id pub-id-type="pmid">22299619</pub-id></citation></ref>
<ref id="B185"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stutzbach</surname> <given-names>L. D.</given-names></name> <name><surname>Xie</surname> <given-names>S. X.</given-names></name> <name><surname>Naj</surname> <given-names>A. C.</given-names></name> <name><surname>Albin</surname> <given-names>R.</given-names></name> <name><surname>Gilman</surname> <given-names>S.</given-names></name> <name><surname>Lee</surname> <given-names>V. M.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer&#x02019;s disease</article-title>. <source>Acta Neuropathol. Commun.</source> <volume>1</volume>:<fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/2051-5960-1-31</pub-id><pub-id pub-id-type="pmid">24252572</pub-id></citation></ref>
<ref id="B186"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sushma</surname> <given-names></given-names></name> <name><surname>Mondal</surname> <given-names>A. C.</given-names></name></person-group> (<year>2019</year>). <article-title>Role of GPCR signaling and calcium dysregulation in Alzheimer&#x02019;s disease</article-title>. <source>Mol. Cell Neurosci.</source> <volume>101</volume>:<fpage>103414</fpage>. <pub-id pub-id-type="doi">10.1016/j.mcn.2019.103414</pub-id><pub-id pub-id-type="pmid">31655116</pub-id></citation></ref>
<ref id="B187"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taalab</surname> <given-names>Y. M.</given-names></name> <name><surname>Ibrahim</surname> <given-names>N.</given-names></name> <name><surname>Maher</surname> <given-names>A.</given-names></name> <name><surname>Hassan</surname> <given-names>M.</given-names></name> <name><surname>Mohamed</surname> <given-names>W.</given-names></name> <name><surname>Moustafa</surname> <given-names>A. A.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Mechanisms of disordered neurodegenerative function: concepts and facts about the different roles of the protein kinase RNA-like endoplasmic reticulum kinase (PERK)</article-title>. <source>Rev. Neurosci.</source> <volume>29</volume>, <fpage>387</fpage>&#x02013;<lpage>415</lpage>. <pub-id pub-id-type="doi">10.1515/revneuro-2017-0071</pub-id><pub-id pub-id-type="pmid">29303785</pub-id></citation></ref>
<ref id="B188"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tamagno</surname> <given-names>E.</given-names></name> <name><surname>Parola</surname> <given-names>M.</given-names></name> <name><surname>Bardini</surname> <given-names>P.</given-names></name> <name><surname>Piccini</surname> <given-names>A.</given-names></name> <name><surname>Borghi</surname> <given-names>R.</given-names></name> <name><surname>Guglielmotto</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2005</year>). <article-title>&#x003B2;-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways</article-title>. <source>J. Neurochem.</source> <volume>92</volume>, <fpage>628</fpage>&#x02013;<lpage>636</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02895.x</pub-id><pub-id pub-id-type="pmid">15659232</pub-id></citation></ref>
<ref id="B189"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tansey</surname> <given-names>M. G.</given-names></name> <name><surname>Wallings</surname> <given-names>R. L.</given-names></name> <name><surname>Houser</surname> <given-names>M. C.</given-names></name> <name><surname>Herrick</surname> <given-names>M. K.</given-names></name> <name><surname>Keating</surname> <given-names>C. E.</given-names></name> <name><surname>Joers</surname> <given-names>V.</given-names></name></person-group> (<year>2022</year>). <article-title>Inflammation and immune dysfunction in Parkinson disease</article-title>. <source>Nat. Rev. Immunol.</source> <volume>22</volume>, <fpage>657</fpage>&#x02013;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-022-00684-6</pub-id><pub-id pub-id-type="pmid">35246670</pub-id></citation></ref>
<ref id="B190"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taso</surname> <given-names>O. V.</given-names></name> <name><surname>Philippou</surname> <given-names>A.</given-names></name> <name><surname>Moustogiannis</surname> <given-names>A.</given-names></name> <name><surname>Zevolis</surname> <given-names>E.</given-names></name> <name><surname>Koutsilieris</surname> <given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Lipid peroxidation products and their role in neurodegenerative diseases</article-title>. <source>Ann. Res. Hosp.</source> <volume>3</volume>:<fpage>2</fpage>. <pub-id pub-id-type="doi">10.21037/arh.2018.12.02</pub-id></citation></ref>
<ref id="B191"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname> <given-names>R. C.</given-names></name> <name><surname>Cullen</surname> <given-names>S. P.</given-names></name> <name><surname>Martin</surname> <given-names>S. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Apoptosis: controlled demolition at the cellular level</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>9</volume>, <fpage>231</fpage>&#x02013;<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2312</pub-id><pub-id pub-id-type="pmid">18073771</pub-id></citation></ref>
<ref id="B192"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teleanu</surname> <given-names>D. M.</given-names></name> <name><surname>Niculescu</surname> <given-names>A.-G.</given-names></name> <name><surname>Lungu</surname> <given-names>I. I.</given-names></name> <name><surname>Radu</surname> <given-names>C. I.</given-names></name> <name><surname>Vladacenco</surname> <given-names>O.</given-names></name> <name><surname>Roza</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>An overview of oxidative stress, neuroinflammation and neurodegenerative diseases</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>:<fpage>5938</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23115938</pub-id><pub-id pub-id-type="pmid">35682615</pub-id></citation></ref>
<ref id="B193"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thawkar</surname> <given-names>B. S.</given-names></name> <name><surname>Kaur</surname> <given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>Inhibitors of NF-&#x003BA;B and P2X7/NLRP3/caspase 1 pathway in microglia: novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer&#x02019;s disease</article-title>. <source>J. Neuroimmunol.</source> <volume>326</volume>, <fpage>62</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2018.11.010</pub-id><pub-id pub-id-type="pmid">30502599</pub-id></citation></ref>
<ref id="B194"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trushina</surname> <given-names>E.</given-names></name> <name><surname>Trushin</surname> <given-names>S.</given-names></name> <name><surname>Hasan</surname> <given-names>M. F.</given-names></name></person-group> (<year>2022</year>). <article-title>Mitochondrial complex I as a therapeutic target for Alzheimer&#x02019;s disease</article-title>. <source>Acta Pharm. Sin. B.</source> <volume>12</volume>, <fpage>483</fpage>&#x02013;<lpage>495</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2021.11.003</pub-id><pub-id pub-id-type="pmid">35256930</pub-id></citation></ref>
<ref id="B195"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valdes</surname> <given-names>P.</given-names></name> <name><surname>Mercado</surname> <given-names>G.</given-names></name> <name><surname>Vidal</surname> <given-names>R. L.</given-names></name> <name><surname>Molina</surname> <given-names>C.</given-names></name> <name><surname>Parsons</surname> <given-names>G.</given-names></name> <name><surname>Court</surname> <given-names>F. A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>111</volume>, <fpage>6804</fpage>&#x02013;<lpage>6809</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1321845111</pub-id><pub-id pub-id-type="pmid">24753614</pub-id></citation></ref>
<ref id="B196"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Dam</surname> <given-names>L.</given-names></name> <name><surname>Dansen</surname> <given-names>T. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Cross-talk between redox signalling and protein aggregation</article-title>. <source>Biochem. Soc. Trans.</source> <volume>48</volume>, <fpage>379</fpage>&#x02013;<lpage>397</lpage>. <pub-id pub-id-type="doi">10.1042/BST20190054</pub-id><pub-id pub-id-type="pmid">32311028</pub-id></citation></ref>
<ref id="B197"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voet</surname> <given-names>S.</given-names></name> <name><surname>Srinivasan</surname> <given-names>S.</given-names></name> <name><surname>Lamkanfi</surname> <given-names>M.</given-names></name> <name><surname>Van Loo</surname> <given-names>G.</given-names></name></person-group> (<year>2019</year>). <article-title>Inflammasomes in neuroinflammatory and neurodegenerative diseases</article-title>. <source>EMBO Mol. Med.</source> <volume>11</volume>:<fpage>e10248</fpage>. <pub-id pub-id-type="doi">10.15252/emmm.201810248</pub-id><pub-id pub-id-type="pmid">31015277</pub-id></citation></ref>
<ref id="B198"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vukic</surname> <given-names>V.</given-names></name> <name><surname>Callaghan</surname> <given-names>D.</given-names></name> <name><surname>Walker</surname> <given-names>D.</given-names></name> <name><surname>Lue</surname> <given-names>L. F.</given-names></name> <name><surname>Liu</surname> <given-names>Q. Y.</given-names></name> <name><surname>Couraud</surname> <given-names>P. O.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer&#x02019;s brain is mediated by the JNK-AP1 signaling pathway</article-title>. <source>Neurobiol. Dis.</source> <volume>34</volume>, <fpage>95</fpage>&#x02013;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2008.12.007</pub-id><pub-id pub-id-type="pmid">19162185</pub-id></citation></ref>
<ref id="B199"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walle</surname> <given-names>L. V.</given-names></name> <name><surname>Lamkanfi</surname> <given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Pyroptosis</article-title>. <source>Curr. Biol.</source> <volume>26</volume>, <fpage>R568</fpage>&#x02013;<lpage>R572</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2016.02.019</pub-id><pub-id pub-id-type="pmid">27404251</pub-id></citation></ref>
<ref id="B202"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>W.-Y.</given-names></name> <name><surname>Tan</surname> <given-names>M.-S.</given-names></name> <name><surname>Yu</surname> <given-names>J. T.</given-names></name> <name><surname>Tan</surname> <given-names>L.</given-names></name></person-group> (<year>2015</year>). <article-title>Role of pro-inflammatory cytokines released from microglia in Alzheimer&#x02019;s disease</article-title>. <source>Ann. Transl. Med.</source> <volume>3</volume>:<fpage>136</fpage>. <pub-id pub-id-type="doi">10.3978/j.issn.2305-5839.2015.03.49</pub-id><pub-id pub-id-type="pmid">26207229</pub-id></citation></ref>
<ref id="B200"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H. F.</given-names></name> <name><surname>Wang</surname> <given-names>Z. Q.</given-names></name> <name><surname>Ding</surname> <given-names>Y.</given-names></name> <name><surname>Piao</surname> <given-names>M. H.</given-names></name> <name><surname>Feng</surname> <given-names>C. S.</given-names></name> <name><surname>Chi</surname> <given-names>G. F.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Endoplasmic reticulum stress regulates oxygen-glucose deprivation-induced parthanatos in human SH-SY5Y cells via improvement of intracellular ROS</article-title>. <source>CNS Neurosci. Ther.</source> <volume>24</volume>, <fpage>29</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1111/cns.12771</pub-id><pub-id pub-id-type="pmid">29045036</pub-id></citation></ref>
<ref id="B201"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>S.</given-names></name> <name><surname>Yuan</surname> <given-names>Y. H.</given-names></name> <name><surname>Chen</surname> <given-names>N. H.</given-names></name> <name><surname>Wang</surname> <given-names>H. B.</given-names></name></person-group> (<year>2019</year>). <article-title>The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson&#x02019;s disease</article-title>. <source>Int. Immunopharmacol.</source> <volume>67</volume>, <fpage>458</fpage>&#x02013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2018.12.019</pub-id><pub-id pub-id-type="pmid">30594776</pub-id></citation></ref>
<ref id="B008"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>H.</given-names></name> <name><surname>Zhou</surname> <given-names>X. M.</given-names></name> <name><surname>Wu</surname> <given-names>L. Y.</given-names></name> <name><surname>Liu</surname> <given-names>G. J.</given-names></name> <name><surname>Xu</surname> <given-names>W. D.</given-names></name> <name><surname>Zhang</surname> <given-names>X. S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Aucubin alleviates oxidative stress and inflammation via Nrf2-mediated signaling activity in experimental traumatic brain injury</article-title>. <source>J. Neuroinflammation</source> <volume>17</volume>:<fpage>188</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-020-01863-9</pub-id><pub-id pub-id-type="pmid">32539839</pub-id></citation></ref>
<ref id="B203"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wessels</surname> <given-names>A. M.</given-names></name> <name><surname>Tariot</surname> <given-names>P. N.</given-names></name> <name><surname>Zimmer</surname> <given-names>J. A.</given-names></name> <name><surname>Selzler</surname> <given-names>K. J.</given-names></name> <name><surname>Bragg</surname> <given-names>S. M.</given-names></name> <name><surname>Andersen</surname> <given-names>S. W.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: the AMARANTH and DAYBREAK-ALZ randomized clinical trials</article-title>. <source>JAMA Neurol.</source> <volume>77</volume>, <fpage>199</fpage>&#x02013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2019.3988</pub-id><pub-id pub-id-type="pmid">31764959</pub-id></citation></ref>
<ref id="B204"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>L.</given-names></name> <name><surname>Luo</surname> <given-names>N.</given-names></name> <name><surname>Zhao</surname> <given-names>H. R.</given-names></name> <name><surname>Gao</surname> <given-names>Q.</given-names></name> <name><surname>Lu</surname> <given-names>J.</given-names></name> <name><surname>Pan</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Salubrinal protects against rotenone-induced SH-SY5Y cell death via ATF4-parkin pathway</article-title>. <source>Brain Res.</source> <volume>1549</volume>, <fpage>52</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2014.01.003</pub-id><pub-id pub-id-type="pmid">24418467</pub-id></citation></ref>
<ref id="B205"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Q.</given-names></name> <name><surname>Zou</surname> <given-names>C.</given-names></name></person-group> (<year>2022</year>). <article-title>Microglial dysfunction in neurodegenerative diseases via RIPK1 and ROS</article-title>. <source>Antioxidants (Basel)</source> <volume>11</volume>:<fpage>2201</fpage>. <pub-id pub-id-type="doi">10.3390/antiox11112201</pub-id><pub-id pub-id-type="pmid">36358573</pub-id></citation></ref>
<ref id="B206"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>M.</given-names></name> <name><surname>Jiang</surname> <given-names>J.</given-names></name></person-group> (<year>2019</year>). <article-title>Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling</article-title>. <source>Mitochondrion</source> <volume>49</volume>, <fpage>35</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.mito.2019.07.003</pub-id><pub-id pub-id-type="pmid">31288090</pub-id></citation></ref>
<ref id="B207"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname> <given-names>H.</given-names></name> <name><surname>Hou</surname> <given-names>S.</given-names></name> <name><surname>Jiang</surname> <given-names>J.</given-names></name> <name><surname>Sekutowicz</surname> <given-names>M.</given-names></name> <name><surname>Kelly</surname> <given-names>J.</given-names></name> <name><surname>Bacskai</surname> <given-names>B. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Rapid cell death is preceded by amyloid plaque-mediated oxidative stress</article-title>. <source>Proc. Natl. Acad. Sci. U S A</source> <volume>110</volume>, <fpage>7904</fpage>&#x02013;<lpage>7909</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1217938110</pub-id><pub-id pub-id-type="pmid">23610434</pub-id></citation></ref>
<ref id="B208"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>J.</given-names></name> <name><surname>Barger</surname> <given-names>S. W.</given-names></name> <name><surname>Drew</surname> <given-names>P. D.</given-names></name></person-group> (<year>2008</year>). <article-title>The PPAR-&#x003B3; agonist 15-deoxy-&#x00394;-prostaglandin J<sub>2</sub> attenuates microglial production of IL-12 family cytokines: potential relevance to Alzheimer&#x02019;s disease</article-title>. <source>PPAR Res.</source> <volume>2008</volume>:<fpage>349185</fpage>. <pub-id pub-id-type="doi">10.1155/2008/349185</pub-id><pub-id pub-id-type="pmid">18615183</pub-id></citation></ref>
<ref id="B209"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>Y.</given-names></name> <name><surname>Jiang</surname> <given-names>W.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Ding</surname> <given-names>C.</given-names></name> <name><surname>Tian</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome</article-title>. <source>Cell</source> <volume>160</volume>, <fpage>62</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.047</pub-id><pub-id pub-id-type="pmid">25594175</pub-id></citation></ref>
<ref id="B210"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>M.</given-names></name> <name><surname>Nguyen</surname> <given-names>T. V.</given-names></name> <name><surname>Pike</surname> <given-names>C. J.</given-names></name></person-group> (<year>2005</year>). <article-title>&#x003B2;-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w</article-title>. <source>J. Neurosci.</source> <volume>25</volume>, <fpage>1149</fpage>&#x02013;<lpage>1158</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4736-04.2005</pub-id><pub-id pub-id-type="pmid">15689551</pub-id></citation></ref>
<ref id="B211"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname> <given-names>J. M.</given-names></name> <name><surname>Lee</surname> <given-names>B. D.</given-names></name> <name><surname>Sok</surname> <given-names>D. E.</given-names></name> <name><surname>Ma</surname> <given-names>J. Y.</given-names></name> <name><surname>Kim</surname> <given-names>M. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Neuroprotective action of N-acetyl serotonin in oxidative stress-induced apoptosis through the activation of both TrkB/CREB/BDNF pathway and Akt/Nrf2/Antioxidant enzyme in neuronal cells</article-title>. <source>Redox Biol.</source> <volume>11</volume>, <fpage>592</fpage>&#x02013;<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2016.12.034</pub-id><pub-id pub-id-type="pmid">28110215</pub-id></citation></ref>
<ref id="B006"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname> <given-names>A. J.</given-names></name> <name><surname>Johnson</surname> <given-names>S.</given-names></name> <name><surname>Steffens</surname> <given-names>D. C.</given-names></name> <name><surname>Doraiswamy</surname> <given-names>P. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Coenzyme Q10: a review of its promise as a neuroprotectant</article-title>. <source>CNS Spectr.</source> <volume>12</volume>, <fpage>62</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1017/s1092852900020538</pub-id><pub-id pub-id-type="pmid">17192765</pub-id></citation></ref>
<ref id="B212"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>K.</given-names></name> <name><surname>Kaufman</surname> <given-names>R. J.</given-names></name></person-group> (<year>2008</year>). <article-title>From endoplasmic-reticulum stress to the inflammatory response</article-title>. <source>Nature</source> <volume>454</volume>, <fpage>455</fpage>&#x02013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1038/nature07203</pub-id><pub-id pub-id-type="pmid">18650916</pub-id></citation></ref>
<ref id="B213"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>L.</given-names></name> <name><surname>Yu</surname> <given-names>H.</given-names></name> <name><surname>Zhao</surname> <given-names>X.</given-names></name> <name><surname>Lin</surname> <given-names>X.</given-names></name> <name><surname>Tan</surname> <given-names>C.</given-names></name> <name><surname>Cao</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Neuroprotective effects of salidroside against beta-amyloid-induced oxidative stress in SH-SY5Y human neuroblastoma cells</article-title>. <source>Neurochem. Int.</source> <volume>57</volume>, <fpage>547</fpage>&#x02013;<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2010.06.021</pub-id><pub-id pub-id-type="pmid">20615444</pub-id></citation></ref>
<ref id="B214"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>S.</given-names></name> <name><surname>Gao</surname> <given-names>L.</given-names></name> <name><surname>Liu</surname> <given-names>X.</given-names></name> <name><surname>Lu</surname> <given-names>T.</given-names></name> <name><surname>Xie</surname> <given-names>C.</given-names></name> <name><surname>Jia</surname> <given-names>J.</given-names></name></person-group> (<year>2017</year>). <article-title>Resveratrol attenuates microglial activation via SIRT1-SOCS1 pathway</article-title>. <source>Evid. Based Complement. Alternat. Med.</source> <volume>2017</volume>:<fpage>8791832</fpage>. <pub-id pub-id-type="doi">10.1155/2017/8791832</pub-id><pub-id pub-id-type="pmid">28781601</pub-id></citation></ref>
<ref id="B215"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>C.</given-names></name> <name><surname>Liao</surname> <given-names>Y.</given-names></name> <name><surname>Rahaman</surname> <given-names>A.</given-names></name> <name><surname>Kumar</surname> <given-names>V.</given-names></name></person-group> (<year>2022</year>). <article-title>Towards understanding the relationship between ER stress and unfolded protein response in amyotrophic lateral sclerosis</article-title>. <source>Front. Aging Neurosci.</source> <volume>14</volume>:<fpage>892518</fpage>. <pub-id pub-id-type="doi">10.3389/fnagi.2022.892518</pub-id><pub-id pub-id-type="pmid">35783140</pub-id></citation></ref>
<ref id="B216"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>R.</given-names></name> <name><surname>Yu</surname> <given-names>Q.</given-names></name> <name><surname>Hou</surname> <given-names>L.</given-names></name> <name><surname>Dong</surname> <given-names>X.</given-names></name> <name><surname>Zhang</surname> <given-names>H.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Cadmium induces mitochondrial ROS inactivation of XIAP pathway leading to apoptosis in neuronal cells</article-title>. <source>Int. J. Biochem. Cell Biol.</source> <volume>121</volume>:<fpage>105715</fpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2020.105715</pub-id><pub-id pub-id-type="pmid">32035180</pub-id></citation></ref>
<ref id="B217"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname> <given-names>L. M.</given-names></name> <name><surname>Zong</surname> <given-names>Y.</given-names></name> <name><surname>Sun</surname> <given-names>L.</given-names></name> <name><surname>Guo</surname> <given-names>J. Z.</given-names></name> <name><surname>Zhang</surname> <given-names>W.</given-names></name> <name><surname>He</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells</article-title>. <source>PLoS One</source> <volume>7</volume>:<fpage>e32195</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0032195</pub-id><pub-id pub-id-type="pmid">22363816</pub-id></citation></ref>
</ref-list>
<sec id="s9">
<title>Glossary</title>
<table-wrap position="anchor">
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="left">4-PBA</td>
<td align="center">4-phenyl butyric acid</td>
</tr>
<tr>
<td align="left">6-OHDA</td>
<td align="center">6-hydroxydopamine</td>
</tr>
<tr>
<td align="left">8-OHdG</td>
<td align="center">8-hydroxydeoxyguanosine</td>
</tr>
<tr>
<td align="left">A1AT</td>
<td align="center">alpha1-antitrypsin</td>
</tr>
<tr>
<td align="left">ABAD</td>
<td align="center">amyloid beta-binding alcohol dehydrogenase</td>
</tr>
<tr>
<td align="left">AD</td>
<td align="center">Alzheimer&#x02019;s disease</td>
</tr>
<tr>
<td align="left">AIF</td>
<td align="center">apoptosis-inducing factor</td>
</tr>
<tr>
<td align="left">ALS</td>
<td align="center">amyotrophic lateral sclerosis</td>
</tr>
<tr>
<td align="left">APP</td>
<td align="center">amyloid precursor protein</td>
</tr>
<tr>
<td align="left">ASC</td>
<td align="center">apoptosis-associated speck-like protein containing a caspase activation and recruitment domain</td>
</tr>
<tr>
<td align="left">ASK1</td>
<td align="center">apoptotic signaling kinase 1</td>
</tr>
<tr>
<td align="left">ATF4</td>
<td align="center">activating transcription factor 4</td>
</tr>
<tr>
<td align="left">ATF6</td>
<td align="center">activating transcription factor 6</td>
</tr>
<tr>
<td align="left">AU</td>
<td align="center">aucubin</td>
</tr>
<tr>
<td align="left">A&#x003B2;</td>
<td align="center">amyloid-beta</td>
</tr>
<tr>
<td align="left">BACE1</td>
<td align="center">beta secretase 1</td>
</tr>
<tr>
<td align="left">BAX</td>
<td align="center">bcl2-associated X protein</td>
</tr>
<tr>
<td align="left">BBB</td>
<td align="center">blood-brain barrier</td>
</tr>
<tr>
<td align="left">BFA</td>
<td align="center">brefeldin A</td>
</tr>
<tr>
<td align="left">BID</td>
<td align="center">BH3 interacting domain death agonist</td>
</tr>
<tr>
<td align="left">BiP</td>
<td align="center">immunoglobulin binding protein</td>
</tr>
<tr>
<td align="left">BITC</td>
<td align="center">benzyl isothiocyanate</td>
</tr>
<tr>
<td align="left">BPA</td>
<td align="center">bisphenol A</td>
</tr>
<tr>
<td align="left">CCL2</td>
<td align="center">monocyte chemoattractant protein-1</td>
</tr>
<tr>
<td align="left">Cd</td>
<td align="center">cadmium</td>
</tr>
<tr>
<td align="left">CHOP</td>
<td align="center">C/EBP homologous protein</td>
</tr>
<tr>
<td align="left">CL</td>
<td align="center">cardiolipin</td>
</tr>
<tr>
<td align="left">CNS</td>
<td align="center">central nervous system</td>
</tr>
<tr>
<td align="left">COX</td>
<td align="center">cyclooxygenase</td>
</tr>
<tr>
<td align="left">CSF</td>
<td align="center">cerebrospinal fluid</td>
</tr>
<tr>
<td align="left">Cyt C</td>
<td align="center">cytochrome c</td>
</tr>
<tr>
<td align="left">DA</td>
<td align="center">dopaminergic</td>
</tr>
<tr>
<td align="left">DAMP</td>
<td align="center">damage-associated molecular pattern</td>
</tr>
<tr>
<td align="left">DBM</td>
<td align="center">dibenzoylmethane</td>
</tr>
<tr>
<td align="left">DHCR24</td>
<td align="center">3-beta-hydroxysteroid delta-24-reductase</td>
</tr>
<tr>
<td align="left">DHM</td>
<td align="center">dihydromyricetin</td>
</tr>
<tr>
<td align="left">DL-NAT</td>
<td align="center">N-acetyl-DL-tryptophan</td>
</tr>
<tr>
<td align="left">DR5</td>
<td align="center">Death Receptor 5</td>
</tr>
<tr>
<td align="left">EGCG</td>
<td align="center">Epigallocatechin-3-gallate</td>
</tr>
<tr>
<td align="left">eIF2&#x003B1;</td>
<td align="center">eukaryotic translation initiation factor 2 &#x003B1;</td>
</tr>
<tr>
<td align="left">ER</td>
<td align="center">endoplasmic reticulum</td>
</tr>
<tr>
<td align="left">ERAD</td>
<td align="center">ER-associated degradation</td>
</tr>
<tr>
<td align="left">ERO1</td>
<td align="center">ER Oxidase 1</td>
</tr>
<tr>
<td align="left">GLP-1R</td>
<td align="center">glucagon-like peptide-1 receptor</td>
</tr>
<tr>
<td align="left">GRP78</td>
<td align="center">78kDa glucose-regulated protein</td>
</tr>
<tr>
<td align="left">GSH</td>
<td align="center">glutathione</td>
</tr>
<tr>
<td align="left">GSK-3&#x003B2;</td>
<td align="center">glycogen synthase kinase-3beta</td>
</tr>
<tr>
<td align="left">GSK3</td>
<td align="center">glycogen synthase kinase 3</td>
</tr>
<tr>
<td align="left">H2O2</td>
<td align="center">hydrogen peroxide</td>
</tr>
<tr>
<td align="left">HD</td>
<td align="center">Huntington&#x02019;s disease</td>
</tr>
<tr>
<td align="left">HN</td>
<td align="center">humanin</td>
</tr>
<tr>
<td align="left">HNE</td>
<td align="center">4-hydroxy-2-nonenal</td>
</tr>
<tr>
<td align="left">HO&#x02022;</td>
<td align="center">hydroxyl radical</td>
</tr>
<tr>
<td align="left">IL</td>
<td align="center">interleukin</td>
</tr>
<tr>
<td align="left">IMM</td>
<td align="center">inner mitochondrial membrane</td>
</tr>
<tr>
<td align="left">IP3R</td>
<td align="center">inositol triphosphate receptor</td>
</tr>
<tr>
<td align="left">IRE1&#x003B1;</td>
<td align="center">inositol-requiring transmembrane kinase/endoribonuclease 1 &#x003B1;</td>
</tr>
<tr>
<td align="left">JAK-STAT</td>
<td align="center">janus kinase-signal transducer and activator of transcription</td>
</tr>
<tr>
<td align="left">JNK</td>
<td align="center">c-Jun N-terminal kinase</td>
</tr>
<tr>
<td align="left">KIRA6</td>
<td align="center">kinase-inhibiting RNase attenuator 6</td>
</tr>
<tr>
<td align="left">L-NAT</td>
<td align="center">N-acetyl-L-tryptophan</td>
</tr>
<tr>
<td align="left">LPO</td>
<td align="center">lipid peroxidation</td>
</tr>
<tr>
<td align="left">LPS</td>
<td align="center">lipopolysaccharide</td>
</tr>
<tr>
<td align="left">MDA</td>
<td align="center">malondialdehyde</td>
</tr>
<tr>
<td align="left">MDM2</td>
<td align="center">mouse double minute 2</td>
</tr>
<tr>
<td align="left">mHTT</td>
<td align="center">mutant huntingtin protein</td>
</tr>
<tr>
<td align="left">MPP+</td>
<td align="center">1-methyl-4-phenyl-pyridinium</td>
</tr>
<tr>
<td align="left">MPTP</td>
<td align="center">1-methyl-4phenyl1,2,3,6-tetrahydropyridine</td>
</tr>
<tr>
<td align="left">mPTP</td>
<td align="center">mitochondrial permeability transition pore</td>
</tr>
<tr>
<td align="left">mSOD1</td>
<td align="center">mutant superoxide dismutase 1</td>
</tr>
<tr>
<td align="left">mtDNA</td>
<td align="center">mitochondrial DNA</td>
</tr>
<tr>
<td align="left">NAS</td>
<td align="center">N-acetyl serotonin</td>
</tr>
<tr>
<td align="left">NF-&#x003BA;B</td>
<td align="center">nuclear factor kappa-light-chain-enhancer of activated B cells</td>
</tr>
<tr>
<td align="left">NFT</td>
<td align="center">neurofibrillary tangle</td>
</tr>
<tr>
<td align="left">NLRP3</td>
<td align="center">NLR family pyrin domain containing 3</td>
</tr>
<tr>
<td align="left">NO</td>
<td align="center">nitric oxide</td>
</tr>
<tr>
<td align="left">NOX</td>
<td align="center">NADPH oxidase</td>
</tr>
<tr>
<td align="left">Nrf2</td>
<td align="center">nuclear factor erythroid 2-related factor 2</td>
</tr>
<tr>
<td align="left">O2-</td>
<td align="center">superoxide anion</td>
</tr>
<tr>
<td align="left">OMM</td>
<td align="center">outer mitochondrial membrane</td>
</tr>
<tr>
<td align="left">p38 MAPK</td>
<td align="center">p38 mitogen-activated protein kinase</td>
</tr>
<tr>
<td align="left">PAMP</td>
<td align="center">pathogen-associated molecular pattern</td>
</tr>
<tr>
<td align="left">PARK7</td>
<td align="center">parkinsonism associated deglycase</td>
</tr>
<tr>
<td align="left">PD</td>
<td align="center">Parkinson&#x02019;s disease</td>
</tr>
<tr>
<td align="left">PERK</td>
<td align="center">PKR-like ER kinase</td>
</tr>
<tr>
<td align="left">PINK1</td>
<td align="center">PTEN-induced putative kinase 1</td>
</tr>
<tr>
<td align="left">PPAR</td>
<td align="center">peroxisome proliferator-activated receptor</td>
</tr>
<tr>
<td align="left">PUFA</td>
<td align="center">polyunsaturated fatty acid</td>
</tr>
<tr>
<td align="left">PUMA</td>
<td align="center">p53-upregulated modulator of apoptosis</td>
</tr>
<tr>
<td align="left">RA</td>
<td align="center">rosmarinic acid</td>
</tr>
<tr>
<td align="left">rAAV</td>
<td align="center">recombinant adeno-associated virus</td>
</tr>
<tr>
<td align="left">REST</td>
<td align="center">repressor element 1-silencing transcription factor</td>
</tr>
<tr>
<td align="left">RIDD</td>
<td align="center">regulated IRE1&#x003B1;-dependent decay</td>
</tr>
<tr>
<td align="left">RNS</td>
<td align="center">reactive nitrogen species</td>
</tr>
<tr>
<td align="left">ROS</td>
<td align="center">reactive oxygen species</td>
</tr>
<tr>
<td align="left">RY</td>
<td align="center">ryanodine</td>
</tr>
<tr>
<td align="left">RYR</td>
<td align="center">ryanodine receptor</td>
</tr>
<tr>
<td align="left">Sald</td>
<td align="center">salidroside</td>
</tr>
<tr>
<td align="left">SN</td>
<td align="center">substantia nigra</td>
</tr>
<tr>
<td align="left">SNpc</td>
<td align="center">substantia nigra pars compacta</td>
</tr>
<tr>
<td align="left">SOD1</td>
<td align="center">superoxide dismutase</td>
</tr>
<tr>
<td align="left">TNF</td>
<td align="center">tumor necrosis factor</td>
</tr>
<tr>
<td align="left">TRAF2</td>
<td align="center">TNF receptor-associated factor 2</td>
</tr>
<tr>
<td align="left">Trib3</td>
<td align="center">tribbles pseudokinase 3</td>
</tr>
<tr>
<td align="left">TRPM2</td>
<td align="center">transient receptor potential melastatin-2</td>
</tr>
<tr>
<td align="left">UPR</td>
<td align="center">unfolded protein response</td>
</tr>
<tr>
<td align="left">VAPB</td>
<td align="center">vesicle-associated membrane protein-associated protein B</td>
</tr>
<tr>
<td align="left">XBP1</td>
<td align="center">X-box binding protein 1</td>
</tr>
<tr>
<td align="left">XIAP</td>
<td align="center">x-linked inhibitor of apoptosis</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</back>
</article>